

Graduate School for Health Sciences  
University of Bern

**u<sup>b</sup>**

**b  
UNIVERSITÄT  
BERN**

# Obstetric and perinatal outcomes of women treated for subfertility and children born after in vitro fertilisation

PhD Thesis submitted by

**Vera Ruth Mitter**

from Täuffelen, BE

for the Degree of

**PhD in Health Sciences (Epidemiology)**

Thesis advisor

**Prof. Dr. med. Michael von Wolff**

Division of Gynecological Endocrinology and Reproductive Medicine, University Women's Hospital,  
Faculty of Medicine, University of Bern

Thesis Co-referee

**Prof. Dr. phil. Marcel Zwahlen**

Institute of Social and Preventive Medicine, Faculty of Medicine, University of Bern



Graduate School for Health Sciences  
University of Bern

**Obstetric and perinatal outcomes of women treated  
for subfertility and children born after in vitro  
fertilisation**

PhD Thesis submitted by

**Vera Ruth Mitter**

from **Täuffelen, BE**

for the degree of

PhD in Health Sciences (Epidemiology)

Thesis advisor

**Prof. Dr. med. Michael von Wolff**

Division of Gynecological Endocrinology and Reproductive Medicine, University  
Women's Hospital  
Faculty of Medicine, University of Bern

Thesis co-referee

**Prof. Dr. phil. Marcel Zwahlen**

Institute of Social and Preventive Medicine  
Faculty of Medicine, University of Bern



Accepted by the Faculty of Medicine and the Faculty of Human Sciences of the  
University of Bern

Bern,

Dean of the Faculty of Medicine

Bern,

Dean of the Faculty of Human Sciences



For Malin, Lenny & Mike

There is no better time for epidemiology

Thesis in times of COVID-19

“We have therefore made the assessment that COVID-19 can be characterized as a  
pandemic”

Tedros Ghebreyesus, March 2020





# Content

ABBREVIATIONS.....	11
SUMMARY .....	13
1. Introduction.....	15
1.1. Infertility – epidemiology, aetiology and consequences.....	15
1.1.1. Female infertility .....	17
1.1.2. Male factor infertility .....	18
1.1.3. Idiopathic infertility .....	19
1.2. Assisted reproduction .....	20
1.2.1. Definitions .....	20
1.2.2. Development and global perspective.....	20
1.2.3. Fertility treatment .....	21
1.3. Treatment schemes used at the University Women’s Hospital in Bern .....	22
1.4. Perinatal health of children born after ART .....	25
1.5. Long-term health of children born after ART .....	29
2. Methods and data .....	31
2.1. The Bern IVF Cohort .....	31
2.1.1. Bern IVF Cohort - description .....	31
2.1.2. The Bern IVF Cohort: establishment of control group .....	33
2.2. The Swiss Infant Feeding Study .....	35
2.3. Endometrial thickness in women after NC-IVF .....	35
2.4. Women with hysteroscopy assessment.....	35
3. Objectives of the thesis .....	37
4. References.....	39
5. Manuscripts.....	53
5.1 Article 1: Small-for-gestational-age.....	55
5.2 Article 2: Breastfeeding following in vitro fertilisation .....	67
5.3 Article 3: Endometrial thickness in NC-IVF.....	95
5.4 Article 4: Time to live birth in subfertile women .....	103

6.	Discussion .....	131
6.1	Main findings .....	131
6.2.	Broader interpretation of the findings .....	132
6.3.	Strengths and limitations .....	135
6.4.	Implications for future research.....	136
6.4.	Implications for future policy .....	139
7.	Conclusion .....	141
8.	References.....	143
	ACKNOWLEDGEMENTS .....	147
	CURRICULUM VITAE .....	149
	PUBLICATIONS .....	151
	CONFERENCE PRESENTATIONS .....	153
	DECLARATION OF ORIGINALITY.....	155

## SUMMARY

The use of assisted reproductive technologies has increased over the past decades. To date, 8 million children have been born worldwide following assisted reproductive technologies. In Switzerland, this refers to around 2-2.5% of newborn's every year, this were 2'188 children in 2017.

The introduction of this thesis gives an overview of the reasons for increasing global infertility, and of the use of medically assisted reproduction. It also presents the treatment options available today, and the risks associated with them for mothers and offspring. It goes on to describe the methods and data used in the research projects conducted for this thesis.

In the following section, the four publications included in this thesis are presented. The first article on children within the Bern IVF Cohort compares the birthweights and birthweight percentiles of children born after natural cycle in vitro fertilisation, to those born after conventional in vitro fertilisation. This shows that the increased risk of small-for-gestational age infants being born may be associated with hyperstimulation of oocyte growth in conventional in vitro fertilisation, especially when high estradiol levels are reached on the day of ovulation induction.

The second article uses follow-up data on breastfeeding collected within the Bern IVF Cohort. Breastfeeding prevalence and duration is compared to data from the Swiss Infant Feeding Study, which served as a control population. The findings demonstrate that women after fertility treatment breastfeed their children as much and for as long as mothers in the control population. This suggests that fertility treatment does not affect the potential and ability to breastfeed in Switzerland.

The third article relates to the endometrium in natural cycle in vitro fertilisation, where the endometrium is not affected by hormonal stimulation. Data on endometrial thickness was collected from women during their first treatment cycle and the outcome measured, was successful pregnancy. It was shown that both very thin but also thick endometrium is associated with adverse pregnancy outcomes in natural cycle in vitro fertilisation.

The fourth article analyses data from a historical cohort of women under treatment due to repeated implantation failure and recurrent pregnancy loss from 2014-2018. The two conditions seem to be associated with chronic endometritis, and their discussion is controversial: so far, no agreement on a standardised diagnosis or treatment has been reached. The aim was to assess the effect of endometrial diagnostic biopsy on subsequent treatment in cases of chronic endometritis, which was introduced in 2016, compared to hysteroscopic assessment alone. This demonstrated that diagnostic endometrial biopsy and subsequent treatment of chronic endometritis shortens time-to-pregnancy and live birth.



## ABBREVIATIONS

aOR	Adjusted odds ratio
AMH	Anti-Müllerian hormone
APS	Antiphospholipid syndrome
ART	Assisted reproductive technology
BMI	Body mass index
CC	Clomiphene citrate
CE	Chronic endometritis
CI	Confidence interval
cIVF	Conventional gonadotropin stimulated in vitro fertilisation
DNA	Deoxyribonucleic acid
DOHaD	Developmental origins of health and disease
EC	Ethic commission
ESHRE	European Society of Human Reproduction and Embryology
ET	Embryo transfer
E2	Estradiol
FET	Frozen embryo transfer
FIVNAT-CH	National registry on data from all ART treatment cycles in Switzerland
FOPH	Federal Office of Public Health (Bundesamt für Gesundheit)
FSH	Follicle stimulating hormone
FSO	Federal Statistical Office (Bundesamt für Statistik)
GnRH	Gonadotropin-releasing hormone
hCG	human chorionic gonadotropin
HIV	Human immunodeficiency virus
HMG	Human menopausal gonadotropins (includes FSH and LH)
HR	Hazard ratio
ICMART	International Committee for Monitoring Assisted Reproductive Technologies
ICSI	Intracytoplasmic sperm injection
ISMAAR	International Society for Mild Approaches in Assisted Reproduction
IU	International unit
IUI	Intrauterine insemination
IVF	In vitro fertilization

LBR	Live birth rate
LBW	Low birthweight (< 2'500g)
LH	Luteinising hormone
MAR	Medically assisted reproduction
mIVF	Minimal stimulation in vitro fertilisation
NSAID	Non-steroidal anti-inflammatory drugs
NC-IVF	Natural cycle in vitro fertilisation treatment
OHSS	Ovarian hyperstimulation syndrome
OPU	Oocyte pick up
OR	Odds ratio
PCOS	Polycystic ovary syndrome
PTB	Preterm birth (< 37 gestational weeks)
RIF	Repeated implantation failure
RMA	Federal act on medically assisted reproduction (Reproductive Medicine Act)
RPL	Recurrent pregnancy loss
SET	Single embryo transfer
SGA	Small-for-gestational-age
SGRM	Swiss Society for Reproductive Medicine (Schweizerische Gesellschaft für Reproduktionsmedizin)
SWIFS	Swiss infant feeding study
SNC	Swiss National Cohort
TESE	Testicular sperm extraction
TSH	Thyroid-stimulating hormone (thyrotropin)
WHO	World Health Organization

# 1. Introduction

The World Health Organization (WHO) and the International Committee for Monitoring Assisted Reproductive Technology (ICMART) define infertility as “a disease of the reproductive system defined by the failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse, or due to impairment of a woman’s capacity to reproduce”.<sup>1,2</sup>

Some couples remaining childless is quite normal, as is couples having abundant offspring. Couples affected by infertility can seek medical help, at least in most countries of the developed world. However, infertility remains an ongoing problem worldwide, impacting gender equity and health equality. Unfortunately, the highest rates of infertility are often in countries with the most limited access to assisted reproductive technologies (ART).<sup>3</sup>

It is important to respect infertility or subfertility as a disease, because affected couples often feel that their bodies are not working properly and healthily. They are not achieving what normal healthy couples can naturally achieve – namely, a pregnancy and a live birth of a child.<sup>4</sup> According to the latest definition by the WHO, infertility is a disease, which constitutes a disability and an impairment. Sometimes infertility is the result of a disorder, which itself needs treatment and therefore should be diagnosed.<sup>4</sup>

## 1.1. Infertility – epidemiology, aetiology and consequences

Infertility is a highly prevalent condition and affects 8-12% of couples of reproductive age.<sup>5</sup> Worldwide, an estimated 97 – 186 million people are suffering from some form of infertility, infecundity or childlessness, mainly in developing countries.<sup>3,6,7</sup> The inability to conceive following a prior pregnancy – secondary infertility – is the most common form of infertility worldwide. 25-30% of women of sub-Saharan African countries suffer from secondary infertility.<sup>6</sup> A high prevalence of sexually transmitted infections may lead to female and male infertility. Additionally, poor maternity care, leading to post-abortive and postpartum infections, causes secondary infertility in females, especially in African countries.<sup>3,8</sup> Despite the fact that in half of the infertile couples male factors contribute, it is often seen as a female failure, and the social burden falls on the woman, possibly leading to stigmatisation.<sup>8</sup> The treatment and diagnosis of infertility is not only important for gender equity, but also in identifying possibly severe underlying health conditions generally reducing health-related quality of life.<sup>4,8</sup>

Major factors affecting the likelihood of spontaneous conception are:

- Time of unwanted non-conception (the longer a couple tries, the lower the chances become)
- Age of the woman
- Disease-related infertility

#### *Time of unwanted non-conception*

The time of unwanted non-conception is an important determinant of the severity of subfertility. Usually, 80% of pregnancies occur within six months of regular unprotected intercourse. After six more months, half of the remaining 20% of couples achieve a pregnancy. After 12 months of trying, the remaining 10% can be diagnosed with subfertility. However, even among this group, nearly 55% will achieve a spontaneous pregnancy within the next 36 months. 5% will remain infertile, with an extremely low chance of becoming pregnant.<sup>9</sup>

#### *Female age-related fertility decline & social trends*

In the 1960's, the first hormonal contraceptive method, the anti-baby pill, came on the market. It allowed women to control their fertility and to become more sexually independent. Today, 73% of women aged 15-49 in Switzerland use some form of contraceptive method.<sup>10</sup> At the same time, expectations for parenthood increased. Women aimed for better and longer educations, and focused on their professional careers. As a consequence of these societal changes, couples delayed starting their families, and the mean childbearing age in many countries increased.<sup>11,12</sup> In Switzerland, the mean age of mothers at birth was 27.9 in the 1980s, 29.8 in 2000 and reached 32.2 in 2019.<sup>13</sup> The total current fertility rate is below the replacement level of 2.1 in all European countries (average EU: 1.6, World: 2.43).<sup>10</sup> Delaying childbearing until less fertile ages is increasing involuntary childlessness, and is an important contributor to the decrease in births and fertility rates.<sup>14</sup> Women are most fertile between the ages of 20-29. From 32 onwards, female fertility decreases gradually, and from 37 on, the decrease becomes more rapid. Women over 35 years do not only have more difficulties in becoming pregnant, but are also at a higher risk of loss of pregnancy.<sup>15</sup> This is due to the continuous decrease of the ovarian reserve in both ovaries, and the hormonal change induced by the perimenopause. Additionally, deterioration of oocyte quality increases the risk of genetic aberrations and spontaneous abortions.<sup>16</sup> Some women are at risk of entering menopause much earlier due to premature ovarian failure.<sup>17</sup> With increasing age, the risk of health problems causing infertility, and the consequences of an unhealthy lifestyle become more important. Sadly, many men and women of younger ages are not aware of age-related declining fertility, and many believe ART can mitigate this problem.<sup>18</sup> However, the response to ovarian stimulation in ART is lower if the ovarian reserve is reduced. This reduces levels of treatment success in older women. Either having already had a live



birth, or having donated eggs, increases the chance of a live birth through ART for women above the age of 40 years, but after 45 the chances are close to zero.<sup>19</sup>

### *Disease related infertilities*

Many diseases, dysfunctions or malformations are associated with lower fertility or subfertility. Pathologies affecting the sexual functioning of the body or sexual organs, as well as systemic diseases, may influence fertility. It may affect both genders or be specific to one gender only.

#### 1.1.1. Female infertility

##### *Ovulatory dysfunction*

Ovulatory dysfunction means the non- or malfunction of the ovaries, and is usually characterized by fewer menstruations (oligomenorrhea) or no menstruation at all (amenorrhea). It is mostly caused by endocrine disorders, meaning the hormones regulating the female cycle are not produced in the necessary amount, or do not function normally. The most common endocrine disorder in women of reproductive age is polycystic ovary syndrome (PCOS), with a prevalence of 5-15%. The follicles fail to release the oocyte, which leads to numerous small persisting follicles in the ovaries which can be detected by ultrasound.<sup>20,21</sup> In rare cases, ovulatory dysfunction is caused by genetic conditions such as Turner syndrome.<sup>22</sup>

##### *Tubal factor*

The fallopian tubes collect the oocyte after ovulation and transport it towards the cavum. Transport relies on effective ciliary activity, which can be impaired by inflammations or pathogens. The most common infectious diseases causing tubal problems are *Chlamydia trachomatis* or *Neisseria gonorrhoea*. Systematic diseases, such as primary ciliary dyskinesia or cystic fibrosis, can also impair ciliary structure and function. Further reasons may be tubal endometriosis, peritubal adhesions or salpingitis isthmica nodosa.<sup>5,23</sup>

##### *Uterine factor*

The uterine physiology and anatomy is important in the successful implantation of a fertilized egg. Uterine myomas are the most common benign tumours of the female reproductive system, and are present in 5-10% of infertile women, but are only the sole cause of infertility in 2-3% of infertile women. Their localisation may interfere with the implantation of the embryo.<sup>24</sup> Other uterine abnormalities such as fibroid, polyps, or adenomyosis can also reduce the chance of achieving a pregnancy.<sup>25</sup> Congenital uterine malformations such as uterus septus or subseptus, or more complex malformations such as uterus unicornus, bicornus or didelphys, may in rare instances lead to infertility or recurrent pregnancy loss.<sup>26</sup> Surgical treatment is sometimes needed.

### *Endometriosis*

Endometriosis is characterised by the presence of endometrial mucosa (the lining of the uterus) in other locations within the female pelvic area. It is a pathological and chronic inflammatory process. Some women have cyclical abdominal pain and/or pelvic pain during or after sexual intercourse. The severity and localisation of endometriosis can vary highly. The association of endometriosis with infertility ranges from anatomical distortions due to adhesions and fibrosis, to endocrine abnormalities and immunological disturbances.<sup>27</sup> Endometriosis decreases the embryonic implantation potential, which reduces ART success. It also leads to a higher risk of miscarriages independent of the origin of the pregnancy.<sup>28</sup> Endometriosis often remains undiagnosed. Its prevalence in women of reproductive age is unclear, and estimates range from 0.8% to 10%. In subfertile women it ranges from 20-50%.<sup>29,30</sup>

#### 1.1.2. Male factor infertility

Male infertility contributes to 40-50% of cases where a couple is infertile, and in 20-30% it is the sole cause. Male infertility is mostly due to testicular deficiency or post-testicular impairment. Both can be congenital, acquired or idiopathic. Congenital problems may be the malformation or lack of testicles, the absence of vas deferens in men with cystic fibrosis or genetic abnormalities. Genetic abnormalities are Klinefelter (47 XXY) syndrome and Y chromosome microdeletions, causing issues from a light disturbance of spermatogenesis up to a complete azoospermia.<sup>5,25</sup> Trauma, testicular torsion or inflammation of the testes can lead to testicular failure, as can medication or varicocele (varicose veins in the scrotum). Varicocele are present in 14.8 - 25.4% of men with abnormal semen.<sup>31</sup> Ejaculatory dysfunction (retrograde ejaculation) or obstruction in the epididymis, vas deferens or ejaculatory duct can be the result of infections, vasectomy or hernia repair. About 6% of men produce antibodies against their own sperm.<sup>5,31</sup>

Another important issue in male fertility is the worldwide decrease in sperm quality seen over the last decades.<sup>32</sup> In 2010 the WHO lowered their reference limits for human semen characteristics based on men whose female partner got pregnant within 12 months (volume: 1.5ml; total sperm count: 39 million; sperm concentration: 15 million/ml; vitality: 58%, progressive motility: 32%; motility: 40%; and 4% morphologically normal forms). In a study on the semen quality of young men recruited for the Swiss army, only 38% reached the sperm concentration, motility and morphology values of the WHO semen reference criteria. The median sperm concentration was among the lowest in Europe.<sup>33</sup> The reasons for this trend are manifold, but environmental and lifestyle factors seem to play important roles. The consumption of caffeine, nicotine, alcohol and fatty acids, and a diet rich in full fat dairy, meat and sugar, as well as obesity, potentially reduce fertility in men.<sup>32,34</sup> Chemicals with a hormonal influence on the body (endocrine disrupting compounds) can interfere with female

and male fertility. Other pollutants such as organohalogenes, air pollutants or heavy metals such as mercury could influence semen quality, as could pesticides and herbicides used in agriculture.<sup>35,36</sup>

### 1.1.3. Idiopathic infertility

In around 20-30% of infertile couples, infertility remains unexplained. It may be due to subtle, undetectable defects in the reproductive process, or just due to incidentally reduced fecundity. Many chronic or systematic diseases may influence fecundity. This is true of unstable diabetes, uncontrolled celiac disease and active autoimmune conditions, which may also be subclinical.<sup>37,38</sup> Psychological stress, lifestyle factors, use of caffeine or nicotine, too much or too little body weight and extensive sport training may be associated with lower fertility in men and women.<sup>36,39,40</sup>

#### *Repeated implantation failure and recurrent pregnancy loss*

Among the main challenges in fertility treatment remain repeated implantation failure (RIF) and recurrent pregnancy loss (RPL) as stated by the European Society of Human Reproduction and Embryology (ESHRE). RIF means the failure to reach a stage of clinical pregnancy after several ART cycles with subsequent embryo transfer, but no distinct definition exists.<sup>41</sup> RPL is defined as three or more consecutive miscarriages by the WHO and 1-5% of women are affected.<sup>42-44</sup> Risk factors associated with RIF and RPL are parental age, obesity, environmental exposure (including smoking and alcohol), genetic factors, uterine malformations and thyroid autoimmunity. Antiphospholipid syndrome is a distinct risk factor for RPL.<sup>44</sup> Additional factors related to IVF therapy might play a role in RIF: gamete/embryo factors such as oocyte quality, sperm quality (e.g. deoxyribonucleic acid (DNA)-fragmentation), ovulation induction protocol, hydrosalpinges and assumed immunological and pathophysiological factors. Other physiological and immunological factors have recently been discussed in relationship to RIF and RPL (e.g. natural killer cells, T-helper 1/T-helper 2 ratio and tumour necrosis factor  $\alpha$  levels, autoantibodies, altered expression of associated molecules, implantation window), but more research is needed to provide evidence of any association.<sup>45,46</sup> Imbalances of the uterine immunological cell pattern can lead to persistent inflammatory processes, and to chronic endometritis (CE). CE often remains undiagnosed, as it can be subtle and asymptomatic, or present with untypical symptoms such as pelvic pain, vaginal discharge, abnormal bleeding, dyspareunia and leucorrhoea.<sup>47,48</sup> ART cannot successfully bypass CE, as the problem lies in the implantation of the embryo. There is little agreement on standardized diagnosis and treatments for CE.<sup>49</sup> The formation of the first connection to the uterine endometrium, and the maintenance and support of this connection to establish a secure pregnancy, is a very complex process.

## 1.2. Assisted reproduction

### 1.2.1. Definitions

The following section clarifies and defines terms often used in medically assisted reproduction (MAR) and assisted reproductive technologies (ART).

Medically assisted reproduction includes “various interventions, procedures, surgeries and technologies to treat different forms of fertility impairment and infertility. These are ovulation induction, ovarian stimulation, ovulation triggering, all ART procedures, uterine transplantation and intra-uterine, intracervical and intravaginal insemination with semen of husband/partner or donor”.<sup>1</sup>

Assisted reproductive technologies “includes all interventions with the in vitro handling of both human oocytes and sperm or embryos for the purpose of reproduction”.<sup>1</sup> This includes in vitro fertilisation (IVF), embryo transfer (ET), intracytoplasmic sperm injection (ICSI) and many other treatments which are not relevant for this thesis. Importantly, ART does not include assisted intrauterine insemination (IUI).<sup>1</sup> In this thesis, the term ART is used when referring to children born after IVF or ICSI.

The term subfertility is interchangeable with infertility. Infertility and subfertility are defined by a specified time period; this is one year of unwanted non-conception, per the WHO definition. Sterility is a permanent state of infertility.<sup>1</sup>

A further distinction can be made between primary and secondary infertility. A woman with primary infertility has never been diagnosed with a clinical pregnancy. Secondary infertility means that a woman has previously been diagnosed with a clinical pregnancy, but is not able to establish a further clinical pregnancy.<sup>1</sup>

### 1.2.2. Development and global perspective

In England in 1978, the first baby was born through IVF. This success was among the major medical breakthroughs of the 20<sup>th</sup> century. IVF was in this case developed to overcome the mother’s blocked tubes.<sup>50,51</sup> Since Steptoe, Edwards and Purdy succeeded with IVF, the use of ART has increased worldwide.<sup>51</sup> Approximately 8 million children have been born following ART since 1978, mainly in high-income countries.<sup>3</sup> In developing countries, access to adequate fertility treatment is still difficult and unaffordable for many, although access is improving every year.<sup>3</sup> Even in developed countries, health insurance does not always cover ART, compromising reproductive autonomy.<sup>52,53</sup> Many infertile couples benefit from improvements in MAR. In only 40 years, many technologies have been developed to address different causes of infertility.<sup>50</sup>

### 1.2.3. Fertility treatment

Fertility treatment usually starts with the investigation of the couple for the cause of subfertility. Firstly, a comprehensive assessment of the medical, gynaecological and urological histories, the function of sexual organs, clinical investigation and specific diagnostic tests are conducted. These tests usually include a transvaginal ultrasound examination including the antral follicle count to assess ovarian reserve. At the beginning of the cycle a measurement of serum hormones (follicle stimulating hormone (FSH), luteinising hormone (LH), estradiol (E2), thyroid stimulating hormone (TSH), prolactin and total testosterone) are performed. Anti-Müllerian hormone (AMH) is measured for additional information on the ovarian reserve. Preovulatory a hysterosalpingography is performed to assess uterine cavity and the patency of the tubes. Male fertility is assessed by the analysis of ejaculate including concentration, motility, and the morphology of the sperm.<sup>22,25</sup>

Today, many causes of infertility are treatable with different techniques developed in MAR. IUI and monofollicular ovarian stimulation may be sufficient for couples with less severe fertility problems, where a spontaneous conception is possible. Both the stimulation and the inhibition of ovulation are important factors in synchronising ovulation within the cycle. If supported spontaneous conception is not successful or possible, the fertilisation can be done in culture in a laboratory. Sperm is collected to inseminate retrieved oocytes outside the human body.

Hormonal ovarian stimulation supports the growth of more than one oocyte and impedes the natural selection of just one oocyte. Ejaculate is provided by the man himself, and then worked-up in the laboratory to select high quality sperm. The oocyte is fertilized in vitro either by adding an amount of sperm to the oocyte (IVF), or by the injection of just one selected sperm directly into it (ICSI). ICSI was originally developed to overcome severe male infertility, more than 25 years ago. In 2015, ICSI was used in 71.2% of treatments in Europe, avoiding natural sperm selection.<sup>54</sup>

The fertilized oocytes are cultured for several days before they are transferred to the uterus of the mother. This is a fresh embryo transfer. They are either transferred at the cleavage stage (day 2 or 3) or at the blastocyst stage (day 5) of their development. The extension of culture duration allows a better assessment of embryo quality, as their morphological structure, their kinetics and their longer survival are good indicators of viability. Freezing techniques have been developed to store supernumerous embryos. Current vitrification techniques allow storage and the thawing of embryos to be transferred in later cycles. This is called a frozen embryo transfer (FET). The advantage of a FET is that the uterus, especially the endometrium, can be specifically prepared. The disadvantage is that the embryo can get damaged by the vitrification technique. Today, it is possible to diagnose embryos for genetic defects before transfer to the uterus. This is called preimplantation genetic testing. If a

couple is a known carrier of a hereditary disease, a few cells of the embryo can be genetically analysed for this mutation. This allows the selection of a healthy embryo for transfer. It is even possible to screen an embryo's potential to develop unknown chromosomal or structural aberrations.

Some versions of MAR are not legal in Switzerland, such as the donation of oocytes or surrogacy motherhood. Sperm donation, on the other hand, is allowed. All these technologies and many more developed in the last 40 years.<sup>55</sup> Reproductive medicine is a relatively young medical field.

Cumulative pregnancy rates in ART can under optimal conditions reach natural fertility rates.<sup>56</sup>

However, even with ART support, a proportion of couples will remain childless. Unsuccessful fertility treatment can lead to psychological distress, or to problems in the couple's relationship.<sup>57,58</sup>

Reproductive medicine is also an area of conflict in many societies. It is caught between ethical, religious and legal factors which shape the options and attitudes of the couples affected, and the way they access and experience support.<sup>57</sup> Health insurance coverage differs between countries.<sup>52</sup>

Different legal restrictions, costs and access to treatment options increase cross-border fertility tourism between countries and continents.<sup>59</sup>

### 1.3. Treatment schemes used at the University Women's Hospital in Bern

At the University Women's Hospital in Bern, individual and patient-oriented IVF therapy is important. Therefore, natural cycle IVF (NC-IVF) is offered as an alternative alongside conventional gonadotropin stimulated IVF therapies (cIVF). In Switzerland, this is only the case at Bern, Baden, St. Gallen and Lausanne, but Bern has the longest experience with this treatment. Centres are organized within the IVF-Naturelle ([www.ivf-naturelle.ch](http://www.ivf-naturelle.ch)) network. This chapter gives an overview of the IVF treatments conducted at the Bern IVF center. The focus is on treatments with IVF/ICSI fertilization followed by a fresh embryo transfer.

#### *Natural cycle IVF (Schema A)*

In natural cycle IVF, gonadotropins are avoided for the stimulation of oocyte growth. The focus is on natural follicle recruitment and selection. The women undergoing NC-IVF have a regular menstrual cycle (26-32 days), and at least one ovary accessible transvaginally for the oocyte pick-up (OPU) needle. The treating physicians monitor the cycle by ultrasound, and measure levels of E2 and LH once before the ovulation is expected. When the follicle reaches a diameter of at least 16 mm and the estimated E2 level reaches > 700 pmol/L, a single injection of 5'000 international units (IU) of human chorionic gonadotropin (hCG) is given, to trigger the ovulation. Within 36 hours, follicular aspiration is conducted using a 19G single lumen needle, without anaesthesia. Follicular flushing up

to five times increases the chance of collecting the oocyte.<sup>60</sup> In case of the LH surge (>10 IU/L) on the day of trigger administration, 400 mg ibuprofen is given every 8 hours until the day of follicular aspiration.<sup>61,62</sup> Non-steroidal anti-inflammatory drugs (NSAID) such as Ibuprofen or indomethacin can postpone the ovulation by several hours if started before or at the onset of the LH surge.<sup>63,64</sup> If the LH surge is already high, the OPU is planned within 24 hours in order not to miss the oocyte. In NC-IVF there is always a risk that ovulation has already taken place, and the oocyte is lost. Besides NSAID, there is also the possibility of giving a single injection of a gonadotropin-releasing hormone (GnRH) antagonist if the LH surge has not yet started. This can be used to postpone follicular aspiration by one day for organisational reasons (e.g. not on a Sunday).

#### *NC-IVF using clomiphene citrate (Schema C)*

Low-dose clomiphene citrate can reduce the risk of premature ovulation by delaying the premature LH surge. The woman takes 25 mg every morning from cycle day 6 or 7, depending on the cycle length, until the day when ovulation is triggered by 5'000 IU of hCG. The subsequent procedure remains similar to the NC-IVF protocol described above.<sup>61,62</sup> Clomiphene citrate can reduce premature ovulation by 21%, and increase subsequent ET rate by 14.6%.<sup>62</sup> However, higher doses of clomiphene citrate should be avoided, as they can reduce endometrial thickness.<sup>25</sup>

#### *Minimal stimulation IVF (Schema E)*

If a woman under IVF treatment has a thin endometrium and is at high risk for preterm ovulation, a minimal hormonal stimulation can be used (mIVF). The woman injects Merional® 75 IE from cycle day 3-5, until one day before the administration of HCG for ovulation trigger. Merional® is human menopausal gonadotropin, which is a mix of human FSH and LH. Menopausal gonadotropin is gained from the urine of postmenopausal women. When the diameter of the leading follicle is 18-20 mm, and E2 concentration is estimated to be  $\geq 700$ -800 pmol/l, 5'000 IU of hCG is injected and oocyte retrieval is conducted 36 hours later as described above. If many follicles have developed, OPU is conducted with anaesthesia. This stimulation scheme is similar to a cIVF protocol using antagonists, with much lower doses of gonadotropins.<sup>25,65</sup> Low-dose gonadotropins are sometimes combined with clomiphene citrate if a better response to the stimulation is desired.<sup>25,66,67</sup>

#### *Conventional gonadotropin stimulated IVF*

The vast majority of ART treatments worldwide are performed with cIVF. For multifollicular stimulation, HMG was primarily used, and is still used, but because of HMG's urinary origin, the use of recombinant FSH is more common nowadays.<sup>68</sup>

Generally in cIVF, multifollicular growth is stimulated by FSH and a GnRH agonist or antagonist is added in combination to inhibit the gonadotropin production of the pituitary gland. This suppresses

LH release from the pituitary gland and prevents spontaneous ovulation. As LH surge therefore does not naturally occur, the ovulation has to be induced by hCG or GnRH agonists, artificially creating an LH surge. Without the LH surge, the first meiotic division and morphological changes of the oocytes would not occur.

In Bern, different cIVF treatment protocols are used, with gonadotropin agonists or antagonists. In the short or long agonist protocol, the downregulation with Decapeptyl® (GnRH agonist) starts from day 1 of the menstrual cycle (short), or in the mid-luteal phase of the preceding cycle (long). The stimulation with 150-300 IU of gonadotropins (either HMG, e.g. Merional®, Menopur® or FSH, e.g. Gonal-F® or Pergoveris®) starts from cycle day 2-3.<sup>69,70</sup> The physician individually decides the dose and the exact product based on the age, body mass index (BMI), AMH level, and antral follicle count and medical history of the woman.

For the antagonist protocol, 150 – 300 IU HMG are administered for follicular stimulation once a day. From day 6 to 8 onwards, the GnRH antagonist (e.g. Cetrotide® or Orgalutran® 0.25 mg) is added to avoid preterm ovulation. In all cIVF protocols, cycles are monitored by ultrasound and serum E2 level is measured. Once the leading follicles reach a diameter of at least 18 mm, and the concentration of E2 corresponds to the number of follicles, ovulation is triggered by urinary hCG (e.g. 6500 IU Ovitrelle®). The transvaginal oocyte retrieval takes place 36 hours after hCG administration under conscious sedation.<sup>71,72</sup>

Due to the downregulation of the pituitary gland and to the reach of supraphysiological E2 levels, the luteal phase after gonadotropin stimulation is insufficient. Progesterone is vaginally administrated to prepare the endometrium for implantation after embryo transfer up to 12 weeks of gestation.<sup>73</sup>

#### *Definition of different treatments*

NC-IVF is defined by the International Society for Mild Approaches in Assisted Reproduction (ISMAAR) as IVF without the use of any medication. However, it is also used as an umbrella term for all IVF treatments not using gonadotropins or other stimulating hormones for follicular growth. Von Wolff suggests naming these treatments “monofollicular IVF”, even if certain medications are used to support steps within the cycle to improve the outcome. He suggests further distinguishing between minimal stimulation IVF, and conventional IVF. In minimal stimulation IVF, a lower dose of stimulating hormones is used to stimulate the growth of some follicles. This could be named “oligofollicular IVF”. In conventional IVF, GnRH antagonists or agonists are used to suppress the LH surge and to stimulate the growth of many follicles, which should be named “polyfollicular IVF”.<sup>61</sup>



## 1.4. Perinatal health of children born after ART

The first successes in ART soon met with religious and ethical concerns. In ART, the treatment not only affects the parental couple, but also the offspring. Concerns followed about complications in pregnancy and birth, and over the health of children conceived using ART.<sup>74</sup> Perinatal outcomes for ART children have since been comprehensively studied. There are many risks, which are particularly associated with multiple births, but are also present in single births after ART.<sup>75</sup> The first systematic reviews on singletons with data from the 80's and 90's showed a twofold higher risk of preterm birth (PTB), low birthweight (LBW) and small-for-gestational age (SGA), in comparison to spontaneously conceived singletons.<sup>75,76</sup> Later systematic reviews and meta-analyses (after the year 2000) still found an odds ratio (OR) of 1.5 for preterm birth.<sup>77,78</sup> Anja Pinborg et al. found increased risks of preterm birth in spontaneously conceived children when time-to-pregnancy was more than one year (adjusted OR 1.35).<sup>78</sup> Furthermore, they found higher risks in ART singletons as compared to their spontaneously conceived siblings (aOR 1.27, 95% CI 1.08 – 1.49), suggesting that factors related to ART methods per se may still play a role.

Epigenetic modifications control the activity of genes, but do not change the DNA structure. They are either associated with the health and fertility levels of the parents, or are a consequence of the early environment of the embryo. The first epigenetic programming occurs during gametogenesis in either parent. A second wave of epigenetic reprogramming happens at fertilization with the demethylation of the paternal and maternal genomes.<sup>78,79</sup> Several studies show differences in DNA methylation levels in children born after ART.<sup>80-82</sup> However, a recent study demonstrates that this epigenetic changes seem not to persist into adult life.<sup>83</sup>

Researchers have identified various factors, which may increase the risk of ART causing epigenetic changes during conception, pregnancy and early life. These are:

- Hormonal stimulation
- Fertilisation
- In vitro culture
- Cryopreservation

The following section offers some insight in the possible associations.

### *Hormonal stimulation*

Hormonal stimulation may interfere with oocyte selection, follicular fluid and early pregnancy.<sup>84-86</sup> Epigenetic changes may occur during gametogenesis, and in genes critical to endometrial remodelling during early implantation.<sup>87</sup>

Different stimulation protocols used within ART have been comprehensively researched and discussed, with a focus on the type and total dose of hormones used.<sup>88,89</sup> Research suggests that the birthweight and gestational age of newborns is lower after gonadotropin stimulation.<sup>90–93</sup> This is especially true when women show a high response to the stimulation, which leads to supraphysiological estrogen levels around ovulation, and so to superovulation.<sup>94</sup> Low birthweight and small-for-gestational-age, as well as the risk of preterm birth, seem to be associated with high estrogen levels and a high number of oocytes.<sup>95–97</sup> However, the risk of low birth weight also seems to be influenced by parental characteristics and pregnancy conditions.<sup>98</sup>

### *Fertilisation*

In IVF, several sperms compete for fertilisation. In ICSI an embryologist arbitrarily selects a single sperm to inject it into the oocyte, which is quite invasive. However, compared to IVF, most large studies found similar or lower risks for PTB and LBW in singletons born after ICSI. A large cohort study found an association between ICSI and a higher risk of birth defects, but this was not confirmed by a meta-analysis.<sup>99,100</sup> Male infertility is inherited from the father by male offspring born after ICSI.<sup>101,102</sup>

### *In vitro culture*

Culture procedures in the laboratory seem to introduce epigenetic changes in the sensitive phase of foetal programming.<sup>103,104</sup> It has been shown that two culture media, from different manufacturers, lead to differences in birthweight. Although the components in the culture media are known, the manufacturers do not disclose the exact concentrations.<sup>105–108</sup>

Changes in Swiss law, and advances in culture techniques, have permitted embryo culture up to day five, until the embryo reaches the blastocyst stage. This enables the self-selection of viable embryos, and a better synchronisation with the maternal cycle. A Cochrane review showed increased live birth rates after fresh blastocyst transfer by OR 1.48 (95% confidence interval (CI) 1.20 – 1.82), as compared to cleavage stage transfer.<sup>109</sup> Blastocyst transfer may also lead to higher birthweight.<sup>110</sup> However, blastocyst transfer was also associated with a higher risk of preterm and very preterm delivery, although the risk of intrauterine growth restriction was lower.<sup>111</sup>

### *Cryopreservation*

To minimise the risks of hormonal stimulation to the onset of pregnancy, freeze-all strategies are becoming increasingly proposed. A single thawed embryo is transferred during a normal menstrual cycle, without gonadotropin stimulation of oocyte growth but only hormonal preparation of the endometrium. Babies born from the transfer of thawed embryos have a higher risk of increased birthweight and large baby syndrome.<sup>112–114</sup> A meta-analysis concluded there was a lower risk of

preterm delivery, low birth weight and small-for-gestational age. However, a systematic review and meta-analysis found the risks of preeclampsia and of hypertensive disorders during pregnancy, were found to be higher.<sup>115</sup> This result was confirmed by a large randomised controlled trial conducted in China, in which they also found a higher pregnancy rate after single frozen blastocyst transfer.

### *Multiple pregnancies*

Multiple pregnancies are increased in ART due to the transfer of more than one embryo. Often multiple embryos are available after hormonal stimulation. Despite the fact that multiple pregnancies are associated with higher risks, the transfer of multiple embryos increases pregnancy and live birth rates.<sup>116</sup> Many experts support the elective single embryo transfer (SET) strategy. Therefore, in some countries, laws or insurance policies encourage or require the use of SET.<sup>117</sup> Even when a singleton is born after the transfer of more than one embryo, there are increased risks. If one embryo does not develop further, this is called a vanishing twin. The remaining singleton is physiologically still seen as a twin during the pregnancy. This can lead to intrauterine growth restrictions, with subsequent lower birth weight and a higher risk of being SGA.<sup>118,119</sup>

### *Risks for the mother*

Hormonal stimulation likewise increases risks for the mother-to-be. The use of hormones is always associated with a higher risk for thrombosis in women. Furthermore, ovarian hyperstimulation syndrome (OHSS) is clearly associated with high-dose gonadotropin or clomiphene stimulation. The risks are generally not foreseeable, as they are dependent on the individual's reaction on the stimulation. OHSS is mainly characterised by increased vascular permeability and ovarian enlargement. OHSS can range from mild to severe, and in rare cases is even fatal. Moderate to severe cases may occur in 3-10% of cases.<sup>120</sup>

In extensive meta-analyses or cohort studies, the following risks have been found to significantly increase during pregnancy after ART: pregnancy-induced hypertension, gestational diabetes, placenta praevia, placental abruption, ante- or postpartum haemorrhage, and, in multiple pregnancies, the premature rupture of membranes. This puts the health of child and mother at risk of complications and preterm birth.<sup>121,122</sup> ART children are more frequently delivered by caesarean section. It is not clear whether this is due to parental wishes, whether complications occur more frequently or simply whether obstetricians tend to be especially careful.<sup>77,112,122</sup> However, an Italian study comparing the delivery of uncomplicated singleton term pregnancies still found higher odds of operative delivery for ART children (adjusted OR 1.40; 95% CI 1.01-1.95), and this is also true within the Bern IVF cohort.<sup>123</sup>

*Research on NC-IVF*

NC-IVF allows research into the influence of gonadotropin stimulation, as outcomes can be compared to those of cIVF. As SET is standard, multiple pregnancies can easily be avoided in NC-IVF. Research at the University Women's Hospital in Bern has proven NC-IVF to be less stressful for infertile patients.<sup>124</sup> It is less expensive but more time consuming per achieved pregnancy when compared to cIVF.<sup>66,125</sup> In NC-IVF, the quality of the embryo seems to be better, due to natural follicle selection and fewer alterations of the follicular fluid.<sup>126-128</sup> Implantation and placentation seem to be improved due to increased endometrium receptivity.<sup>85,86,129,130</sup> NC-IVF and minimal-stimulation IVF are valuable, cost-effective alternatives to cIVF, and it is important to investigate the possible reduction of further risks associated with ART by promoting NC-IVF.<sup>66,131</sup>

## 1.5. Long-term health of children born after ART

In David Barker's investigations into infant mortality and stroke, he found a relationship between conditions in early life and later health outcomes. At that time, low birthweight was the most frequent cause of infant mortality.<sup>132</sup> He developed the theory of developmental origins of health and disease (DOHaD).<sup>133</sup> In a Finnish cohort, in which fetal growth was measured, he identified fetal growth restriction, undernutrition and compensatory growth in childhood as the key risk factors associated with cardiovascular risk and type 2 diabetes. He postulated that the circumstances of conception, and conditions during pregnancy, may influence later health, even in adult life. Hunger and growth restriction in the womb may especially affect cardiometabolic outcomes.<sup>134</sup> Some concerning results have recently been published regarding the cardiovascular health of children born after ART. A Spanish research group found cardiovascular remodelling even during pregnancy in foetuses conceived through ART, which persisted until age 3.<sup>135,136</sup> A cohort study conducted in Switzerland found increased intima-media thickness, increased flow-mediated dilation, higher pulse wave velocity and higher blood pressure in children at age seven to nine born after ART.<sup>137</sup> These findings were later found to persist into adolescence (16-18 years).<sup>138</sup> A study of an ART cohort at the Netherlands found elevated blood pressure at age four, although this was not found to persist at age nine.<sup>139-141</sup> An Australian study of 193 ART and 86 non-ART adults did not find elevated vascular or cardiometabolic risks, when adjusted for important perinatal factors and quality of life.<sup>142</sup> A recent systematic review and meta-analysis including 19 studies with 2'112 ART and 4'096 non-ART children, found small but significantly higher blood pressure levels in ART children.<sup>143</sup>

Singletons born after IVF perform well in neurological and mental development, and show normal intelligence, although Zhu et al. found a modest delay in psychomotor developments in a large Danish birth cohort.<sup>144,145</sup> However, the duration of infertility seems to be associated with lower cognition and behavioural performance.<sup>146</sup> The incidence of autism spectrum disorders seems to be inconclusive, but rather not to be elevated in singletons, but is in multiples following ART.<sup>147,148</sup> Initial results in adolescents show no persistence of autism spectrum disorders.<sup>149</sup> A tendency toward an increased risk for cerebral palsy has been observed, mainly associated with preterm birth or multiples.<sup>144,145</sup> No difference has been identified regarding growth (weight & height) in ART children in comparison to spontaneously conceived children.<sup>150-152</sup>

Cancer is very rare during childhood; it is therefore difficult to identify differences between ART and non-ART children. Two systematic reviews and meta-analyses summarized several large cohort- and linkage studies, and found a small but significantly increased risk for all types of childhood cancer in children born following ART.<sup>153,154</sup> The more recent review from 2019 found that risks were mainly

increased for leukaemia and retinoblastoma.<sup>154</sup> Two recent studies from the USA and Denmark, not yet included in the latest reviews, found a significant association between childhood cancer and frozen embryo transfer.<sup>155,156</sup>

The question of whether children conceived through ART are at an increased risk of infections, especially severe infections requiring hospitalisation, has mainly been studied by looking at general health and morbidity or hospital admissions.<sup>157–163</sup> A somewhat increased risk was mainly associated with multiple births and lower birthweight.<sup>160,163</sup> For infectious and parasitic diseases, Kettner et al. found in their review eight studies presenting odds ratios (OR) between 0.37 – 5.7.<sup>164</sup> For the burden of otitis media, acute tonsillitis, urinary infections or pneumonia, Kallen et al. found a higher odds (OR 1.08 – 1.33) among ART children, in a population based study,<sup>161</sup> whereas Pinborg et al. did not find differences in a questionnaire-based study in which they compared ART twins to ART singletons and SC twins.<sup>160</sup>

Only a few immune-mediated diseases have been studied in ART children. Of these, asthma is probably the most studied.<sup>165–170</sup> Many of these studies show an association between ART and increased odds ratios from 1.9 to 6.0.<sup>157,159,161,167,168</sup> Those studies which have information on parental subfertility (time to conception), all found a higher risk of asthma among the spontaneously conceived children of subfertile parents, as compared to the children of parents without fertility problems.<sup>168,169,171,172</sup> Kuiper et al. found the higher use of asthma medication in ART children to be associated with hormonal-stimulated IVF, as compared to modified natural cycle IVF.<sup>173</sup> Two studies on adolescents and young adults describe a higher prevalence of breathing problems and asthma in ART children; however, this difference was no longer observed in adolescence.<sup>142,166</sup>

Another important disease to look at is type 1 diabetes. Only two studies have been published on the topic, both very recently.<sup>174,175</sup> Norrman et al. found increased HR for diabetes type 1 in an unadjusted analysis, but no longer once adjusted. They also observed an association between type 1 diabetes with FET.<sup>175</sup> Kettner et al. found no association between type 1 diabetes and fertility treatment in a primary analysis, but found some increased risk associated with follicle-stimulating hormones in a secondary analysis.<sup>174</sup> However, while these two studies remained somewhat inconclusive, there is evidence that glucose metabolism might be altered by ART.<sup>143,176</sup> This may increase the risk of the development of type 2 diabetes later in life. The DOHaD theory also supports this hypothesis. As low birthweight is associated with impaired metabolic functions, a higher susceptibility to type 2 diabetes might be expected.<sup>177,178</sup>

## 2. Methods and data

In the following section, the study designs and data sets used in the different projects included in this thesis will be presented.

### 2.1. The Bern IVF Cohort

The main data source for this thesis is the Bern IVF Cohort. I coordinated the cohort's establishment by helping secure ethical approval, setting up the RedCap database and recruiting the participants. One of the main aims of my thesis was the set-up of a control group of spontaneously conceived children. I performed the matching of cohort members with control group members, and coordinated the participant recruitment and data collection.

The aim of the Bern IVF Cohort is to compare different fertility treatments, mainly NC-IVF and cIVF. NC-IVF avoids gonadotropins for stimulation of oocyte growth. cIVF uses  $\geq 150$  IU of gonadotropins per day for the stimulation. The Bern IVF Cohort allows comparison of outcomes between the two treatments. This allows estimating influence of hormonal stimulation on pregnancy and health of children. In Bern, NC-IVF and cIVF are offered, and sufficient numbers of both treatments are conducted to allow comparison. The cohort is therefore unique, both in Switzerland and even at an international level.

#### 2.1.1. Bern IVF Cohort - description

The Bern IVF cohort was established in 2016-2017, retrospectively including women treated from 2010 to 2015, and with the aim of including women treated in 2016 and 2017. The registration of women treated in 2017 is not yet complete. Data is collected on parental characteristics, medical and fertility history, ART treatment, pregnancy complications and outcome, the characteristics of births and perinatal health. Follow-up data on breastfeeding duration and child growth until age four is also collected. All participants are contacted for informed consent, and receive a newsletter every year. The newsletter contains information about current and planned projects, and helps in keeping addresses updated. The Bern IVF cohort has ethical approval, issued by the cantonal ethics committee of Bern (No. 2012-00235).

Inclusion criteria: All couples (mothers and fathers) where the woman was 18-42 years at the time of treatment, and all children born after successful IVF treatment and fresh embryo transfer performed at the Bern University Hospital from 2010-2017.

Exclusion criteria: Children born after FET, and women whose treatment cycles did not lead to a pregnancy. Pregnancy as defined as having had one positive pregnancy test for hCG.

In 2017, the law governing reproductive medicine in Switzerland was changed, allowing for a longer duration of embryo culture. This change was adopted from October 2017 onwards at the Bern University Hospital. Women treated after this change are not recruited into the cohort, as the duration of embryo culture is considered an important factor affecting perinatal outcomes.<sup>109</sup>

The Bern IVF Cohort currently includes n=319 women, with a total of n=488 pregnancies. Of the pregnancies n=190 ended in a miscarriage and n=298 in a delivery (272 singletons, 25 twins, 1 triplet), with 269 singletons born alive (Table 1). (Article 1 and Article 2)

Table 1: Live births per treatment in the Bern IVF Cohort (per achieved pregnancy)

	Pregnancies	Adverse pregnancy outcomes			Livebirths	
		Biochem. only	Miscarriages	Perinatal death*	Singletons (LBR)	Multiples (twins/triplets)
<b>NC-IVF (A)</b>	110	14	26		70 (63.6%)	0
<b>NC-IVF (C) with CC</b>	124	21	25	1	74 (62.1%)	3
<b>mIVF (D) with CC</b>	25	4	2		17 (76.0%)	2
<b>mIVF (E)</b>	47	10	9	1	23 (57.4%)	4
<b>cIVF</b>	182	44	35	1	85 (56.0%)	16 /1
<b>Total</b>	<b>488</b>	<b>93</b>	<b>97</b>	<b>3</b>	<b>269</b>	<b>26 (53)</b>

LBR: Live birth rate including multiples; NC-IVF: Natural cycle IVF, mIVF: minimal stimulation IVF, CC: Clomiphene citrate, cIVF: conventional stimulated IVF

\*Perinatal death is defined as death from 28 gestational weeks until 7 days after birth

Table 2: Singletons born alive by treatment scheme and year of OPU in the Bern IVF Cohort

Treatment	2010	2011	2012	2013	2014	2015	2016	Total
<b>NC-IVF (A)</b>	10	1	14	3	11	12	19	70
<b>NC-IVF (C) with CC</b>	5	5	9	14	9	18	14	74
<b>mIVF (D) with CC</b>	0	0	0	5	0	6	6	17
<b>mIVF (E)</b>	2	0	2	5	5	2	7	23
<b>cIVF</b>	15	17	7	7	6	12	21	85
<b>Total</b>	<b>32</b>	<b>23</b>	<b>32</b>	<b>34</b>	<b>31</b>	<b>50</b>	<b>67</b>	<b>269</b>

NC-IVF: Natural cycle IVF, mIVF: minimal stimulation IVF, CC: Clomiphene citrate, cIVF: conventional stimulated IVF



### 2.1.2. The Bern IVF Cohort: establishment of control group

In 2018, the decision was made to establish a control group of spontaneously conceived children for comparison to the IVF children of the Bern IVF Cohort Study. The recruitment of possible controls was conducted through the obstetrics department of the University Women's Hospital in Bern. Women coming for ultrasound in the first trimester of their pregnancy were matched with the mothers of singletons from the Bern IVF cohort. It was decided to only match women treated with NC-IVF or cIVF. A total of n=155 women were matched in a 1:3 ratio. The matching criteria were the age of the mother (+/- 1 year), the parity (primipara vs multipara) and the (planned) due date (+/- 6 months).

Exclusion criteria were the same as for ART treatment at the Bern University Women's hospital: Mothers with problems of drug abuse or parents infected by human immunodeficiency virus (HIV) were excluded. Additionally couples, which used more than 12 months to become pregnant were declared as subfertile. Couples who used ART treatment to achieve the pregnancy were excluded as well. To identify the couples to exclude, a questionnaire was sent with the patient information and the informed consent form. The plan was to match 465 controls. 398 women were eligible for contact. A first reminder letter was sent to 255 (65.5%) women and 227 got a phone call as a second reminder (58.4%) Figure 1 shows the procedure for the contact of the controls. Figure 2 shows the population of the control group. Finally, complete data on 268 women, their pregnancies and births, was available.




Figure 1: Contact of controls and reminders, process to retrieve informed consent




Figure 2: Final population of the control group \* either general consent or no documented refusal available at Inselspital. ART: Assisted reproductive technologies, HIV: Human immunodeficiency virus

## 2.2. The Swiss Infant Feeding Study

The Swiss Infant Feeding Study (SWIFS) was the third study on the prevalence and duration of breastfeeding and infant nutrition in Switzerland. It was conducted by the Swiss Tropical and Public Health Institute at the University of Basel. It is a cross-sectional study using written postal questionnaires. Data was collected on social-economic status, nationality and lifestyle, alongside information on pregnancy and birth. Additionally, in 2014, information on employment conditions, child and maternal health, health-related behaviour and social networks was collected. The questionnaire also contained a 24-hour nutrition protocol. The Swiss Parent Counselling Services (Mütter- und Väterberatungsstellen) randomly recruited mothers from the German, French and Italian speaking regions of Switzerland. They sent a reminder two weeks after the first questionnaire. 40% (n=1650) of the questionnaires were returned.<sup>179</sup>

The Swiss Tropical and Public Health Institute provided the data they used to analyse breastfeeding duration in Switzerland during the first year of life (n=1421). It served as reference group to the breastfeeding data from the Bern IVF Cohort. (Article 2)

## 2.3. Endometrial thickness in women after NC-IVF

This was a retrospective cohort in which 225 women undergoing their first NC-IVF cycle were identified. 111 did not have subsequent embryo transfer, and nine were excluded for other reasons (endometriosis and TESE). In this sample of 105 women who met the inclusion criteria, the influence of endometrial thickness on pregnancy rates is analysed. In NC-IVF, the endometrium is not influenced by the hormonal stimulation of follicular growth. Research on the association between endometrial thickness and pregnancy rates has mostly been done on stimulated IVF cycles. (Article 3)

## 2.4. Women with hysteroscopy assessment

A cohort of 217 women who had a planned hysteroscopy assessment for different reasons between 2014-2019 was set up at the Bern University Women's Hospital. Women diagnosed with RIF and RPL usually have a hysteroscopy assessment in order to identify possible causes. 127 women did fulfil the definitions of repeated implantation failure and recurrent pregnancy loss. This group of women was used for our retrospective analysis on time-to-pregnancy and time to live birth after the diagnosis and treatment of chronic endometritis. (Article 4)



### 3. Objectives of the thesis

The aim of this thesis is to contribute to the understanding of factors influencing pregnancy and perinatal outcomes after different ART treatments for infertility.

Specific objectives included:

- 1) To further develop the Bern IVF cohort by including patients treated in 2016 and setting up a control group of spontaneously conceived children
- 2) To evaluate perinatal outcomes within the Bern IVF cohort: birthweight, gestational age and birthweight percentile (Article 1)
- 3) To assess breastfeeding behaviour and duration of mothers with children born within the Bern IVF cohort in comparison to a random sample of mothers in Switzerland (Article 2)
- 4) To support the understanding of CE in women with RIF and RPL and to analyse time-to-pregnancy and live birth depending on the biopsy and subsequent treatment in cases of CE (Article 4)
- 5) To support the research on fertility and fertility treatments and their outcomes in the division of gynaecological endocrinology (Article 3)



## 4. References

1. Zegers-Hochschild F, David Adamson G, Dyer S, et al. The International Glossary on Infertility and Fertility Care, 2017. *Hum Reprod*. 2017;32(9):1786-1801.
2. <https://www.who.int/reproductivehealth/topics/infertility/multiple-definitions/en/>. WHO | Multiple definitions of infertility.  
<https://www.who.int/reproductivehealth/topics/infertility/multiple-definitions/en/>.
3. Inhorn MC, Patrizio P. Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century. *Hum Reprod Update*. 2015;21(4):411-426.
4. Maung HH. Is infertility a disease and does it matter? *Bioethics*. 2019;33(1):43-53.
5. Vander Borgh M, Wyns C. Fertility and infertility: Definition and epidemiology. *Clin Biochem*. 2018;62:2-10.
6. Rutstein SO, Shah IH. Infecundity, infertility, and childlessness in developing countries. *DHS Comp Reports*. 2004;9:13-50.
7. Mascarenhas MN, Flaxman SR, Boerma T, Vanderpoel S, Stevens GA. National, Regional, and Global Trends in Infertility Prevalence Since 1990: A Systematic Analysis of 277 Health Surveys. Low N, ed. *PLoS Med*. 2012;9(12):1-12.
8. Ombelet W, Cooke I, Dyer S, Serour G, Devroey P. Infertility and the provision of infertility medical services in developing countries. *Hum Reprod Update*. 2008;14(6):605-621.
9. Gnoth C, Godehardt E, Frank-Herrmann P, Friol K, Tigges J, Freundl G. Definition and prevalence of subfertility and infertility. *Hum Reprod*. 2005;20(5):1144-1147.
10. Worldbank. Fertility rate, total (births per woman) | Data.  
<https://data.worldbank.org/indicator/SP.DYN.TFRT.IN>.
11. Zaidi B, Morgan SP. The Second Demographic Transition Theory: A Review and Appraisal. *Annu Rev Sociol*. 2017;43:473-492.
12. Van De Kaa DJ. Europe's second demographic transition. *Popul Bull*. 1987;42(1):1-59.
13. Federal Statistical Office. Fruchtbarkeit.  
<https://www.bfs.admin.ch/bfs/de/home/statistiken/bevoelkerung/geburten-todesfaelle/fruchtbarkeit.html>.
14. te Velde E, Habbema D, Leridon H, Eijkemans M. The effect of postponement of first motherhood on permanent involuntary childlessness and total fertility rate in six European countries since the 1970s. *Hum Reprod*. 2012;27(4):1179-1183.
15. Committee Opinion No. 589 ASRM Pages. Female age-related fertility decline. *Fertil Steril*. 2014;101(3):633-634.

16. te Velde ER, Pearson PL. The variability of female reproductive ageing. *Hum Reprod Update*. 2002;8(2):141-154.
17. Luborsky J, Meyer P, Sowers M, Gold E, Santoro N. Premature menopause in multi-ethnic population study of the menopause transition. *Hum Reprod*. 2002;18(1):199-206.
18. Pedro J, Brandão T, Schmidt L, Costa ME, Martins M V. What do people know about fertility? A systematic review on fertility awareness and its associated factors. *Ups J Med Sci*. 2018;123(2):71-81.
19. Templeton A, Morris JK, Parslow W. Factors that affect outcome of in-vitro fertilisation treatment. *Lancet*. 1996;348:1402-1406.
20. Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E. American association of clinical endocrinologists, American college of endocrinology, and androgen excess and pcos society disease state clinical review: Guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - Part 1. *Endocr Pract*. 2015;21(11):1291-1300.
21. Goldrat O, Delbaere A. PCOS: update and diagnostic approach. *Clin Biochem*. 2018;62:24-31.
22. Female subfertility. *Nat Rev Dis Prim*. 2019;5(1):8.
23. Hart R. Physiological aspects of female fertility: role of the environment, modern lifestyle, and genetics. *Physiol Rev*. 2016;96:873-909.
24. Vlahos NF, Theodoridis TD, Partsinevelos GA. Myomas and Adenomyosis: Impact on Reproductive Outcome. *Biomed Res Int*. 2017;2017:1-14.
25. von Wolff M, Stute P. *Gynäkologische Endokrinologie Und Reproduktionsmedizin*. Stuttgart: Schattauer GmbH, Hölderlinstrasse 3, 70174 Stuttgart, Germany; 2013.
26. Santi A, Rohner S. Anatomische Ursachen bei habituellen Aborten: Diagnostik und Therapie. *Gynakologische Endokrinol*. 2013;11(2):89-94.
27. Tanbo T, Fedorcsak P. Endometriosis-associated infertility: aspects of pathophysiological mechanisms and treatment options. *Acta Obstet Gynecol Scand*. 2017;96(6):659-667.
28. Kohl Schwartz AS, Wölfler MM, Mitter V, et al. Endometriosis, especially mild disease: a risk factor for miscarriages. *Fertil Steril*. 2017;108(5):806-814.
29. Viganò P, Parazzini F, Somigliana E, Vercellini P. Endometriosis: epidemiology and aetiological factors. *Best Pract Res Clin Obstet Gynaecol*. 2004;18(2):177-200.
30. Cramer DW, Missmer SA. The epidemiology of endometriosis. In: *Annals of the New York Academy of Sciences*. Vol 955. ; 2002:11-22.
31. Jungwirth A, Giwercman A, Tournaye H, et al. European association of urology guidelines on male infertility: The 2012 update. *Eur Urol*. 2012;62(2):324-332.



32. Mann U, Shiff B, Patel P. Reasons for worldwide decline in male fertility. *Curr Opin Urol*. March 2020:1.
33. Rahban R, Priskorn L, Senn A, et al. Semen quality of young men in Switzerland: a nationwide cross-sectional population-based study. *Andrology*. 2019;7(6):818-826.
34. Nassan FL, Chavarro JE, Tanrikut C. Diet and men's fertility: does diet affect sperm quality? *Fertil Steril*. 2018;110(4):570-577.
35. Mima M, Greenwald D, Ohlander S. Environmental Toxins and Male Fertility. *Curr Urol Rep*. 2018;19(7):1-8.
36. Babakhanzadeh E, Nazari M, Ghasemifar S, Khodadadian A. Some of the factors involved in male infertility: A prospective review. *Int J Gen Med*. 2020;13:29-41.
37. Gleicher N, Barad D. Unexplained infertility: Does it really exist? *Hum Reprod*. 2006;21(8):1951-1955.
38. Ray A, Shah A, Gudi A, Homburg R. Unexplained infertility: an update and review of practice. *Reprod Biomed Online*. 2012;24(6):591-602.
39. Palomba S, Daolio J, Romeo S, Battaglia FA, Marci R, La Sala GB. Lifestyle and fertility: The influence of stress and quality of life on female fertility 11 Medical and Health Sciences 1114 Paediatrics and Reproductive Medicine Rosario Pivonello. *Reprod Biol Endocrinol*. 2018;16(1):1-11.
40. De Angelis C, Nardone A, Garifalos F, et al. Smoke, alcohol and drug addiction and female fertility. *Reprod Biol Endocrinol*. 2020;18(21):1-26.
41. Coughlan C, Ledger W, Wang Q, et al. Recurrent implantation failure: Definition and management. *Reprod Biomed Online*. 2014;28(1):14-38.
42. Von Wolff M. Habituelle Aborte. *Ther Umschau*. 2016;73(7):363-369.
43. Bender Atik R, Christiansen OB, Elson J, et al. ESHRE guideline: recurrent pregnancy loss. *Hum Reprod Open*. 2018;2018(2):1-12.
44. El Hachem H, Crepaux V, May-Panloup P, Descamps P, Legendre G, Bouet PE. Recurrent pregnancy loss: Current perspectives. *Int J Womens Health*. 2017;9:331-345.
45. Bashiri A, Halper KI, Orvieto R. Recurrent Implantation Failure-update overview on etiology, diagnosis, treatment and future directions 11 Medical and Health Sciences 1114 Paediatrics and Reproductive Medicine. *Reprod Biol Endocrinol*. 2018;16(121):1-18.
46. Bellver J, Simón C. Implantation failure of endometrial origin: What is new? *Curr Opin Obstet Gynecol*. 2018;30(4):229-236.
47. Kimura F, Takebayashi A, Ishida M, et al. Review: Chronic endometritis and its effect on reproduction. *J Obstet Gynaecol Res*. 2019;45(5):951-960.

48. Kitaya K, Takeuchi T, Mizuta S, Matsubayashi H, Ishikawa T. Endometritis, new time, new concepts. *Fertil Steril*. 2018;110(3):344-350.
49. Vitagliano A, Saccardi C, Noventa M, et al. Effects of chronic endometritis therapy on in vitro fertilization outcome in women with repeated implantation failure: a systematic review and meta-analysis. *Fertil Steril*. 2018;110(1):103-112.
50. Kamphuis E, Bhattacharya S, van der Veen F, Mol B, Templeton A, for the Evidence Based IVF Group. Are we overusing IVF? *BMJ*. 2014;348(g252):1-5.
51. Steptoe PC, Edwards RG. Birth after the reimplantation of a human embryo. *Lancet*. 1978;2:366.
52. Berg Brigham K, Cadier B, Chevreul K. The diversity of regulation and public financing of IVF in Europe and its impact on utilization. *Hum Reprod*. 2013;28(3):666-675.
53. Insogna IG, Ginsburg ES. Infertility, Inequality, and How Lack of Insurance Coverage Compromises Reproductive Autonomy. *AMA J Ethics*. 2018;20(12):E1152-E1159.
54. De Geyter C, Calhaz-Jorge C, Kupka M, et al. ART in Europe, 2015: results, generated from European registries by ESHRE. *Hum Reprod Open*. 2019:1-17.
55. Niederberger C, Pellicer A, Cohen J, et al. Forty years of IVF. *Fertil Steril*. 2018;110(2):185-324.e5.
56. Gnoth C, Maxrath B, Skonieczny T, Friol K, Godehardt E, Tigges J. Final ART success rates: a 10 years survey. *Hum Reprod*. 2011;26(8):2239-2246.
57. Lechner L, Bolman C, van Dalen A. Definite involuntary childlessness: Associations between coping, social support and psychological distress. *Hum Reprod*. 2007;22(1):288-294.
58. Martins M V., Costa P, Peterson BD, Costa ME, Schmidt L. Marital stability and repartnering: Infertility-related stress trajectories of unsuccessful fertility treatment. *Fertil Steril*. 2014;102(6):1716-1722.
59. Van Beers BC. Is Europe 'giving in to baby markets'? 1 reproductive tourism in Europe and the gradual erosion of existing legal limits to reproductive markets. *Med Law Rev*. 2014;23(1):103-134.
60. von Wolff M, Kohl Schwartz A, Stute P, et al. Follicular flushing in natural cycle IVF does not affect the luteal phase – a prospective controlled study. *Reprod Biomed Online*. 2017;35(1):37-41.
61. von Wolff M. The role of Natural Cycle IVF in assisted reproduction. *Best Pract Res Clin Endocrinol Metab*. 2019;33(1):35-45.
62. von Wolff M, Nitzschke M, Stute P, Bitterlich N, Rohner S. Low-dosage clomiphene reduces premature ovulation rates and increases transfer rates in natural-cycle IVF. *Reprod Biomed Online*. 2014;29(2):209-215.

63. Kawachiya S, Matsumoto T, Bodri D, Kato K, Takehara Y, Kato O. Short-term, low-dose, non-steroidal anti-inflammatory drug application diminishes premature ovulation in natural-cycle IVF. *Reprod Biomed Online*. 2012;24(3):308-313.
64. Rijken-Zijlstra TM, Haadsma ML, Hammer C, et al. Effectiveness of indometacin to prevent ovulation in modified natural-cycle IVF: A randomized controlled trial. *Reprod Biomed Online*. 2013;27(3):297-304.
65. Teramoto S, Kato O. Minimal ovarian stimulation with clomiphene citrate: a large-scale retrospective study. *Reprod Biomed Online*. 2007;15(2):134-148.
66. von Wolff M, Rohner S, Santi A, Stute P, Popovici R, Weiss B. Modified natural cycle in vitro fertilization - An alternative in vitro fertilization treatment with lower costs per achieved pregnancy but longer treatment time. *J Reprod Med*. 2014;59(11-12):553-559.
67. Kato K, Takehara Y, Segawa T, et al. Minimal ovarian stimulation combined with elective single embryo transfer policy: Age-specific results of a large, single-centre, Japanese cohort. *Reprod Biol Endocrinol*. 2012;10(35):1-7.
68. Gleicher N, Vietzke M, Vidali A. Bye-bye urinary gonadotrophins?: Recombinant FSH: A real progress in ovulation induction and IVF? *Hum Reprod*. 2003;18(3):476-482.
69. Maheshwari A, Gibreel A, Siristatidis CS, Bhattacharya S. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Maheshwari A, ed. *Cochrane Database Syst Rev*. 2011;(8):Art. No.: CD006919.
70. Xiao JS, Su CM, Zeng XT. Comparisons of GnRH antagonist versus GnRH agonist protocol in supposed normal ovarian responders undergoing ivf: A systematic review and meta-analysis. *PLoS One*. 2014;9(9):e106854.
71. Al-Inany H, Youssef M, Ayeleke R, Brown J, Lam W, Broekmans F. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology ( Review ). *Cochrane Database Syst Rev*. 2016;(4):Art. No.: CD001750.
72. Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used ? A systematic review and meta-analysis. *Hum Reprod Update*. 2006;12(6):651-671.
73. Abdelhakim AM, Abd-ElGawad M, Hussein RS, Abbas AM. Vaginal versus intramuscular progesterone for luteal phase support in assisted reproductive techniques: a systematic review and meta-analysis of randomized controlled trials. *Gynecol Endocrinol*. February 2020:1-9.
74. Cohen ME. The "brave new baby" and the law: fashioning remedies for the victims of in vitro fertilization. *Am J Law Med*. 1978;4(3):319-336.
75. Helmerhorst FM. Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies. *Br Med J*. 2004;328(7434):261-266.

76. Jackson RA, Gibson KA, Wu YW, Croughan MS. Perinatal outcomes in singletons following in vitro fertilization: a meta-analysis. *Obstet Gynecol.* 2004;103(3):551-563.
77. Pandey S, Shetty A, Hamilton M, Bhattacharya S, Maheshwari A. Obstetric and perinatal outcomes in singleton pregnancies resulting from IVF/ICSI: a systematic review and meta-analysis. *Hum Reprod Update.* 2012;18(5):485-503.
78. Pinborg A, Wennerholm UB, Romundstad LB, et al. Why do singletons conceived after assisted reproduction technology have adverse perinatal outcome? Systematic review and meta-analysis. *Hum Reprod Update.* 2013;19(2):87-104.
79. Hales BF, Grenier L, Lalancette C, Robaire B. Epigenetic programming: From gametes to blastocyst. *Birth Defects Res Part A Clin Mol Teratol.* 2011;91(8):652-665.
80. Lazaraviciute G, Kauser M, Bhattacharya S, Haggarty P, Bhattacharya S. A systematic review and meta-analysis of DNA methylation levels and imprinting disorders in children conceived by IVF/ICSI compared with children conceived spontaneously. *Hum Reprod Update.* 2014;20(6):840-852.
81. Vermeiden JPW, Bernardus RE. Are imprinting disorders more prevalent after human in vitro fertilization or intracytoplasmic sperm injection? *Fertil Steril.* 2013;99(3):642-651.
82. Choux C, Binquet C, Carmignac V, et al. The epigenetic control of transposable elements and imprinted genes in newborns is affected by the mode of conception: ART versus spontaneous conception without underlying infertility. *Hum Reprod.* 2018;33(2):331-340.
83. Novakovic B, Lewis S, Halliday J, et al. Assisted reproductive technologies are associated with limited epigenetic variation at birth that largely resolves by adulthood. *Nat Commun.* 2019;10(1):3922.
84. Kollmann Z, Schneider S, Fux M, Bersinger NA, Von Wolff M. Gonadotrophin stimulation in IVF alters the immune cell profile in follicular fluid and the cytokine concentrations in follicular fluid and serum. *Hum Reprod.* 2017;32(4):820-831.
85. Bourgain C, Devroey P. The endometrium in stimulated cycles for IVF. *Hum Reprod Update.* 2003;9(6):515-522.
86. Devroey P, Bourgain C, Macklon NS, Fauser BCJM. Reproductive biology and IVF: Ovarian stimulation and endometrial receptivity. *Trends Endocrinol Metab.* 2004;15(2):84-90.
87. Senapati S, Wang F, Ord T, Coutifaris C, Feng R, Mainigi M. Superovulation alters the expression of endometrial genes critical to tissue remodeling and placentation. *J Assist Reprod Genet.* 2018;35(10):1799-1808.
88. Fatemi HM, Blockeel C, Devroey P. Ovarian Stimulation: Today and Tomorrow. *Curr Pharm Biotechnol.* 2012;13(3):392-397.
89. Alper MM, Fauser BC. Ovarian stimulation protocols for IVF: is more better than less? *Reprod Biomed Online.* 2017;34(4):345-353.

90. Nakashima A, Araki R, Tani H, et al. Implications of assisted reproductive technologies on term singleton birth weight: An analysis of 25,777 children in the national assisted reproduction registry of Japan. *Fertil Steril*. 2013;99(2):450-455.
91. Roesner S, Pflaumer U, Germeyer A, Montag M, Strowitzki T, Toth B. Natural cycle IVF: Evaluation of 463 cycles and summary of the current literature. *Arch Gynecol Obstet*. 2014;289(6):1347-1354.
92. Mak W, Kondapalli LA, Celia G, Gordon J, Dimattina M, Payson M. Natural cycle IVF reduces the risk of low birthweight infants compared with conventional stimulated IVF. *Hum Reprod*. 2016;31(4):789-794.
93. Kamath MS, Kirubakaran R, Mascarenhas M, Sunkara SK. Perinatal outcomes after stimulated versus natural cycle IVF: a systematic review and meta-analysis. *Reprod Biomed Online*. 2018;36(1):94-101.
94. Kohl Schwartz AS, Mitter VR, Amylidi-Mohr S, et al. The greater incidence of small-for-gestational-age newborns after gonadotropin-stimulated in vitro fertilization with a supraphysiological estradiol level on ovulation trigger day. *Acta Obstet Gynecol Scand*. 2019;98(12):1575-1584.
95. Pereira N, Reichman DE, Goldschlag DE, Lekovich JP, Rosenwaks Z. Impact of elevated peak serum estradiol levels during controlled ovarian hyperstimulation on the birth weight of term singletons from fresh IVF-ET cycles. *J Assist Reprod Genet*. 2015;32:527-532.
96. Pereira N, Elias RT, Christos PJ, et al. Supraphysiologic estradiol is an independent predictor of low birth weight in full-term singletons born after fresh embryo transfer. *Hum Reprod*. 2017;32(7):1410-1417.
97. Sunkara SK, La Marca A, Seed PT, Khalaf Y. Increased risk of preterm birth and low birthweight with very high number of oocytes following IVF: An analysis of 65 868 singleton live birth outcomes. *Hum Reprod*. 2015;30(6):1473-1480.
98. Pelinck MJ, Hadders-Algra M, Haadsma ML, et al. Is the birthweight of singletons born after IVF reduced by ovarian stimulation or by IVF laboratory procedures? *Reprod Biomed Online*. 2010;21:245-251.
99. Davies MJ, Moore VM, Willson KJ, et al. Reproductive technologies and the risk of birth defects. *N Engl J Med*. 2012;366(19):1803-1813.
100. Wen J, Jiang J, Ding C, et al. Birth defects in children conceived by in vitro fertilization and intracytoplasmic sperm injection: a meta-analysis. *Fertil Steril*. 2012;97(6):1331-1337.e4.
101. Belva F, Bonduelle M, Roelants M, et al. Semen quality of young adult ICSI offspring: the first results. *Hum Reprod*. 2016;31(12):2811-2820.
102. Belva F, Bonduelle M, Tournaye H. Endocrine and reproductive profile of boys and young adults conceived after ICSI. *Curr Opin Obstet Gynecol*. 2019;31(3):163-169.

103. Whitelaw N, Bhattacharya S, Hoad G, Horgan GW, Hamilton M, Haggarty P. Epigenetic status in the offspring of spontaneous and assisted conception. *Hum Reprod.* 2014;29(7):1452-1458.
104. Pinborg A, Loft A, Romundstad LB, et al. Epigenetics and assisted reproductive technologies. *Acta Obstet Gynecol Scand.* 2016;95(1):10-15.
105. Dumoulin JC, Land JA, Van Montfoort AP, et al. Effect of in vitro culture of human embryos on birthweight of newborns. *Hum Reprod.* 2010;25(3):605-612.
106. Kleijkers SHM, Van Montfoort APA, Smits LJM, et al. IVF culture medium affects post-natal weight in humans during the first 2 years of life. *Hum Reprod.* 2014;29(4):661-669.
107. Zandstra H, Van Montfoort APA, Dumoulin JCM. Does the type of culture medium used influence birthweight of children born after IVF? *Hum Reprod.* 2015;30(3):530-542.
108. Kleijkers SHM, Mantikou E, Slappendel E, et al. Influence of embryo culture medium (G5 and HTF) on pregnancy and perinatal outcome after IVF: A multicenter RCT. *Hum Reprod.* 2016;31(10):2219-2230.
109. Glujovsky D, Farquhar C, Quinteiro Retamar AM, Alvarez Sedo CR, Blake D. Cleavage stage versus blastocyst stage embryo transfer in assisted reproductive technology. *Cochrane Database Syst Rev.* 2016;2016(6).
110. Zhu J, Lin S, Li M, et al. Effect of in vitro culture period on birthweight of singleton newborns. *Hum Reprod.* 2014;29(3):448-454.
111. Maheshwari A, Kalampokas T, Davidson J, Bhattacharya S. Obstetric and perinatal outcomes in singleton pregnancies resulting from the transfer of blastocyst-stage versus cleavage-stage embryos generated through in vitro fertilization treatment: A systematic review and meta-analysis. *Fertil Steril.* 2013;100(6):1615-1621.
112. Wennerholm UB, Henningsen AKA, Romundstad LB, et al. Perinatal outcomes of children born after frozen-thawed embryo transfer: A Nordic cohort study from the CoNARTaS group. *Hum Reprod.* 2013;28(9):2545-2553.
113. Pinborg A, Henningsen AA, Loft A, Malchau SS, Forman J, Andersen AN. Large baby syndrome in singletons born after frozen embryo transfer (FET): is it due to maternal factors or the cryotechnique? *Hum Reprod.* 2014;29(3):618-627.
114. Spijkers S, Lens JW, Schats R, Lambalk CB. Fresh and Frozen-Thawed Embryo Transfer Compared to Natural Conception: Differences in Perinatal Outcome. *Gynecol Obstet Invest.* 2017;82(6):538-546.
115. Maheshwari A, Pandey S, Amalraj Raja E, Shetty A, Hamilton M, Bhattacharya S. Is frozen embryo transfer better for mothers and babies? Can cumulative meta-analysis provide a definitive answer? *Hum Reprod Update.* 2018;24(1):35-58.

116. Murray SR, Norman JE. Multiple pregnancies following assisted reproductive technologies - A happy consequence or double trouble? *Semin Fetal Neonatal Med.* 2014.
117. Henningsen AA, Gissler M, Skjaerven R, et al. Trends in perinatal health after assisted reproduction: a Nordic study from the CoNARTaS group. *Hum Reprod.* 2015;30(3):710-716.
118. Pinborg A, Lidegaard Ø, la Cour Freiesleben N, Andersen AN. Consequences of vanishing twins in IVF/ICSI pregnancies. *Hum Reprod.* 2005;20(10):2821-2829.
119. Pinborg A, Lidegaard Ø, La Cour Freiesleben N, Andersen AN. Vanishing twins: A predictor of small-for-gestational age in IVF singletons. *Hum Reprod.* 2007;22(10):2707-2714.
120. Nastri CO, Teixeira DM, Moroni RM, Leitão VMS, Martins WP. Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention. *Ultrasound Obstet Gynecol.* 2015;45(4):377-393.
121. Qin J, Wang H, Sheng X, Liang D, Tan H, Xia J. Pregnancy-related complications and adverse pregnancy outcomes in multiple pregnancies resulting from assisted reproductive technology: A meta-analysis of cohort studies. *Fertil Steril.* 2015;103(6):1492-1508.
122. Qin J, Liu X, Sheng X, Wang H, Gao S. Assisted reproductive technology and the risk of pregnancy-related complications and adverse pregnancy outcomes in singleton pregnancies: A meta-analysis of cohort studies. *Fertil Steril.* 2016;105(1):73-85e6.
123. Vannuccini S, Ferrata C, Perelli F, et al. Peripartum and postpartum outcomes in uncomplicated term pregnancy following ART: a retrospective cohort study from two Italian obstetric units. *Hum Reprod Open.* 2018;2018(3):1-7.
124. Haemmerli Keller K, Alder G, Loewer L, Faeh M, Rohner S, von Wolff M. Treatment-related psychological stress in different in vitro fertilization therapies with and without gonadotropin stimulation. *Acta Obstet Gynecol Scand.* 2018;97(3):269-276.
125. von Wolff M. Natural Cycle IVF: Follicle Physiology and Treatment Costs. In: *Minimal Stimulation and Natural Cycle In Vitro Fertilization.* New Delhi: Springer India; 2015:11-21.
126. Von Wolff M, Kollmann Z, Flück CE, et al. Gonadotrophin stimulation for in vitro fertilization significantly alters the hormone milieu in follicular fluid: A comparative study between natural cycle IVF and conventional IVF. *Hum Reprod.* 2014;29(5):1049-1057.
127. Bersinger NA, Kollmann Z, Von Wolff M. Serum but not follicular fluid cytokine levels are increased in stimulated versus natural cycle IVF: A multiplexed assay study. *J Reprod Immunol.* 2014;106:27-33.
128. Wu G, Bersinger NA, Mueller MD, von Wolff M. Intrafollicular inflammatory cytokines but not steroid hormone concentrations are increased in naturally matured follicles of women with proven endometriosis. *J Assist Reprod Genet.* 2017;34(3):357-364.

129. Rackow BW, Kliman HJ, Taylor HS. GnRH antagonists may affect endometrial receptivity. *Fertil Steril*. 2008;89(5):1234-1239.
130. Tomic V, Kasum M, Vucic K. Impact of embryo quality and endometrial thickness on implantation in natural cycle IVF. *Arch Gynecol Obstet*. March 2020:1-6.
131. Ho JR, Paulson RJ. Modified natural cycle in in vitro fertilization. *Fertil Steril*. 2017;108(4):572-576.
132. Barker D. Infant Mortality, Childhood Nutrition, and Ischaemic Heart Disease in England and Wales. *Lancet*. 1986;327(8489):1077-1081.
133. Barker DJP. Developmental origins of adult health and disease. *J Epidemiol Community Heal*. 2004;58(2):114-115.
134. Arima Y, Fukuoka H. Developmental origins of health and disease theory in cardiology. *J Cardiol*. 2020;Feb:EPub ahead of print.
135. Valenzuela-Alcaraz B, Crispi F, Bijmens B, et al. Assisted reproductive technologies are associated with cardiovascular remodeling in utero that persists postnatally. *Circulation*. 2013;128(13):1442-1450.
136. Valenzuela-Alcaraz B, Serafini A, Sepulveda-Martínez A, et al. Postnatal persistence of fetal cardiovascular remodelling associated with assisted reproductive technologies: a cohort study. *BJOG An Int J Obstet Gynaecol*. 2019;126(2):291-298.
137. Scherrer U, Rexhaj E, Allemann Y, Sartori C, Rimoldi SF. Cardiovascular dysfunction in children conceived by assisted reproductive technologies. *Eur Heart J*. 2015;36(25):1583-1589.
138. Meister TA, Rimoldi SF, Soria R, et al. Association of Assisted Reproductive Technologies With Arterial Hypertension During Adolescence. *J Am Coll Cardiol*. 2018;72(11):1267-1274.
139. Seggers J, Haadsma ML, Gemert SLB Van, et al. Is ovarian hyperstimulation associated with higher blood pressure in 4-year-old IVF offspring? Part I: Multivariable regression analysis. *Hum Reprod*. 2014;29(3):502-509.
140. La Bastide-Van Gemert S, Seggers J, Haadsma ML, et al. Is ovarian hyperstimulation associated with higher blood pressure in 4-year-old IVF offspring? Part II: An explorative causal inference approach. *Hum Reprod*. 2014;29(3):510-517.
141. Kuiper D, Hoek A, la Bastide-van Gemert S, et al. Cardiovascular health of 9-year-old IVF offspring: no association with ovarian hyperstimulation and the in vitro procedure. *Hum Reprod*. 2017;32(12):2540-2548.
142. Halliday J, Ph D, Lewis S, et al. Health of adults aged 22 to 35 years conceived by assisted reproductive technology. *Fertil Steril*. 2019;in press:1-9.
143. Guo XY, Liu XM, Jin L, et al. Cardiovascular and metabolic profiles of offspring conceived by assisted reproductive technologies: a systematic review and meta-analysis. *Fertil Steril*. 2017;107(3):622-631.e5.



144. Hvidtjørn D, Schieve L, Schendel D, Jacobsson B, Sværke C, Thorsen P. Cerebral Palsy, Autism Spectrum Disorders, and Developmental Delay in Children Born After Assisted Conception. *Arch Pediatr Adolesc Med*. 2009;163(1):72-83.
145. Bergh C, Wennerholm U-B. Long-term health of children conceived after assisted reproductive technology. *Ups J Med Sci*. February 2020:1-6.
146. Schendelaar P, Van Den Heuvel ER, Heineman MJ, et al. Increased time to pregnancy is associated with less optimal neurological condition in 4-year-old singletons, in vitro fertilization itself is not. *Hum Reprod*. 2014;29(12):2773-2786.
147. Hediger ML, Bell EM, Druschel CM, Buck Louis GM. Assisted reproductive technologies and children's neurodevelopmental outcomes. *Fertil Steril*. 2013;99(2):311-317.
148. Liu L, Gao J, He X, Cai Y, Wang L, Fan X. Association between assisted reproductive technology and the risk of autism spectrum disorders in the offspring: a meta-analysis. *Sci Rep*. 2017;7(1):46207.
149. Fruchter E, Beck-Fruchter R, Hourvitz A, et al. Health and functioning of adolescents conceived by assisted reproductive technology. *Fertil Steril*. 2017;107(3):774-780.
150. Knoester M, Helmerhorst FM, Vandenbroucke JP, van der Westerlaken LAJ, Walther FJ, Veen S. Perinatal outcome, health, growth, and medical care utilization of 5- to 8-year-old intracytoplasmic sperm injection singletons. *Fertil Steril*. 2008;89(5):1133-1146.
151. Basatemur E, Shevlin M, Sutcliffe A. Growth of children conceived by IVF and ICSI up to 12 years of age. *Reprod Biomed Online*. 2010;20(1):144-149.
152. Yeung EH, Sundaram R, Bell EM, et al. Infertility treatment and children's longitudinal growth between birth and 3 years of age. *Hum Reprod*. 2016;31(7):1621-1628.
153. Hargreave M, Jensen A, Toender A, Andersen KK, Kjaer SK. Fertility treatment and childhood cancer risk: a systematic meta-analysis. *Fertil Steril*. 2013;100(1):150-161.
154. Wang T, Chen LL, Yang T, et al. Cancer risk among children conceived by fertility treatment. *Int J Cancer*. 2019;144(12):3001-3013.
155. Spector LG, Brown MB, Wantman E, et al. Association of In Vitro Fertilization With Childhood Cancer in the United States. *JAMA Pediatr*. 2019;173(6):e190392.
156. Hargreave M, Jensen A, Hansen MK, et al. Association Between Fertility Treatment and Cancer Risk in Children. *JAMA*. 2019;322(22):2203.
157. Ericson A, Nygren KG, Olausson PO, Källén B. Hospital care utilization of infants born after IVF. *Hum Reprod*. 2002;17(4):929-932.
158. Pinborg A, Loft A, Schmidt L, Andersen AN. Morbidity in a Danish National cohort of 472 IVF/ICSI twins, 1132 non-IVF/ICSI twins and 634 IVF/ICSI singletons: Health-related and social implications for the children and their families. *Hum Reprod*. 2003;18(6):1234-1243.

159. Koivurova S, Hartikainen AL, Sovio U, Gissler M, Hemminki E, Järvelin MR. Growth, psychomotor development and morbidity up to 3 years of age in children born after IVF. *Hum Reprod.* 2003;18(11):2328-2336.
160. Pinborg A, Loft A, Rasmussen S, Nyboe Andersen A. Hospital care utilization of IVF/ICSI twins followed until 2–7 years of age: a controlled Danish national cohort study. *Hum Reprod.* 2004;19(11):2529-2536.
161. Källén B, Finnström O, Nygren KG, Olausson PO. In vitro fertilization in Sweden: Child morbidity including cancer risk. *Fertil Steril.* 2005;84(3):605-610.
162. Hansen M, Colvin L, Petterson B, Kurinczuk JJ, de Klerk N, Bower C. Admission to hospital of singleton children born following assisted reproductive technology (ART). *Hum Reprod.* 2008;23(6):1297-1305.
163. Hansen M, Colvin L, Petterson B, Kurinczuk JJ, de Klerk N, Bower C. Twins born following assisted reproductive technology: perinatal outcome and admission to hospital. *Hum Reprod.* 2009;24(9):2321-2331.
164. Kettner LO, Henriksen TB, Bay B, Ramlau-Hansen CH, Kesmodel US. Assisted reproductive technology and somatic morbidity in childhood: a systematic review. *Fertil Steril.* 2015;103(3):707-719.
165. Cetinkaya F, Gelen SAA, Kervancioglu E, Oral E. Prevalence of asthma and other allergic diseases in children born after in vitro fertilisation. *Allergol Immunopathol (Madr).* 2009;37(1):11-13.
166. Sicignano N, Beydoun HA, Russell H, Jones H, Oehninger S. A descriptive study of asthma in young adults conceived by IVF. *Reprod Biomed Online.* 2010;21(6):812-818.
167. Källén B, Finnström O, Nygren K-GG, Olausson PO, Otterblad Olausson P. Asthma in Swedish children conceived by in vitro fertilisation. *Arch Dis Child.* 2013;98(2):92-96.
168. Carson C, Sacker A, Kelly Y, Redshaw M, Kurinczuk JJ, Quigley MA. Asthma in children born after infertility treatment: findings from the UK Millennium Cohort Study. *Hum Reprod.* 2013;28(2):471-479.
169. Harju M, Keski-Nisula L, Raatikainen K, Pekkanen J, Heinonen S. Maternal fecundity and asthma among offspring—is the risk programmed preconceptionally? Retrospective observational study. *Fertil Steril.* 2013;99(3):761-767.e1.
170. Kettner LO, Henriksen TB, Bay B, Ramlau-Hansen CH, Kesmodel US. Assisted reproductive technology and somatic morbidity in childhood: a systematic review. *Fertil Steril.* 2015;103(3):707-719.
171. Magnus MC, Karlstad Ø, Parr CL, et al. Maternal history of miscarriages and measures of fertility in relation to childhood asthma. *Thorax.* 2019;74:106-113.
172. Malchau SS, Loft A, Henningsen A-KA, Nyboe Andersen A, Pinborg A. Perinatal outcomes in 6,338 singletons born after intrauterine insemination in Denmark, 2007 to 2012: the influence of ovarian stimulation. *Fertil Steril.* 2014;102(4):1110-1116.e2.

173. Kuiper DB, Seggers J, Schendelaar P, et al. Asthma and asthma medication use among 4-year-old offspring of subfertile couples - Association with IVF? *Reprod Biomed Online*. 2015;31(5):711-714.
174. Kettner LO, Matthiesen NB, Ramlau-Hansen CH, Kesmodel US, Bay B, Henriksen TB. Fertility treatment and childhood type 1 diabetes mellitus: a nationwide cohort study of 565,116 live births. *Fertil Steril*. 2016;106(7):1751-1756.
175. Norrman E, Petzold M, Clausen TD, et al. Type 1 diabetes in children born after assisted reproductive technology: a register-based national cohort study. *Hum Reprod*. 2020;35(1):221-231.
176. Cerny D, Sartori C, Rimoldi SF, et al. Assisted Reproductive Technologies Predispose to Insulin Resistance and Obesity in Male Mice Challenged With a High-Fat Diet. *Endocrinology*. 2017;158:1152-1159.
177. Hyrapetian M, Loucaides EM, Sutcliffe AG. Health and disease in children born after assistive reproductive therapies (ART). *J Reprod Immunol*. 2014;106:21-26.
178. Chen M, J. Norman R, K. Heilbronn L. Does in vitro Fertilisation Increase Type 2 Diabetes and Cardiovascular Risk? *Curr Diabetes Rev*. 2011;7(6):426-432.
179. Gross K, Späth A, Dratva J, Zemp Stutz E. *SWIFS - Swiss Infant Feeding Study*. Basel; 2014.



## 5. Manuscripts



## 5.1 Article 1: Small-for-gestational-age

### **The greater incidence of small-for gestational-age newborns after gonadotropin-stimulated in vitro fertilization with a supraphysiological estradiol level on ovulation trigger day**

#### Contributions

This project was the first planned publication out of the Bern IVF Cohort. As project coordinator, I was involved in this project from the very beginning, supporting all the steps mentioned in the manuscript. Furthermore, I was responsible for the data management, including data extraction, cleaning, data quality and preparation for analysis.

I contributed to the conception and design of this manuscript, to the collection of the data and to the drafting of the text, including a literature review and citing of references.

I planned and conducted the analysis and interpreted the data.

Alexandra Kohl-Schwartz and I wrote the first draft.

I contributed substantially to the finalisation of the manuscript.

I created Figure 1, Figure 2, Figure 3 and Figure 4, and Tables 1, 2 and 3.








I was heavily involved in revising the analysis and rewriting the manuscript.





ORIGINAL RESEARCH ARTICLE

# The greater incidence of small-for-gestational-age newborns after gonadotropin-stimulated in vitro fertilization with a supraphysiological estradiol level on ovulation trigger day

Alexandra S. Kohl Schwartz<sup>1</sup>  | Vera R. Mitter<sup>1</sup>  | Sofia Amylidi-Mohr<sup>2</sup>  |  
Pascale Fasel<sup>1</sup> | Mirja A. Minger<sup>1</sup>  | Costanzo Limoni<sup>3</sup>  | Marcel Zwahlen<sup>4</sup>  |  
Michael von Wolff<sup>1</sup> 

<sup>1</sup>Division of Gynecological Endocrinology and Reproductive Medicine, Bern University Hospital, University of Bern, Inselspital, Bern, Switzerland

<sup>2</sup>Department of Feto-maternal Medicine and Obstetrics, University Women's Hospital, University Hospital, University of Bern, Inselspital, Bern, Switzerland

<sup>3</sup>University of Applied Sciences and Arts of Southern Switzerland, Lugano, Switzerland

<sup>4</sup>Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

## Correspondence

Alexandra Sabrina Kohl Schwartz, Division of Gynecological Endocrinology and Reproductive Medicine, Inselspital, Bern University Hospital, Friedbuehlstrasse 19, 3010 Bern, Switzerland.  
Email: alexandra.kohl-schwartz@insel.ch

## Funding information

The data evaluation for this study was supported by a grant from Merck (Switzerland) AG, Zug, Switzerland.

## Abstract

**Introduction:** Reproductive scientists have postulated various risk factors for lower birthweight following conventional gonadotropin-stimulated in vitro fertilization compared with spontaneously conceived children: parental factors (age, health, duration of subfertility and smoking habits); ovarian stimulation; laboratory procedures; the number of oocytes retrieved and the number of embryos transferred. Our aim was to investigate the impact of gonadotropin stimulation and serum estradiol level on the risk of a newborn being small-for-gestational-age.

**Material and methods:** We conducted a cohort study (2010-2016) of singletons ( $n = 155$ ) born either after conventional gonadotropin-stimulated in vitro fertilization (using  $\geq 150$  IU/d human gonadotropin for stimulation) or after natural cycle in vitro fertilization without any stimulation. We analyzed perinatal outcomes using birthweight percentiles, adjusted for gestational age and sex.

**Results:** The proportion of small-for-gestational-age was 11.8% following conventional gonadotropin-stimulated in vitro fertilization and 2.9% after natural cycle in vitro fertilization ( $P = 0.058$ ). The odds of small-for-gestational-age were significantly higher with supraphysiological estradiol levels in maternal serum on ovulation trigger day (unadjusted odds ratio 4.58; 95% confidence interval 1.35-15.55;  $P = 0.015$ ). It remained significant after adjusting for maternal height, age and body mass index (adjusted odds ratio 3.83; 95% confidence interval 1.06-13.82;  $P = 0.041$ ).

**Conclusions:** We found an associated risk of children being born small-for-gestational-age after conventional gonadotropin-stimulated in vitro fertilization compared with natural cycle in vitro fertilization. This higher risk is significantly associated with supraphysiological estradiol levels. We propose a reduction in the dosage of

**Abbreviations:** BMI, body mass index; CI, confidence interval; c-IVF, conventional gonadotropin-stimulated IVF; E2, estradiol; FA, follicle aspiration; IVF, in vitro fertilization; LBW, low birthweight; NC-IVF, natural cycle in vitro fertilization; OR, odds ratio; SGA, small-for-gestational-age.

Alexandra S. Kohl Schwartz and Vera R. Mitter are joint first authors.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2019 The Authors. *Acta Obstetrica et Gynecologica Scandinavica* published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG)

gonadotropin to minimize the risk of small-for-gestational-age and future health consequences.

#### KEYWORDS

gonadotropin, high-risk pregnancy, in vitro fertilization, infertility, pregnancy, reproductive endocrinology

## 1 | INTRODUCTION

Birthweights in children born following conventional gonadotropin-stimulated in vitro fertilization (c-IVF) and fresh embryo transfer are shown in several systematic reviews and meta-analyses<sup>1,2</sup> to be lower than birthweights of spontaneously conceived singletons. Various risk factors were postulated:<sup>3</sup> parental factors (mainly pre-existing diseases, duration of subfertility<sup>4</sup> and parental smoking); in vitro fertilization (IVF) laboratory procedures;<sup>5</sup> the number of oocytes retrieved;<sup>6</sup> and the number of embryos transferred. After the transfer of more than one embryo, fetal intrauterine growth restriction may be a consequence of vanishing twins.<sup>2</sup> Two studies addressing E2 levels in maternal serum at ovulation trigger day postulated a dosage-dependent impact of gonadotropins on birthweight and birthweight percentile.<sup>7,8</sup>

Comparing c-IVF with natural cycle IVF (NC-IVF) with natural follicle selection and without the use of gonadotropins offers an excellent way to study the influence of hormones on obstetric and perinatal outcomes. A recent systematic review found a significantly higher risk of low birthweight (LBW) after c-IVF (risk ratio 1.95; 95% confidence interval [CI] 1.03-3.67) compared with modified IVF/NC-IVF therapy.<sup>9</sup> Studies included in the review focused on birthweight as the main outcome and defined LBW as <2500 g, without taking into consideration exact gestational age.<sup>6,10,11</sup> Using birthweight percentiles adjusts for gestational age and sex of the neonate.

Our study compares birthweight and birthweight percentiles of c-IVF with those of NC-IVF newborns.

## 2 | MATERIAL AND METHODS

### 2.1 | Study population

The cohort of this study includes women treated for infertility at the Bern University Hospital, Division of Gynecological Endocrinology and Reproductive Medicine, Switzerland, from 2010 to 2016. We retrieved prospectively collected data and prepared it for analysis using REDCap electronic data (REDCap 8.5.19 Vanderbilt University, Nashville, USA) capture tools hosted at the Clinical Trials Unit, University of Bern.

We included data on all women with a singleton live birth after a fresh cleavage-stage embryo transfer who underwent either c-IVF or NC-IVF. Women with a regular menstrual cycle chose the treatment (NC-IVF or c-IVF) as per their preference. We did not include

### Key message

Supraphysiological serum estradiol levels under gonadotropin stimulation in in vitro fertilization are associated with a higher incidence of children born small-for-gestational-age. We propose a reduction in gonadotropin dosage to minimize potential negative health consequences.

women receiving thawing cycles and cycles with modified IVF treatment (eg, the use of clomiphene citrate [CC]). At our clinic, we offer treatments with modifying drugs such as CC and low-dose human menopausal gonadotropin only as second-line options after several unsuccessful NC-IVF treatments. Women receiving those treatments had previously several unsuccessful treatment cycles. Our aim was to compare two clearly distinct approaches, namely, NC-IVF without the use of any stimulating drugs with c-IVF, both used as first-line treatments.

### 2.2 | Data sources

We collected data on patient characteristics and reproductive treatment from medical records. Chronic disease included asthma, Hashimoto's thyroiditis and arterial hypertension. From the treating gynecologist or the maternity hospital we received results of later pregnancies, delivery reports and perinatal information on mother and child. We considered the following conditions to be pregnancy complications: gestational hypertension, gestational diabetes, placental pathologies (eg, abnormal placentation such as placenta previa or placenta accreta/increta), antepartum hemorrhage, preterm contractions, preterm rupture of membranes and fetal growth restriction. We calculated fetal weight during pregnancy using the Hadlock formula. From the available fetal growth charts, we evaluated uteroplacental dysfunction (decrease in growth rate) and characteristic fetal perfusion changes if Doppler ultrasound was available. We defined according to the TRUFFLE study for fetal growth restriction<sup>12</sup> an abnormal umbilical artery Doppler with a pulsatility index above the 95th percentile of the Doppler reference chart<sup>13</sup> with or without reversed or absent end-diastolic flow as pathologic. We calculated gestational age as the time from fertilization at the day of follicular aspiration (FA) to delivery, plus 14 days. We used growths charts from Voigt & Fenton<sup>14</sup> to determine the birthweight percentile. We defined a priori small-for-gestational-age (SGA) as a birthweight

≤5th percentile. This reflects a degree of smallness that is more likely to be pathologic rather than constitutional.<sup>15,16</sup>

### 2.3 | Conventional gonadotropin-stimulated IVF

At our center, we perform c-IVF as either a short agonist protocol or an antagonist protocol. For the short agonist protocol, we use triptoreline (gonadotropin-releasing hormone agonist, eg, Decapeptyl®) and 150-300 units of follicle-stimulating hormone (eg, Fostimon®) or human menopausal gonadotropin (Menopur® or Merional®) for follicular stimulation, depending on age, Anti-Müllerian hormone level and antral follicle count. For the antagonist protocol, we use human menopausal gonadotropin (150-300 units a day) for follicular stimulation and 0.25 mg cetrorelix (gonadotropin-releasing hormone antagonist, eg, Cetrotide®) once a day, beginning at stimulation day 6 or 7. We monitor cycles using ultrasound, check serum E2 levels, and trigger ovulation with human chorionic gonadotropin (eg, Ovitrelle®) when the size of the leading follicles is >17 mm. We perform FA 36 hours later under conscious sedation.

### 2.4 | Natural cycle IVF

We perform NC-IVF in accordance with best practice.<sup>17</sup> We perform follicle monitoring by ultrasound and analysis of E2 and luteinizing hormone (LH) concentrations, once preovulatory. When the follicular diameter reaches at least 16 mm and the E2 concentration

is expected to be ≥800 pmol/L, we administer a single dose of 5000 IU human chorionic gonadotropin as a trigger and FA is performed 36 hours later without anesthesia using a 19G single lumen needle. In the event of luteinizing hormone-surge (>10 IU/L) on the day of human chorionic gonadotropin administration, we give 400 mg ibuprofen every 8 hours starting a maximum of 48 hours before FA until the day of FA. If information on the E2 concentration on ovulation trigger day is not available, we calculate it based on follicular phase measurements.

For both types of treatment, we fertilize the mature oocytes by intracytoplasmic sperm injection, and we culture a cleavage stage embryo. For the assessment of embryo quality, we use ASEBIR classification<sup>18</sup> based on the number of cells, the heterogeneity of the cells, and the fragmentation rate of the embryo. We transfer the embryo at cleavage stage with a soft transfer catheter under ultrasound surveillance. Women receive luteal phase support twice a day after c-IVF with intravaginal micronized progesterone (eg, Utrogestan® 200 mg or Crinone®), beginning the evening of the day of FA until the 12th week of pregnancy.

### 2.5 | Statistical analyses

We performed statistical analysis using Fisher's exact test (SGA and LBW) or chi-square test and Mantel-Haenszel statistics for categorical outcomes and linear regression for continuous outcomes. As seven women with two IVF children each were included in the dataset, we used

**TABLE 1** Patient characteristics

	NC-IVF		c-IVF		P value
	n = 70	%/SD	n = 85	%/SD	
Maternal age (y)	34.23	3.76	34.57	4.15	0.598 <sup>a</sup>
Maternal height (cm)	166.99	6.04	167.01	7.98	0.982 <sup>a</sup>
Maternal weight (kg)	62.18	10.57	62.28	11.17	0.956 <sup>a</sup>
Maternal BMI (kg/m <sup>2</sup> )	22.32	3.76	22.33	3.72	0.982 <sup>a</sup>
Parity (nulliparous)	52	74.29	72	84.71	0.107 <sup>b</sup>
Smoking before pregnancy (y/n)	7	10	15	17.65	0.248 <sup>c</sup>
Smoking during pregnancy (y/n)	0	0	4	4.71	0.141 <sup>c</sup>
Chronic disease mother (y/n)	12	17.14	19	22.40	0.420 <sup>b</sup>
AMH mother	21.52	22.30	24.79	21.32	0.358 <sup>a</sup>
Indication for IVF					
Male factor	45	64.30	42	49.41	0.381 <sup>c</sup>
Endometriosis	11	15.70	18	21.18	
Tube factor	3	4.30	5	5.88	
PCO-S	0	0.00	3	3.53	
Idiopathic	10	14.29	15	17.65	
Other	1	1.43	2	2.35	

AMH, Anti-Müllerian hormone; BMI, body mass index; c-IVF, conventional IVF; cm, centimeter; IVF, in vitro fertilization; kg, kilogram; m<sup>2</sup>, square meter NC-IVF, natural cycle IVF; PCO-S, polycystic ovary syndrome; SD, standard deviation; y, years; y/n, yes/no.

<sup>a</sup>Linear regression.

<sup>b</sup>Chi-square test.

<sup>c</sup>Fisher's exact test.

**TABLE 2** Stimulation and pregnancy outcome characteristics

	NC-IVF		c-IVF		P value
	N = 70	%/SD	N = 85	%/SD	
<b>Stimulation</b>					
Nb previous transfers (n)	1.94	1.74	1.62	0.88	0.138 <sup>a</sup>
Day of retrieval (d)	12.65	1.87	12.19	2.09	0.207 <sup>a</sup>
Nb oocytes retrieved (n)	1.01	0.12	8.20	4.73	<b>&lt;0.001<sup>a</sup></b>
Nb of embryos transferred (n)	1.01	0.12	2.01	0.36	<b>&lt;0.001<sup>a</sup></b>
Day of embryo transfer (d)	2.69	0.71	2.61	0.74	0.531 <sup>a</sup>
Total gonadotropin dosage (IU)	–	–	2322.77	758.41	–
Estradiol at trigger day (pmol/L)	1028.94	330.39	10 459.78	4552.12	<b>&lt;0.001<sup>a</sup></b>
Estradiol at trigger day (>10 000 pmol/L)	0	0	40	48.19	<b>&lt;0.001<sup>b</sup></b>
Endometrium thickness (mm)	8.59	1.75	9.86	2.37	<b>&lt;0.001<sup>a</sup></b>
<b>Pregnancy</b>					
Duration of pregnancy (wk.d)	39.2	1.52	38.94	2.51	0.451 <sup>a</sup>
Pregnancy hypertension (n)	1	1.43	1	1.18	0.890 <sup>c</sup>
Pregnancy complication (n)	16	22.56	26	30.59	0.309 <sup>b</sup>
Induction of labor (n)	22	35.48	28	34.57	0.909 <sup>b</sup>
Very preterm birth (<31 wk)	0	0	2	2.35	0.418 <sup>c</sup>
Preterm birth (31-36 wk)	5	7.14	5	5.88	
Term birth (≥37 wk)	65	92.85	78	91.76	
Infant gender female	36	51.43	34	40	0.155 <sup>b</sup>
Infant gender male	34	48.57	51	60	
Birthweight (g)	3310.34	475.08	3218.25	704.38	0.352 <sup>a</sup>
VLBW (<1500 g)	0	0	3	3.53	0.231 <sup>b</sup>
LBW (1500-2500 g)	2	2.86	4	4.71	
Birthweight ≥2500 g (n)	68	65.9	78	91.76	
Birthweight ≥4000 g (n)	6	8.57	9	10.59	0.673 <sup>b</sup>
Percentile (mean)	43.14	26.74	38.58	27.91	0.304 <sup>a</sup>
SGA (≤5th percentile)	2	2.86	10	11.76	<b>0.039<sup>b</sup></b>
Birthweight ≤10th percentile (n)	10	14.49	18	21.18	0.285 <sup>b</sup>
Vanishing twin (n)	1	1.43	6	7.32	0.088 <sup>c</sup>

Values are presented as means with standard deviations or n with proportions (%).

c-IVF, conventional IVF; d, day; g, gram; IU, international units; IVF, in vitro fertilization; LBW, low birthweight; mm, millimeter; NC-IVF, natural cycle IVF; n, number; pmol/L, pico mol per liter; SD, standard deviation; SGA, small-for-gestational-age; VLBW, very low birthweight; wk, week of gestation; wk.d, week.day.

<sup>a</sup>Linear regression.

<sup>b</sup>Chi-square test.

<sup>c</sup>Fisher's exact test.


Bold values are statistically significant.

robust standard errors controlling for clusters in the regressions. For E2 and birth percentile, we performed multivariate linear regression, and for binary outcomes, multivariate logistic regression. We adjusted for the known risk factors: maternal age, maternal height and body mass index (BMI) according the large US multicenter study from Gardosi & Francis<sup>19</sup> and controlled for multicollinearity between BMI and height. For parity (nulliparous/parous), vanishing twins and smoking during pregnancy (yes/no), we conducted a sensitivity analysis using exact logistic regression. We also used suprphysiological E2 levels (>10 000 pmol/L) as a binary

exposure. The E2 cut-off levels in previous studies ranged between 9178 and 12 665 pmol/L.<sup>7,8,20</sup> We considered E2 >10 000 pmol/L to be suprphysiological, "because this E2 level is higher than that of 10 mature follicles and lower than that of high-risk ovarian hyperstimulation syndrome"<sup>8</sup> and it comprises median and mean E2 levels of our c-IVF patients (9590 pmol/L; 10 459 pmol/L). We present odds ratios (OR) and 95% CIs; a P value <0.05 is considered statistically significant.

For statistical analysis, we used STATA statistical software Version 15 (Stata Corporation, College Station, Texas, USA).

**FIGURE 1** Boxplot of birthweight percentiles of conventional gonadotropin-stimulated in vitro fertilization (c-IVF) vs natural cycle in vitro fertilization (NC-IVF) [Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)]



## 2.6 | Ethics approval

The cantonal ethical committee of Bern (KEK Bern, 397/15), Switzerland, approved the study on 26 January 2016.

## 3 | RESULTS

We identified 643 pregnancies from the 2010-2016 period. We excluded 159 births after frozen embryo transfer. Of 484 women who underwent a fresh embryo transfer, one woman was lost to follow up, 188 had a miscarriage and 26 had a multiple pregnancy. We excluded 114 singleton deliveries because of modifications (see Study population 2.1.). These resulted in 155 singleton deliveries in the analysis: 85 conceived after c-IVF and 70 after a NC-IVF treatment. Twelve women did not consent to further data collection associated with their child.

### 3.1 | Study population characteristics

Within the c-IVF group, 21 had an agonist protocol and 64 had an antagonist protocol. See Table 1 for patient and treatment characteristics. We could not find a significant difference in age, BMI, parity or smoking between the two groups. Prevalence of chronic diseases was comparable between c-IVF and NC-IVF (22.40% vs 17.14%;  $P = 0.420$ ).

We found that stimulation characteristics were significantly higher in c-IVF but the number of previous embryo transfers was similar (Table 2).

### 3.2 | Pregnancy characteristics

We note that there were no differences in pregnancy complications, eg, gestational hypertension, between the two groups (Table 2). The rate of preterm births (<37 gestational weeks) was

8.24% ( $n = 7$ ) in the c-IVF group and 7.14% ( $n = 5$ ) in the NC-IVF ( $P = 1.000$ ) group.

The overall mean birthweight and percentile were 3218 g ( $\pm 704$  g), 38.6th percentile for c-IVF and 3310 g ( $\pm 475$ ), 43.1st percentile for NC-IVF, respectively,  $P = 0.352$ . The proportion of LBW was 8.24% ( $n = 7$ ) in c-IVF and 2.90% ( $n = 2$ ) in NC-IVF,  $P = 0.188$ , whereas the incidence of birthweight >4000 g was 10.59% ( $n = 9$ ) in the c-IVF group and 8.57% ( $n = 6$ ) in the NC-IVF group,  $P = 0.673$ .

### 3.3 | Small-for-gestational-age

More children were born as SGA following c-IVF (11.76%,  $n = 10$ ; 4 male, 6 female) than following NC-IVF (2.86%,  $n = 2$ ; both male), with an odds ratio of 4.53 for an SGA child in a logistic regression (95% CI 0.95-21.61,  $P = 0.058$ , Figure 1). After we adjusted for confounding factors such as maternal age, height and BMI, the odds ratio was somewhat attenuated (OR 4.23; 95% CI 0.87-20.41;  $P = 0.073$ , Model I in Table 3). If we additionally adjust for the E2 level, the odds ratio is further reduced to 1.01 (95% CI 0.87-1.19,  $P = 0.971$ , Model III in Table 3).

### 3.4 | Supraphysiological estradiol level

The influence on birthweight percentile of an E2 level of >10 000 pmol/L on ovulation trigger day was significant in the crude analysis (unadjusted OR 4.58; 95% CI 1.35-15.55;  $P = 0.015$ ) and remained significant when adjusted (adjusted OR 3.83; 95% CI 1.06-13.82;  $P = 0.041$ ) (Model II in Table 3; Figure 2). The sensitivity analysis regarding parity, smoking and vanishing twins showed very similar odds ratios for stimulation schemes in crude and adjusted analyses (OR 1.45 vs 1.41, 1.48 and 1.41, respectively). In the linear regression, the association between E2 level and birthweight and birthweight percentile is modest. Birthweights and birthweight

**TABLE 3** Multilevel logistic regression for small-for-gestational-age

N = 155	Unadjusted OR (95% CI) (for each determinant individually)	P value	Model I		Model II		Model III	
			Adjusted OR (95% CI)	P value	Adjusted OR (95% CI)	P value	Adjusted OR (95% CI)	P value
Stimulation (c-IVF)	4.53 (0.95-21.61)	0.058	4.23 (0.87-20.41)	0.073			1.05 (0.87-1.17)	0.971
Mother age (continuous)	1.01 (0.89-1.17)	0.820	0.99 (0.88-1.13)	0.952	1.01 (0.87-1.19)	0.811	1.01 (0.87-1.17)	0.901
Mother age (>36 y)	0.98 (0.28-3.48)	0.987						
Mother height (continuous)	0.88 (0.79-0.99)	0.026	0.89 (0.81-0.98)	0.019	0.90 (0.81-0.99)	0.042	0.90 (0.81-0.99)	0.032
Mother height (<160 cm)	5.46 (1.42-20.92)	0.013						
Mother BMI (continuous)	0.99 (0.83-1.18)	0.944	0.96 (0.78-1.17)	0.668	0.96 (0.74-1.24)	0.753	0.98 (0.77-1.24)	0.847
Mother BMI (<20 m <sup>2</sup> )	1.24 (0.35-4.40)	0.735						
E2 level (continuous)	1 (1.00-1.00)	0.003					1.00 (1.00-1.00)	0.127
E2 level on trigger day (<10 000 vs ≥10 000)	4.58 (1.35-15.55)	0.015			3.83 (1.06-13.82)	0.041		
Nulliparous (0 vs ≥1)	3.81 <sup>a,b</sup>	0.188						
Smoking during pregnancy (y/n)	0.99 (0-1.04) <sup>b</sup>	0.984						
Vanishing twin (y/n)	2.25 (0.24-20.73)	0.474						
Pregnancy complication (y/n)	2.88 (0.87-9.6)	0.083						
Pregnancy hypertension (y/n)	12.90 (0.75-222.94)	0.078						
Induction of labor (y/n)	0.92 (0.26-3.26)	0.902						
LBW (<2500 vs ≥2500 g)	24.64 (5.4-113.98)	<0.001						

Model I: adjusted multivariate logistic regressions with SGA as outcome and stimulation as exposure adjusted for age, height and BMI as continuous variables.

Model II: adjusted multivariate logistic regression with SGA as outcome and suprphysiological E2 level as exposure adjusted for age, height and BMI as continuous variables.

Model III: adjusted multivariate logistic regression with SGA as outcome and stimulation as exposure adjusted for E2, age, height and BMI as continuous variables.

c-IVF, conventional IVF; cm, centimeters; g, gram; IVF, in vitro fertilization; NC-IVF, natural cycle IVF; y, years; n, number; m<sup>2</sup>, square meter; OR, odds ratio; pmol/L, picomol per liter; y/n, yes/no; 95% CI, 95% confidence interval.

<sup>a</sup>Median unbiased estimate.

<sup>b</sup>Exact logistic regression.

percentiles are lower with higher E2 levels on ovulation trigger day. The adjusted linear regression of NC-IVF children shows a significant decrease of three percentiles by E2 increase of 100 pmol/L at ovulation trigger day (CI -4.61 to -1.39;  $P < 0.001$ , Figure 3). For c-IVF this is a decrease of 0.05 percentiles with an E2 increase of 100 pmol/L (CI -0.02 to 0.18;  $P = 0.451$ , Figure 4). The effect of the stimulation scheme was completely leveled out when we controlled for the E2 level.

### 3.5 | Doppler analysis


We obtained complete pregnancy records for 8 of 12 children born as SGA. The evaluation of their fetal growth charts showed

four (42%; 1 NC-IVF, 3 c-IVF) cases with utero-placental dysfunction (late flattening growth, pathological Doppler analysis) and one case with a placental infarction (c-IVF) and pathological Doppler analysis. We did not have comparable information for the other four cases because the treating gynecologist did not perform a Doppler measurement.


## 4 | DISCUSSION

This cohort study of singletons conceived after fresh IVF therapy focuses on the effect of ovarian stimulation on birth outcomes. Overall, gonadotropins seem to reduce birthweight and birthweight

**FIGURE 2** Boxplot of birthweight percentiles estradiol (E2) level <10 000 pmol/L vs  $\geq$ 10 000 pmol/L E2 level [Color figure can be viewed at wileyonlinelibrary.com]



**FIGURE 3** Birthweight percentile with higher estradiol (E2) level (in maternal serum, pmol/L) on ovulation trigger day in natural cycle in vitro fertilization [Color figure can be viewed at wileyonlinelibrary.com]




percentiles, especially when used for ovarian stimulation reaching supraphysiological E2 levels on ovulation trigger day. The two main findings of our study are: (1) the risk associated of children being born SGA after c-IVF compared with NC-IVF; and (2) the association of SGA children with supraphysiological E2 levels on ovulation trigger day. After adjusting for established risk factors, the supraphysiological E2 level in particular was determined to be a relevant risk factor for SGA; this even levels out completely the effect of the stimulation scheme.

These results contribute to the important debate on whether ovarian stimulation poses a risk for SGA or LBW and to the health of the IVF children later in life and what could be the determining factors.

For children conceived by NC-IVF, the incidence of SGA was analyzed only once, by Mak et al.<sup>10</sup> They compared 190 singletons after NC-IVF with 174 after c-IVF. In both groups, the percentage of preterm births was exceptionally high (31.5% vs 42%) but the difference in birthweights was significant (NC-IVF  $3426 \pm 420$  g vs c-IVF  $3273 \pm 574$  g,  $P = 0.01$ ). Because of the high rate of preterm neonates (36.3%), this population is not completely comparable to ours (7.74% preterm only).

Our results suggest that the stimulation is detrimental if a supraphysiological estradiol level is reached. Measures of intensive ovarian hyperstimulation, such as supraphysiological E2 levels on ovulation trigger day<sup>7,20</sup> and a high number of oocytes retrieved,<sup>6</sup> have been identified previously as independent risk factors for lower



**FIGURE 4** Birthweight percentile with higher estradiol (E2) level (in maternal serum, pmol/L) on ovulation trigger day in conventional gonadotropin-stimulated in vitro fertilization [Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)]

birthweight in IVF therapy. Supraphysiological E2 levels are also associated with a higher risk of preeclampsia (18). Our results even suggest that the effect of E2 level on ovulation trigger day outweighs the choice of stimulation scheme and the amount of gonadotropins used. It would be necessary to predict more accurately individual stimulation responses and the E2 levels.

The strength of our study is the equal access of all couples to both treatments in our center, which reduces (but does not eliminate) selection bias. The only difference between the groups is the use of gonadotropins for stimulation, resulting in higher serum E2 levels, a higher number of oocytes retrieved, and a higher number of embryos transferred within the c-IVF group, also resulting in more vanishing twins. All other factors, such as laboratory conditions and the staff providing the treatment, were similar for the two groups. With regard to parental health and underlying subfertility as well as manipulation and culture of the embryos, we would not expect any differences between the two groups. Additionally, the use of birthweight percentiles increases the prognostic value of this particular parameter compared with birthweight alone.

A limitation of our study is the small sample size. We recruited within our center to increase comparability between both groups and we were able to have access to complete treatment data for all cases. A prospective design with random allocation of fertility treatment is not possible in Switzerland because the couple completely pays for fertility treatment themselves.

Further factors may affect our results; when two or more embryos are transferred and one gestation vanishes, the remaining fetus is physiologically seen as a twin. Pinborg showed its association with LBW and SGA (2). In our population, we had six vanishing twins in the c-IVF group and one in the NC-IVF group; this did not affect the incidence of SGA.

Animal models showed that high serum E2 levels suppress the extra villous trophoblast vascular endothelial growth factor and

hinder uterine spiral artery invasion into the placenta.<sup>21</sup> A supra-physiological E2 environment, such as in gonadotropin-stimulated cycles, may result in an edematous endometrium impairing trophoblast differentiation and abnormal placentation, compared with the physiologic endometrium conditions in NC-IVF.<sup>22</sup> We hypothesize that these mechanisms might be one reason for the increased incidence of SGA children after gonadotropin-stimulated IVF therapies compared with spontaneously conceived children.

In 1998, Barker linked maternal nutrition during the preimplantation period to intrauterine growth; his work showed that intrauterine-affected individuals are at greater risk of developing coronary heart disease, hypertension and diabetes; this is known as the “Barker’s hypothesis” or the “developmental origins of health and disease theory”.<sup>23</sup>

IVF offspring have not yet reached late adult life. Multiple studies suggest that c-IVF children, especially with an associated fetal growth restriction,<sup>24</sup> may face health issues later in life, such as reduced insulin sensitivity, cardiovascular dysfunction and higher blood pressure at school age.<sup>25,26</sup> Larger prospective cohort studies should investigate further the effects of gonadotropins and supra-physiological E2 levels on intrauterine growth and the health of IVF children.

The extent to which gonadotropin stimulation is associated with LBW and SGA, and consequently their possible negative health conditions, is still not clear. However, while we cannot alter many factors in IVF therapy to achieve acceptable pregnancy outcomes, we can reduce the use of gonadotropin and the dosage when it is used. Furthermore, the risk of SGA can be reduced by frozen embryo transfer cycles, but there instead a higher risk of large-for-gestational-age (LGA),<sup>27</sup> and preeclampsia<sup>28</sup> has been described recently. In NC-IVF, the serum E2 milieu remains within physiologic limits,<sup>17,29</sup> whereas gonadotropin stimulation in c-IVF alters it. NC-IVF as well as low-dose



stimulation-IVF may be options to reduce the risk of supraphysiological E2 levels and consequently LBW and SGA. Several studies that looked at mild stimulation found similar pregnancy and live birth rates, better quality oocytes and less adverse effects of the stimulation. Although Baart et al.<sup>30</sup> found fewer aneuploidy and mosaic embryos following mild stimulation, there is still not much known about perinatal outcome including the effect on LBW and SGA.

## 5 | CONCLUSION

Lower stimulation dosages are associated with lower E2 levels at ovulation trigger day. There is consecutively a lower risk of ovarian hyperstimulation syndrome and we assume lower associated perinatal health risks. Even if the effect of gonadotropins on the risk for SGA is not yet fully proven, we advise reproductive specialists to consider natural cycle or low-dose ovarian stimulation.


## ACKNOWLEDGMENTS

We thank Andreas Limacher for statistical consulting and Anja Fink, Livia Purtschert, Daniela Steiner and Marlene Berchtold for support with data collection.

## CONFLICT OF INTEREST

The authors have stated explicitly that there are no conflicts of interest in connection with this article.

## ORCID

Alexandra S. Kohl Schwartz  <https://orcid.org/0000-0002-7558-1327>

Vera R. Mitter  <https://orcid.org/0000-0002-1483-5020>

Sofia Amylidi-Mohr  <https://orcid.org/0000-0001-5996-4064>

Mirja A. Minger  <https://orcid.org/0000-0002-0022-9580>

Costanzo Limoni  <https://orcid.org/0000-0002-2549-9050>

Marcel Zwahlen  <https://orcid.org/0000-0002-6772-6346>

Michael Wolff  <https://orcid.org/0000-0003-4303-2734>

## REFERENCES

- Pandey S, Shetty A, Hamilton M, Bhattacharya S, Maheshwari A. Obstetric and perinatal outcomes in singleton pregnancies resulting from IVF/ICSI: a systematic review and meta-analysis. *Hum Reprod Update*. 2012;18:485-503.
- Pinborg A, Wennerholm UB, Romundstad LB, et al. Why do singletons conceived after assisted reproduction technology have adverse perinatal outcome? Systematic review and meta-analysis. *Hum Reprod Update*. 2013;19:87-104.
- Berntsen S, Söderström-Anttila V, Wennerholm U-B, et al. The health of children conceived by ART: "the chicken or the egg?". *Hum Reprod Update*. 2019;25:137-158.
- Davies MJ, Moore VM, Willson KJ, et al. Reproductive technologies and the risk of birth defects. *N Engl J Med*. 2012;366:1803-1813.
- Kleijkers SHM, Van Montfoort APA, Smits LJM, et al. IVF culture medium affects post-natal weight in humans during the first 2 years of life. *Hum Reprod*. 2014;29:661-669.
- Sunkara SK, La Marca A, Seed PT, Khalaf Y. Increased risk of preterm birth and low birthweight with very high number of oocytes following IVF: an analysis of 65 868 singleton live birth outcomes. *Hum Reprod*. 2015;30:1473-1480.
- Pereira N, Elias RT, Christos PJ, et al. Supraphysiologic estradiol is an independent predictor of low birth weight in full-term singletons born after fresh embryo transfer. *Hum Reprod*. 2017;32:1410-1417.
- Hu XL, Feng C, Lin XH, et al. High maternal serum estradiol environment in the first trimester is associated with the increased risk of small-for-gestational-age birth. *J Clin Endocrinol Metab*. 2014;99:2217-2224.
- Kamath MS, Kirubakaran R, Mascarenhas M, Sunkara SK. Perinatal outcomes after stimulated versus natural cycle IVF: a systematic review and meta-analysis. *Reprod Biomed Online*. 2018;36:94-101.
- Mak W, Kondapalli LA, Celia G, Gordon J, Dimattina M, Payson M. Natural cycle IVF reduces the risk of low birthweight infants compared with conventional stimulated IVF. *Hum Reprod*. 2016;31:789-794.
- Pelinc MJ, Hadders-Algra M, Haadsma ML, et al. Is the birthweight of singletons born after IVF reduced by ovarian stimulation or by IVF laboratory procedures? *Reprod Biomed Online*. 2010;21:245-251.
- Lees CC, Marlow N, van Wassenaer-Leemhuis A, et al. 2 year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trial. *Lancet*. 2015;385:2162-2172.
- Harrington K, Carpenter RG, Nguyen M, Campbell S. Changes observed in Doppler studies of the fetal circulation in pregnancies complicated by pre-eclampsia or the delivery of a small-for-gestational-age baby. I. Cross-sectional analysis. *Ultrasound Obstet Gynecol*. 1995;6:19-28.
- Fenton TR, Kim JH, Secker D, et al. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. *BMC Pediatr*. 2013;13:59.
- Zhang J, Mikolajczyk R, Grewal J, Neta G, Klebanoff M. Prenatal application of the individualized fetal growth reference. *Am J Epidemiol*. 2011;173:539-543.
- McIntire DD, Bloom SL, Casey BM, Leveno KJ. Birth weight in relation to morbidity and mortality among newborn infants. *N Engl J Med*. 1999;340:1234-1238.
- von Wolff M. The role of natural cycle IVF in assisted reproduction. *Best Pract Res Clin Endocrinol Metab*. 2019;33:35-45.
- Jos de los Santos M, Arroyo G, Busquet A, et al. A multicenter prospective study to assess the effect of early cleavage on embryo quality, implantation, and live-birth rate. *Fertil Steril*. 2014;101:981-987.
- Gardosi J, Francis A. Adverse pregnancy outcome and association with small for gestational age birthweight by customized and population-based percentiles. *Am J Obstet Gynecol*. 2009;201:28.e1-28.e8.
- Imudia AN, Awonuga AO, Doyle JO, et al. Peak serum estradiol level during controlled ovarian hyperstimulation is associated with increased risk of small for gestational age and preeclampsia in singleton pregnancies after in vitro fertilization. *Fertil Steril*. 2012;97:1374-1379.
- Bonagura TW, Pepe GJ, Enders AC, Albrecht ED. Suppression of extravillous trophoblast vascular endothelial growth factor expression and uterine spiral artery invasion by estrogen during early baboon pregnancy. *Endocrinology*. 2008;149:5078-5087.
- Devroey P, Bourgain C, Macklon NS, Fauser BCJM. Reproductive biology and IVF: ovarian stimulation and endometrial receptivity. *Trends Endocrinol Metab*. 2004;15:84-90.

23. Barker DJP. The origins of the developmental origins theory. *J Intern Med.* 2007;261:412-417.
24. Crispi F, Miranda J, Gratacós E. Long-term cardiovascular consequences of fetal growth restriction: biology, clinical implications, and opportunities for prevention of adult disease. *Am J Obstet Gynecol.* 2018;218:S869-S879.
25. Kuiper D, Hoek A, la Bastide-van Gemert S, et al. Cardiovascular health of 9-year-old IVF offspring: no association with ovarian hyperstimulation and the in vitro procedure. *Hum Reprod.* 2017;32:2540-2548.
26. Ceelen M, Van Weissenbruch MM, Vermeiden JPW, Van Leeuwen FE, Delemarre-Van De Waal HA. Cardiometabolic differences in children born after in vitro fertilization: follow-up study. *J Clin Endocrinol Metab.* 2008;93:1682-1688.
27. Pinborg A, Henningsen AA, Loft A, Malchau SS, Forman J, Andersen AN. Large baby syndrome in singletons born after frozen embryo transfer (FET): is it due to maternal factors or the cryotechnique? *Hum Reprod.* 2014;29:618-627.
28. Wei D, Liu J-Y, Sun Y, et al. Frozen versus fresh single blastocyst transfer in ovulatory women: a multicentre, randomised controlled trial. *Lancet.* 2019;393:1310-1318.
29. DiMattina M, Gordon JD, Botes A, Celia G, Payson M, Graves-Herring J. Follicular and estradiol parameters that improve success with natural cycle in vitro fertilization. *J Reprod Med.* 2014;59:267-273.
30. Baart EB, Martini E, Eijkemans MJ, et al. Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human pre-implantation embryo: a randomized controlled trial. *Hum Reprod.* 2007;22:980-988.

**How to cite this article:** Kohl Schwartz AS, Mitter VR, Amylidi-Mohr S, Fasel P, Minger MA, Limoni C, Zwahlen M, von Wolff M. The greater incidence of small-for-gestational-age newborns after gonadotropin-stimulated in vitro fertilization with a supraphysiological estradiol level on ovulation trigger day. *Acta Obstet Gynecol Scand.* 2019; 98:1575–1584.  
<https://doi.org/10.1111/aogs.13691>

## 5.2 Article 2: Breastfeeding following in vitro fertilization

### **Breastfeeding following in vitro fertilization in Switzerland - does mode of conception affect breastfeeding behaviour?**

#### Contributions

This project uses follow up data on breastfeeding from the Bern IVF Cohort and compares them to a random sample of mothers recruited within the Swiss Infant Feeding Study.

For this manuscript, I contributed to the conception and design of the study and to the collection of data on breastfeeding. I established the contact with the team of the Swiss Infant Feeding Study, negotiated the contract on the use of SWIFS data with the Federal Food Safety and Veterinary Office and coordinated data transfer.

I was responsible for data management and the preparation of data for analysis.

I planned and conducted the analysis and interpreted the data.

I supported writing and finalising the manuscript; I produced Figure 1, Figure 2 and Figure 3, and contributed to Table 1 and Table 2. I also contributed the revision of the manuscript.

Submitted

---



1 **Breastfeeding following in vitro fertilization in Switzerland**  
2 **– does mode of conception affect breastfeeding**  
3 **behavior?**

4 Short title: In vitro fertilization has no impact on breastfeeding

5

6 **Livia Amanda Purtschert MMed<sup>a,b,c,\*</sup>, Vera Ruth Mitter MSc<sup>a</sup>, Jarmila Anna Zdanowicz MD<sup>d</sup>, Mirja**  
7 **Amadea Minger MMed<sup>a,b,e</sup>, Anna Spaeth MPH<sup>f,g</sup>, Michael von Wolff MD<sup>a</sup>, Alexandra Sabrina Kohl**  
8 **Schwartz MD<sup>a</sup>**

9

10 <sup>a</sup> Division of Gynecological Endocrinology and Reproductive Medicine, Department of Obstetrics and  
11 Gynecology, Bern University Hospital, University of Bern, Inselspital, Friedbuehlstrasse 19, 3010 Bern,  
12 Switzerland

13 <sup>b</sup> Medical Faculty, University of Bern, Murtenstrasse 11, 3008 Bern, Switzerland

14 <sup>c</sup> Department of Internal Medicine, Cantonal Hospital of Nidwalden, Ennetmooserstrasse 19, 6370 Stans,  
15 Switzerland

16 <sup>d</sup> Department of Obstetrics and Gynecology, Bern University Hospital, University of Bern, Inselspital,  
17 Friedbuehlstrasse 19, 3010 Bern, Switzerland

18 <sup>e</sup> Department of Pediatric Surgery, Bern University Hospital, University of Bern, Inselspital,  
19 Freiburgstrasse 15, 3010 Bern, Switzerland

20 <sup>f</sup> Swiss Tropical and Public Health Institute, Socinstrasse 57, 4002 Basel, Switzerland

21 <sup>g</sup> University of Basel, Basel, Switzerland

22

23 **\*Corresponding author:**

24 Alexandra Sabrina Kohl Schwartz

25 Division of Gynecological Endocrinology and Reproductive Medicine, Department of Obstetrics and

26 Gynecology, Bern University Hospital, University of Bern, Inselspital, Friedbuehlstrasse 19, 3010 Bern,

27 Switzerland

28 alexandra.kohl-schwartz@insel.ch

29 Tel.: +41 31 632 13 03

30 **Abstract**

31 **Aim:** To investigate whether breastfeeding initiation and duration differ between women with  
32 pregnancies conceived through in vitro fertilization and women who conceived spontaneously.

33 **Methods:** Breastfeeding behavior was studied using a comparative cross-sectional study  
34 design. The in vitro fertilization group included mothers who had a singleton live birth between  
35 2010 and 2016 conceived through in vitro fertilization (N=198), either with or without  
36 gonadotropin stimulation. The population-based control population (N=1421) consisted of a  
37 randomly selected sample of mothers living in Switzerland, who gave birth to a singleton in  
38 2014.

39 **Results:** A total of 1619 women were included in this analysis. Breastfeeding initiation rate was  
40 similar between the in vitro fertilization group (93.4%) and control group (94.8%). No increased  
41 risk of earlier breastfeeding cessation after in vitro fertilization treatment could be found  
42 compared to the control group over the whole observational period of 12 months (HR=1.00, 95%  
43 CI 0.83-1.20, p=0.984). There was no difference in breastfeeding initiation or duration after  
44 gonadotropin stimulated in vitro fertilization compared to in vitro fertilization performed without  
45 gonadotropin stimulation.

46 **Conclusions:** In Switzerland, in vitro fertilization treatments are not associated with earlier  
47 breastfeeding cessation. This result is reassuring for mothers undergoing in vitro fertilization.

48

49 **Keywords**

50 breastfeeding, lactation, breastfeeding duration, fertility, gonadotropins

51 **Key Notes**

- 52 - Our cross-sectional study found that breastfeeding initiation and duration are not affected  
53 by in vitro fertilization.
- 54 - Mothers and health care professionals who might be concerned about an adverse impact  
55 of in vitro fertilization on maternal breastfeeding ability can be reassured.
- 56 - High doses of gonadotropin do not influence breastfeeding ability.



## 57 **Introduction**

58 The World Health Organization (WHO) recommends exclusive breastfeeding for a minimum  
59 period of six months after delivery, and to continue breastfeeding for two years or more after the  
60 introduction of complementary food.(1) Numerous advantages of breastfeeding have been  
61 shown, not only for the health and wellbeing of the infant, but also for the mother and mother-  
62 infant relationship.(2,3) These include a decreased risk of respiratory infections, as well as as a  
63 lower mean blood pressure, lower prevalence of diabetes or a decreased risk of becoming  
64 overweight in adulthood.(2,3) To support breastfeeding identification of possible influencing  
65 factors associated with unfavorable breastfeeding outcomes is crucial.

66 Previous studies have shown a decreased probability of breastfeeding initiation and a shorter  
67 mean breastfeeding duration with infants born preterm, of low birth weight, by caesarean  
68 section, of male sex or with health issues. Maternal factors associated with breastfeeding  
69 outcomes include: maternal age (showing the longest breastfeeding duration between 30-39  
70 years of age), smoking, obesity and maternal level of education.(2,4-6)

71 The effect of fertility treatment on breastfeeding initiation and duration has only been sparsely  
72 assessed. Subfertility and infertility treatments include in vitro fertilization (IVF) and  
73 intracytoplasmic sperm injection (ICSI), and are referred to as assisted reproductive  
74 technologies (ART).(7) ART impose substantial distress on parents.(8) Previous studies showed  
75 that ART may affect breastfeeding behavior.(6,9–13) Moreover, pregnancies after ART are  
76 associated with higher risks of small for gestational age, low birthweight, caesarean sections and  
77 preterm births.(14,15) These risk factors, especially when provoked by gonadotropin  
78 hyperstimulation, may possibly multiply the risks for disadvantageous breastfeeding  
79 behavior.(15,16)

80 This paper aims to answer the following two questions:

81 First, what effectively influences breastfeeding behavior: infertility and ART treatment, or its  
82 association with adverse obstetric and perinatal outcomes, and second, what is the effect of  
83 high-dose gonadotropin stimulation on breastfeeding behavior?  
84 An American cross-sectional study, the largest to date (N=15.615), showed lower odds of  
85 breastfeeding at eight weeks postpartum among women who conceived after fertility treatment,  
86 but this difference was no longer significant after adjustment for multiples and preterm  
87 deliveries.(13) Studies with a longer observation period showed an increased risk for earlier  
88 breastfeeding cessation after fertility treatments at four (11), six (10) or eight months.(12) In  
89 adjusted analysis often other factors additionally to ART were as well influencing breastfeeding  
90 behavior such as maternal age, mode of delivery or adverse perinatal outcomes (10-13,17). On  
91 the other hand, a small Canadian study assessing breastfeeding difficulties including 76 infants  
92 conceived by ART did not show any difference to spontaneously conceived children.(18) For  
93 Switzerland, no research on breastfeeding after ART exists so far as well as on the impact of  
94 gonadotropin stimulation on breastfeeding outcomes. Given the great importance of  
95 breastfeeding for mother and child, further research in different cultural settings is needed.  
96 The aim of our study was to investigate whether breastfeeding initiation and duration in women  
97 with pregnancies after ART differs from the breastfeeding behavior of a randomly selected  
98 sample of mothers. Additionally, we assessed the potential effect of gonadotropin stimulation.

99

## 100 **Methods**

### 101 *Setting*

102 This is a comparison of two cross-sectional surveys about the initiation and duration of  
103 breastfeeding, with a total number of 1619 mothers of singletons included. They either had  
104 fertility treatment at the Division of Endocrinology and Reproductive Medicine at the Department  
105 of Obstetrics and Gynecology in University Hospital Bern (IVF population), or participated in the  
106 Swiss Infant Feeding Study (SWIFS population) (see Figure 1).

107 *Population*

108 The IVF population included 198 women who had singleton live births after fertility treatment with  
109 or without hormonal stimulation followed by a fresh embryo transfer from 2010 to 2016.

110 Fertilization was achieved either by IVF or by ICSI. Conventional IVF treatment (cIVF) was  
111 conducted according to standard agonist or antagonist protocols using  $\geq 150$  international units  
112 (IU) of human menopausal gonadotropin (HMG) for hormonal stimulation and urinary human  
113 chorionic gonadotropin (hCG) for ovulation induction.(15) Natural cycle in vitro fertilization (NC-  
114 IVF) avoids gonadotropin stimulation to enable spontaneous follicular recruitment.(19) In NC-  
115 IVF, a trigger of 5000 IU urinary hCG for ovulation induction was applied, when the follicular  
116 maturity was achieved as described elsewhere.(15,19) Women with a regular menstrual cycle  
117 chose either NC-IVF or cIVF according to their preference.(15,19)

118 Pregnancies originating from cryopreserved embryo transfers were excluded, as were  
119 pregnancies resulting in miscarriages, perinatal deaths and multiple births.

120 The SWIFS population (N = 1421) served as the control population. It was the third national  
121 cross-sectional study about early infant feeding within Switzerland. The survey includes mothers  
122 with infants born in 2014, randomly selected by their local parent counselling service.(2) All  
123 women with missing information on either breastfeeding initiation or breastfeeding duration were  
124 excluded for this analysis.

125

126 *Data collection IVF population*

127 Data on breastfeeding initiation and duration were collected using postal questionnaires.

128 Questions were "Have you ever breastfed your baby?" (yes/no), "If 'yes', for how long?" and  
129 possible answers were < 1 month, 1 month, 2 months, 3 months etc. up to 12 months or > 12  
130 months. Mothers who did not initially respond were additionally contacted by phone.

131 Demographic data, data on medical and obstetric history, information on ART treatment,  
132 pregnancy and delivery outcomes was either collected from medical records, or from the delivery

133 clinic. Data was collected using REDCap electronic data capture tools (REDCap 8.5.19 Vanderbilt  
134 University, Nashville, USA) hosted at the Clinical Trials Unit, University of Bern.

135

### 136 *Outcomes*

137 The primary outcomes were defined as 1) breastfeeding initiation rate and 2) duration of  
138 breastfeeding. Primary outcomes were compared between the IVF- and the SWIFS population  
139 and between mothers after IVF treatment with and without gonadotropin stimulation (NC-IVF vs.  
140 cIVF).

141 Breastfeeding initiation was defined as receiving any breast milk after delivery (breastfed or  
142 pumped). Breastfeeding duration was defined as the period of time infants received any breast  
143 milk in addition to food or other liquids.

144 Further factors were assessed: maternal age, level of education, smoking during pregnancy,  
145 body mass index (BMI), parity, mode of delivery, gestational age, birthweight and infants'  
146 sex.(2,6) For the IVF population, we also assessed duration of preceding subfertility ( $\leq 24$   
147 months and  $>24$  months) and cause of subfertility (male, female or idiopathic).

148 A high level of education was defined as graduation from an university, moderate level of  
149 education as an apprenticeship, vocational school or high school diploma and low level of  
150 education as elementary school level or below. BMI categories were defined as underweight  
151  $< 18.5$ , overweight  $25.1-29.9$  or obese  $\geq 30$  kg/m<sup>2</sup>. For delivery data, low birth weight was  
152 defined as below 2 500g, and preterm delivery as delivery before 37 completed gestational  
153 weeks.

154

### 155 *Statistical analysis*

156 Statistical analysis was performed using Stata 16.0 (StataCorp LLC, Texas, USA). To compare  
157 groups, the Chi Square test was used for categorical variables, and univariable linear regression  
158 for continuous variables. Time-to-event analysis, using Kaplan-Meier survival estimates, was

159 performed to compare duration of breastfeeding between different study groups. Follow-up time  
160 started at delivery and the event of interest was the complete cessation of breastfeeding. In the  
161 SWIFS, breastfeeding duration was recorded in weeks and for the IVF population in months.  
162 This was kept for the analysis as to not lose any information. For women who did not initiate  
163 breastfeeding at all, the duration was set to 0.01. This allows the survival probabilities to reflect  
164 the true proportion of women breastfeeding at each stage. Risk of breastfeeding cessation was  
165 evaluated using multivariable Cox regression to adjust for confounding factors. Results were  
166 considered significant if  $p < 0.05$ .

167 To analyze the effect of hormonal stimulation and perinatal outcomes, three statistical models  
168 were built. The first model included important maternal characteristics (age, BMI, smoking,  
169 education) as covariate, the second focused on delivery characteristics (parity, delivery mode,  
170 gestational age) and the third included perinatal characteristics (birthweight, infant's sex). All  
171 significant covariate from each model were introduced in the final model (smoking, BMI,  
172 cesarean section, gestational age, birthweight, infant sex).

173

#### 174 *Ethics*

175 The study "Obstetric and perinatal outcome of children born after different IVF therapies (Bern  
176 IVF cohort) compared to spontaneously conceived children" was approved by the local Ethics  
177 Committee (EC Bern, 397/15) on 26 January 2016 and again on 29 August 2019 (3<sup>rd</sup>  
178 Amendment). SWIF Study was approved by the ethic commission of Basel (EC 259/13) on  
179 October 17<sup>th</sup> 2013.

180

**181 Results***182 Characteristics of study populations*

183 The population characteristics are summarized in Table 1. Mothers in the IVF population were  
184 on average 2.6 years older than SWIFS mothers smoked less often during pregnancy and had  
185 on average a lower BMI. The maternal level of education was higher in the SWIFS population,  
186 as was parity. Regarding delivery, the proportion of caesarean section was higher after IVF, but  
187 preterm deliveries did not differ.

188

*189 Breastfeeding initiation*

190 In both groups, a very high proportion of mothers started breastfeeding, with 93.4% among the  
191 IVF population and 94.8% among the control group ( $p=0.427$ ). Overall, maternal smoking during  
192 pregnancy and increased maternal BMI were both strongly associated with lower breastfeeding  
193 initiation. 11.0% of mothers who smoked during pregnancy did not initiate breastfeeding versus  
194 only 4.7% of non-smokers ( $p=0.001$ ). Mean BMI of breastfeeding mothers was 22.4 versus 23.5  
195 in mothers not breastfeeding ( $p=0.008$ ). Only 4.0% of mothers with a higher level of education  
196 did not start breastfeeding compared to 7.2% of mothers with low or middle education ( $p=0.015$ ).  
197 Furthermore, primiparous women were more likely to initiate breastfeeding than multiparous  
198 women (95.6% vs. 93.3%;  $p=0.042$ ). Mothers after caesarean section had a higher risk of not  
199 initiating breastfeeding when compared to mothers after a vaginal delivery (92.4% vs 95.7%;  
200  $p=0.006$ ). Preterm versus term birth (89.7% vs 95.2%;  $p=0.014$ ) and low versus regular  
201 birthweight (89.6% vs 94.9%;  $p=0.044$ ) were important factors with a negative influence on  
202 breastfeeding initiation. Mothers with cIVF (92.6%) started breastfeeding as often as mothers  
203 with NC-IVF (93.8%).

204

205

206 *Breastfeeding duration*

207 The duration of breastfeeding did not differ between the IVF population and the SWIFS  
208 population in the first year after delivery (Figure 2). At four weeks postpartum, 92.4% of the  
209 women conceived by IVF and 88.5% of the women in the control group were still breastfeeding.  
210 Similar results were seen at 12 weeks (IVF: 81.3% vs. control: 79.7%), 24 weeks (IVF: 65.2%  
211 vs. control: 62.9%) or 32 weeks (IVF: 48.5 vs. control: 46.5). After the tenth month, 35.4% of the  
212 IVF population was still breastfeeding and 18.2% continued breastfeeding for more than a year.  
213 There was no difference between cIVF and NC-IVF for the duration of breastfeeding. Four  
214 weeks postpartum, 88.89% of the mothers after cIVF treatment were breastfeeding their infants  
215 versus 93.75% after NC-IVF.

216 Factors significantly associated with a shorter duration of breastfeeding were maternal smoking  
217 during pregnancy, increased BMI and caesarean section. No difference could be found in  
218 breastfeeding duration between male and female infants (see Table 2).

219 The higher the gestational age and the birthweight, the longer the babies were breastfed.

220 Preterm birth in general was not significantly associated with shorter breastfeeding duration, but  
221 low birthweight was.

222 In the final model after adjustment for the important influencing factors, the HR regarding IVF  
223 was not changed (see Table 2).

224 In the subanalysis within the IVF population, the cause of infertility did not influence  
225 breastfeeding initiation or duration. If male infertility was the reason for IVF treatment, mothers  
226 were breastfeeding in 94.02% compared to 90.57% with female subfertility ( $p=0.553$ ). The  
227 duration of preceding infertility  $\leq 24$  months had no influence on breastfeeding outcomes  
228 compared to longer duration of infertility ( $\leq 24$  months: 93.42% vs.  $>24$  months: 93.44%,  
229  $p=0.995$ ).

230

**231 Discussion**

232 This study aimed to analyze the influence of IVF treatment on breastfeeding behavior in  
233 Switzerland by comparing a random population sample from the Swiss Infant Feeding Study to  
234 the population of the Bern IVF cohort. In Switzerland, the proportion of mothers starting  
235 breastfeeding is 95%, which is very high in comparison to other countries such as France  
236 (60.2%) or Germany (90%).(2,6,20) In our sample, breastfeeding initiation was high and at a  
237 similar level in both the IVF group and the SWIFS population sample.

238 Our results allow us to conclude that the mode of conception does not affect breastfeeding  
239 duration – a reassuring finding for mothers and health care professionals concerned about IVF  
240 adversely affecting maternal breastfeeding ability.

241 These findings are in line with previous studies, presenting similar breastfeeding initiation rates  
242 and breastfeeding durations when comparing mothers who conceived through any form of  
243 fertility treatments to mothers with spontaneous conceptions.(18,21–23)

244 Of the studies cited above, only the Canadian study of O’Quinn et al. focused on breastfeeding  
245 rates, difficulties and duration as outcomes. The other three studies collected information on  
246 breastfeeding as covariates, but their focus was motherhood or aspects of the development of  
247 the child.

248 O’Quinn et al. found that 54.1% of the infants who were conceived through intrauterine  
249 insemination, fertility enhancing drugs, IVF or ICSI (n=76), and 59.7% of the infants conceived  
250 spontaneously (n=150), were breastfed at four months postpartum and no differences existed  
251 regarding breastfeeding initiation, breastfeeding duration or breastfeeding difficulties.(18) From  
252 the studies collecting breastfeeding as covariates, an Australian study from 1997 showed no  
253 differences regarding breastfeeding behavior focusing on the psychological adjustment to early  
254 motherhood after conception by IVF (n=65, 68.8%) versus spontaneous (n=62, 74.6%) at four  
255 months postpartum.(21) A prospective cohort study from Belgium (ART: n=118, non-ART: n=59)  
256 (23), and a cross-sectional study from France (ART: n=66, non-ART: n=33) (22), both



257 investigating psychomotor development in infants, found no differences in breastfeeding  
258 behavior between the two groups.

259 A particular strength of our study is the focus on breastfeeding behavior as an outcome in a  
260 country like Switzerland. Another strength is the confirmation of previous risk factors for impaired  
261 breastfeeding. A recent meta-analysis showed a relative risk (RR) of 1.23 for caesarean section  
262 to be associated with shorter breastfeeding duration, and our study confirmed this finding (HR  
263 1.22).(17,24) Furthermore, our data confirms that the higher the gestational age (HR 0.99) and  
264 the birthweight (HR 0.99), the longer babies were breastfed, as described in previous  
265 research.(4) Women within our IVF group had a higher rate of caesarean sections and mean  
266 gestational age was lower. Both are important risk factors for shorter breastfeeding duration,  
267 especially after fertility treatment.(10,13,25) Despite the higher incidence of these risk factors in  
268 the IVF population, breastfeeding initiation and duration are not affected. This could be due to  
269 overcompensation on the part of the mother, which might be due to the strong internalized  
270 pressure of perception of failing further at motherhood. This is often reported by mothers after  
271 fertility treatments.(18,25,26)

272 Our study further confirms influence of lifestyle and demographic factors on breastfeeding  
273 duration.(2,4,5,27) Smoking during pregnancy was associated with earlier breastfeeding  
274 cessation (HR 1.71), similar to findings of Cohen et al. (RR 1.91).(24) Our HR of 1.04 for shorter  
275 breastfeeding duration in obese women confirms what is known from a large systematic review  
276 with HR's ranging from 1.24 to 2.54.(28) However, it is difficult to disentangle the different risk  
277 factors within the IVF group (more caesarean sections/lower gestational age), as they smoke  
278 less and have a lower BMI – both factors that positively influence breastfeeding.(24,28) As  
279 presented in the meta-analysis from Cohen et al. (RR 1.68) our results further confirm that  
280 women with a lower level of education breastfeed for a shorter time period (HR 1.48).(24)

281 The critical factors affecting breastfeeding behavior are the same in women after IVF as after  
282 spontaneous conception, and include the perinatal health of the infant, maternal factors and the

283 support of the health care system. Support in early motherhood is an important factor in  
284 promoting breastfeeding.(29) In Switzerland, one third of all obstetric clinics are certified by the  
285 United Nations Children's Fund (UNICEF) and the WHO as baby-friendly hospitals, which  
286 accounts for the high breastfeeding initiation rate.(30,31) Breastfeeding support in Switzerland  
287 further includes: discussions about breastfeeding during routine pregnancy consultations,  
288 support in breastfeeding management postnatally through nursing staff at the delivery clinic and  
289 breastfeeding support through a midwife after discharge.(2,32) These services are covered by  
290 the mandatory health insurance, which all persons have.(2,32) The mode of conception itself  
291 does not seem to influence breastfeeding behavior.

292 However, there is also controversial literature on the effect of mode of conception.(9–  
293 13,17,18,21–23) Five studies on breastfeeding following fertility treatment found differences at  
294 certain time points during the first year postpartum.(9–13) First, a large Chinese prospective  
295 cohort study (N=935) found lower breastfeeding rates at 6 months postpartum in the fertility  
296 treatment group compared to a spontaneous conception group; however, similar breastfeeding  
297 rates were found at 12 months postpartum.(10) Similarly to our study, they accounted for  
298 confounding factors such as maternal BMI or infant's birthweight.(10) Second, a smaller Italian  
299 retrospective case-control study (N=188) found that a lower percentage of women after fertility  
300 treatment were breastfeeding at 6 weeks postpartum, compared to women who gave birth after  
301 spontaneous conception, but at 6 months postpartum breastfeeding rates no longer differed.(9)  
302 Third, similar results are reported in an Australian prospective cohort study (N=183) showing  
303 lower percentages of women breastfeeding at 6 weeks and 8 months in the ART group.(12)  
304 However, in both latter studies, small sample sizes and a single center study design limit their  
305 evidence.(9,12) Fourth, Michels et al. showed that mothers after fertility treatment were more  
306 likely to cease breastfeeding before the 12th month after birth, even after adjustment for  
307 confounders such as preterm birth.(11) In a US cohort study including 1361 women after ART,  
308 they accounted for different factors, but not for twins.(11) Contrary to the results of Michels et al.

309 (11), the fifth, a recent cross-sectional surveillance from the US reported lower odds of  
310 breastfeeding at 8 weeks postpartum among women who conceived through fertility treatments  
311 (n=1056), but this difference was no longer significant after adjustment for multiples and preterm  
312 birth.(13) However, breastfeeding duration was only analyzed at 8 weeks postpartum.(13)  
313 Furthermore, both US studies were unable to conclude whether a specific treatment or a  
314 combination of treatments may impact breastfeeding, as different fertility treatments were  
315 grouped together (e.g. intrauterine insemination, ovulation induction only, IVF).(11,13) Unlike  
316 previous studies, we were able to focus on breastfeeding outcomes specifically after IVF and  
317 ICSI in combination with fresh embryo transfer, by excluding fertility enhancing methods or  
318 intrauterine insemination. Furthermore, by comparing gonadotropin stimulated IVF to non-  
319 gonadotropin stimulated IVF, it is possible to assess the effect of high-dose hormonal stimulation  
320 on breastfeeding outcomes. Since this comparison showed no significant impact on  
321 breastfeeding initiation and duration in our study, it is reassuring that the use of high doses of  
322 hormones does not seem to influence breastfeeding ability.

323 The following two aspects are limitations of this study: First, the randomized sample of mothers  
324 in the SWIFS could possibly include infants conceived through fertility treatments, as the SWIFS  
325 did not collect information on mode of conception. Because only 2.5% of children born in  
326 Switzerland are generated by fertility treatments, the potential effect on our data analysis is very  
327 small.(33) Second, a selection bias cannot be ruled out, meaning that well-educated women are  
328 possibly more interested in research, and that this has subsequently led to higher participation  
329 rate in both study groups.

330

### 331 **Conclusion**

332 Three conclusions can be drawn from this study. First, in Switzerland, in vitro fertilization  
333 treatments are not associated with earlier breastfeeding cessation. Second, our results confirm

334 findings from other studies: infants with low gestational age, low birthweight or infants born by  
335 caesarean section are less frequently breastfed, and maternal obesity, smoking and low level of  
336 education negatively influence breastfeeding behavior. Third, in our study there is no difference  
337 in breastfeeding behavior between mothers undergoing NC-IVF compared to mothers  
338 undergoing hormonally stimulated cIVF therapy.

### 339 **Acknowledgements**

340 The authors would like to express their gratitude to the participants for their time and interest in  
341 the study. We are thankful to Pascale Fasel, Daniela Steiner, Marlene Berchtold for support in  
342 data collection and Karin Gross, Julia Dratva and Elisabeth Zemp Stutz for providing the data  
343 from the SWIF Study. For language editing, we would like to thank Robert Cohen.

### 344 **List of abbreviations**

- 345 - ART: Assisted reproductive technology
- 346 - BMI: Body mass index
- 347 - cIVF: Conventional in vitro fertilization
- 348 - EC: Ethic commission
- 349 - hCG: Human chorionic gonadotropin
- 350 - HMG: Human menopausal gonadotropin
- 351 - HR: Hazard ratio
- 352 - ICSI: Intracytoplasmic sperm injection
- 353 - IU: International units
- 354 - IVF: In vitro fertilization
- 355 - NC-IVF: Natural cycle in vitro fertilization
- 356 - SWIFS: Swiss Infant Feeding Study
- 357 - UNICEF: United Nations Children's Fund
- 358 - WHO: World Health Organization
- 359 - 95% CI: 95% Confidence interval

360

361 **Conflict of interest**

362 The authors declare no potential conflicts of interest with respect to research, authorship, and/or  
363 publication of this article.

364 **Financial support**

365 Data evaluation was supported by a grant from Merck (Switzerland) AG, Zug, Switzerland. The  
366 PhD of Vera Mitter is supported by an unrestricted grant from IBSA Institut Biochimique SA. The  
367 funder did not have any influence on the conduct of the study. It is an investigator-initiated study;  
368 the funding body was not included in the design or execution of the study.

369

370 **References**

- 371 1. Kramer MS, Kakuma R. The optimal duration of exclusive breastfeeding, a systematic  
372 review. World Health Organization [internet], Switzerland 2001 [cited 2020 Apr 18].  
373 Available from: URL:  
374 [https://www.who.int/nutrition/publications/infantfeeding/WHO\\_NHD\\_01.08/en/](https://www.who.int/nutrition/publications/infantfeeding/WHO_NHD_01.08/en/)
- 375 2. Gross K, Spaeth A, Dratva J, Zemp Stutz E. SWIFS - Swiss infant feeding study. Basel  
376 Swiss Tropical and Public Health Institute. 2014.
- 377 3. Horta BL, Bahl R, Martines JC, Victora CG. Evidence on the long-term effects of  
378 breastfeeding, systematic review and meta-analyses. World Health Organization [internet],  
379 Switzerland 2007 [cited 2020 Apr 18]. Available from: URL:  
380 <https://apps.who.int/iris/handle/10665/43623>
- 381 4. Neifert M, Bunik M. Overcoming clinical barriers to exclusive breastfeeding. *Pediatr Clin*  
382 *North Am.* 2013 Feb;60(1):115–45.
- 383 5. Kronborg H, Væth M. The influence of psychosocial factors on the duration of  
384 breastfeeding. *Scand J Public Health.* 2004 Jun 1;32(3):210–6.
- 385 6. Castelli C, Perrin J, Thirion X, Comte F, Gamberre M, Courbiere B. Maternal Factors  
386 Influencing the Decision to Breastfeed Newborns Conceived with IVF. *Breastfeed Med.*  
387 2015 Feb;10(1):26–30.
- 388 7. Cousineau TM, Domar AD. Psychological impact of infertility. *Best Pract Res Clin Obstet*  
389 *Gynaecol.* 2007 Apr;21(2):293–308.
- 390 8. Demyttenaere K, Nijs P, Evers-Kiebooms G, Koninckx PR. Coping, ineffectiveness of  
391 coping and the psychoendocrinological stress responses during in-vitro fertilization. *J*  
392 *Psychosom Res.* 1991;35(2–3):231–43.
- 393 9. Cromi A, Serati M, Candeloro I, Uccella S, Scandroglio S, Agosti M, et al. Assisted  
394 reproductive technology and breastfeeding outcomes: a case-control study. *Fertil Steril.*  
395 2015 Jan;103(1):89–94.
- 396 10. Sha T, Yan Y, Gao X, Liu S, Chen C, Li L, et al. Association of Assisted Reproductive  
397 Techniques with Infant Feeding Practices: A Community-Based Study in China. *Breastfeed*  
398 *Med.* 2019 Aug 1;14(9):654–61.
- 399 11. Michels KA, Mumford SL, Sundaram R, Bell EM, Bello SC, Yeung EH. Differences in infant  
400 feeding practices by mode of conception in a United States cohort. *Fertil Steril.* 2016  
401 Apr;105(4):1014-1022.e1.
- 402 12. Hammarberg K, Fisher JRW, Wynter KH, Rowe HJ. Breastfeeding after assisted  
403 conception: a prospective cohort study. *Acta Paediatr Oslo Nor* 1992. 2011  
404 Apr;100(4):529–33.
- 405 13. Barrera CM, Kawwass JF, Boulet SL, Nelson JM, Perrine CG. Fertility treatment use and  
406 breastfeeding outcomes. *Am J Obstet Gynecol.* 2019 Mar 1;220(3):261.e1-261.e7.

- 407 14. Pandey S, Shetty A, Hamilton M, Bhattacharya S, Maheshwari A. Obstetric and perinatal  
408 outcomes in singleton pregnancies resulting from IVF/ICSI: a systematic review and meta-  
409 analysis. *Hum Reprod Update*. 2012 Sep 1;18(5):485–503.
- 410 15. Kohl Schwartz AS, Mitter VR, Amylidi-Mohr S, Fasel P, Minger MA, Limoni C, et al. The  
411 greater incidence of small-for-gestational-age newborns after gonadotropin-stimulated in  
412 vitro fertilization with a supraphysiological estradiol level on ovulation trigger day. *Acta  
413 Obstet Gynecol Scand*. 2019;98:1575-1584.
- 414 16. Sunkara SK, Lamarca A, Polyzos NP, Seed PT, Khalaf Y. Live birth and perinatal  
415 outcomes following stimulated and unstimulated IVF: Analysis of over two decades of a  
416 nationwide data. *Hum Reprod*. 2016;31(10):2261–7.
- 417 17. Fisher J, Hammarberg K, Wynter K, McBain J, Gibson F, Boivin J, et.al. Assisted  
418 conception, maternal age and breastfeeding: an Australian cohort study. *Acta Paediatr  
419 Oslo*. 2013;102:970-976.
- 420 18. O’Quinn C, Metcalfe A, McDonald SW, Raguz N, Tough SC. Exclusive breastfeeding and  
421 assisted reproductive technologies: a Calgary cohort. *Reproductive Sys Sexual Disord*  
422 2012; S 5: 2.
- 423 19. Von Wolff M. The role of Natural Cycle IVF in assisted reproduction. *Best Pract Res Clin  
424 Endocrinol Metab*. 2019 Nov 9;33:35–45.
- 425 20. Kohlhuber M, Rebhan B, Schwegler U, Koletzko B, Fromme H. Breastfeeding rates and  
426 duration in Germany: a Bavarian cohort study. *Br J Nutr*. 2008 May;99(5):1127–32.
- 427 21. McMahon CA, Ungerer JA, Tennant C, Saunders D. Psychosocial adjustment and the  
428 quality of the mother-child relationship at four months postpartum after conception by in  
429 vitro fertilization. *Fertil Steril*. 1997 Sep;68(3):492–500.
- 430 22. Raoul-Duval A, Bertrand-Servais M, Frydman R. Comparative prospective study of the  
431 psychological development of children born by in vitro fertilization and their mothers. *J  
432 Psychosom Obstet Gynecol*. 1993 Jan 1;14(2):117–26.
- 433 23. Place I, Englert Y. A prospective longitudinal study of the physical, psychomotor, and  
434 intellectual development of singleton children up to 5 years who were conceived by  
435 intracytoplasmic sperm injection compared with children conceived spontaneously and by  
436 in vitro fertilization. *Fertil Steril*. 2003 Dec;80(6):1388–97.
- 437 24. Cohen SS, Alexander DD, Krebs NF, Young BE, Cabana MD, Erdmann P, et al. Factors  
438 Associated with Breastfeeding Initiation and Continuation: A Meta-Analysis. *J Pediatr*.  
439 2018;203:190-196.e21.
- 440 25. Ladores S, Aroian K. First-Time Mothers with a History of Infertility: Their Internalized  
441 Pressure to Breastfeed. *J Hum Lact*. 2015 Aug;31(3):504–10.
- 442 26. Barnes M, Roiko A, Reed R, Williams C, Willcocks K. Experiences of birth and  
443 breastfeeding following assisted conception. *Breastfeed Rev Prof Publ Nurs Mothers Assoc  
444 Aust*. 2013 Mar;21(1):9–15.

- 445 27. Meedya S, Fahy K, Kable A. Factors that positively influence breastfeeding duration to 6  
446 months: a literature review. *Women Birth J Aust Coll Midwives*. 2010 Dec;23(4):135–45.
- 447 28. Turcksin R, Bel S, Galjaard S, Devlieger R. Maternal obesity and breastfeeding intention,  
448 initiation, intensity and duration: a systematic review. *Matern Child Nutr*. 2014  
449 Apr;10(2):166–83.
- 450 29. Sikorski J, Renfrew MJ, Pindoria S, Wade A. Support for breastfeeding mothers: a  
451 systematic review. *Paediatr Perinat Epidemiol*. 2003 Oct;17(4):407–17.
- 452 30. Merten S, Ackermann-Liebrich U. Exclusive Breastfeeding Rates and Associated Factors in  
453 Swiss Baby-Friendly Hospitals. *J Hum Lact*. 2004 Feb;20(1):9–17.
- 454 31. United Nations Children's Fund. Baby-friendly hospital. UNICEF [Internet], [cited 2020 Apr  
455 18]. Available from: URL: [https://www.unicef.ch/de/unsere-arbeit/schweiz-](https://www.unicef.ch/de/unsere-arbeit/schweiz-liechtenstein/baby-freundliches-spital)  
456 [liechtenstein/baby-freundliches-spital](https://www.unicef.ch/de/unsere-arbeit/schweiz-liechtenstein/baby-freundliches-spital)
- 457 32. Breastfeeding Promotion Switzerland. Breastfeeding - a healthy start to life. Breastfeeding  
458 Promotion Switzerland [Internet booklet] 2017, [cited 2020 Mar 19]. Available from: URL:  
459 [https://www.stillfoerderung.ch/logicio/pmws/stillen\\_\\_intern\\_4\\_2\\_\\_de.html](https://www.stillfoerderung.ch/logicio/pmws/stillen__intern_4_2__de.html)
- 460



461 **Table legends**

462

463 **Table 1:** Characteristics of IVF population and SWIFS (Swiss Infant Feeding Study) population.464 *Note.* Values are presented as means with standard deviations or n with proportions (%).

465 a) in vitro fertilization, b) mean, c) standard deviation, d) body mass index kg/m<sup>2</sup>, e) maternal  
466 level of education was defined as follows: high (graduation from a university), moderate  
467 (apprenticeship or high school degree), low (elementary school level or below), f) preterm  
468 delivery ≤ 37 weeks, g) vacuum extraction or forceps.

469

470 **Table 2:** Multivariable Cox regression models for the duration of breastfeeding.471 *Note.* HR >1 means a higher risk for breastfeeding cessation, so shorter breastfeeding time

472 Model I: adjusted multivariable Cox regression model with breastfeeding duration as outcome  
473 and IVF treatment as exposure adjusted for maternal characteristics

474 Model II: adjusted multivariable Cox regression model with breastfeeding duration as outcome  
475 and IVF treatment as exposure adjusted for delivery characteristics

476 Model III: adjusted multivariable Cox regression model with breastfeeding duration as outcome  
477 and IVF treatment as exposure adjusted for perinatal characteristics

478 Final Model: adjusted multivariable Cox regression model with breastfeeding duration as  
479 outcome and IVF treatment as exposure adjusted for smoking, BMI, cesarean section,  
480 gestational age, birthweight and infant sex

481 a) hazard ratio, b) confidence interval, c) maternal level of education was defined as follows:  
482 high (graduation from a university), moderate (apprenticeship or high school degree), low  
483 (elementary school level or below), d) body mass index kg/m<sup>2</sup>, e) vacuum extraction or forceps,  
484 f) preterm delivery ≤ 37 weeks

485

486 **Figure legends**

487

488 **Figure 1:** Study population flow-chart.

489

490 **Figure 2:** Kaplan-Meier estimates displaying the proportion of women breastfeeding over time  
491 after delivery.


492 Up: IVF population vs SWIFS population; below: Subanalysis within IVF population



**Table 1: Characteristics of study population**

	IVF <sup>a</sup> Group n = 198 n/ $\mu^b$	%/SD <sup>c</sup>	SWIFS Group n = 1421 n/ $\mu^b$	%/SD <sup>c</sup>	P-value
<b>Demographics</b>					
<b>Maternal age (years) (n=1615)</b>	34.79	3.76	32.23	4.30	<b>&lt;0.001</b>
<b>Maternal smoking during pregnancy</b>	5	2.53	168	11.84	<b>&lt;0.001</b>
<b>Maternal BMI (kg/m<sup>2</sup>)<sup>d</sup> (n=1563)</b>	21.97	3.29	22.51	3.64	<b>0.047</b>
<b>Maternal education in categories<sup>d</sup> (n=1569)</b>					
High	71	44.10	757	53.76	<b>0.003</b>
Moderate	89	55.28	600	42.61	
Low	1	0.62	51	3.62	
<b>Fertility status</b>					
<b>Parity (n=1607)</b>					
Primiparous	157	79.29	751	53.30	<b>&lt;0.001</b>
Multiparous	41	20.71	658	46.70	
<b>Delivery details</b>					
<b>Gestational age (days) (n=1533)</b>	274.59	13.02	276.23	12.37	<b>0.085</b>
<b>Gestational age in categories</b>					
$\geq 37$ gestational weeks	187	94.44	1239	92.81	<b>0.047</b>
33-37 gestational weeks	9	4.55	87	6.52	
29-32 gestational weeks	1	0.51	9	0.67	
24-28 gestational weeks	1	0.51	0	0.00	
<b>Preterm birth<sup>f</sup> (n=1542)</b>	11	5.56	96	7.14	<b>0.412</b>
<b>Delivery mode (n=1619)</b>					
Spontaneous vaginal delivery	80	40.40	843	59.32	<b>&lt;0.001</b>
Instrumental vaginal delivery <sup>g</sup>	28	14.14	159	11.19	
Caesarean Section	90	45.45	419	29.70	
<b>Infant</b>					
<b>Birthweight (grams) (n=1588)</b>	3274.99	580.12	3321.16	505.99	<b>0.239</b>
<b>Birthweight in categories</b>					
Normal	186	93.94	65	4.68	<b>0.396</b>
Low	12	6.06	1325	95.32	
<b>Infant sex</b>					
Female	89	44.95	704	49.61	<b>0.219</b>
Male	109	55.05	715	50.39	

**Table 2. Multivariable Cox regression models for the duration of breastfeeding**

	Unadjusted HR <sup>a</sup> (95% CI <sup>b</sup> ) (for each covariate individually)	P value	Model I Adjusted for maternal characteristics HR <sup>a</sup> (95% CI <sup>b</sup> )	P value	Model II Adjusted for delivery characteristics HR <sup>a</sup> (95% CI <sup>b</sup> )	P value	Model III Adjusted for perinatal characteristics HR <sup>a</sup> (95% CI <sup>b</sup> )	P value	Final model Adjusted HR <sup>a</sup> (95% CI <sup>b</sup> )	P value
<b>In vitro fertilization</b>	1.00 (0.83 – 1.20)	0.984	1.04 (0.85 – 1.28)	0.698	0.96 (0.80 – 1.16)	0.695	1.00 (0.83 – 1.21)	0.968	1.05 (0.87 – 1.27)	0.615
<b>Maternal demographics</b>										
<b>Maternal age (years)</b>	0.98 (0.97 – 1.00)	0.054	0.99 (0.98 – 1.01)	0.438						
<b>Maternal education<sup>c</sup></b>										
High	1.00		1.00							
Moderate	1.41 (1.23 – 1.62)	<0.001	1.31 (1.13 – 1.52)	<0.001						
Low	1.83 (1.25 – 2.67)	0.002	1.48 (0.97 – 2.25)	0.067						
<b>Maternal factors</b>										
<b>Smoking during pregnancy (yes/no)</b>	1.68 (1.37 – 2.06)	<0.001	1.60 (1.30 – 1.99)	<0.001					1.71 (1.38 – 2.13)	<0.001
<b>BMI (kg/m<sup>2</sup>)<sup>d</sup></b>	1.04 (1.02 – 1.06)	<0.001	1.05 (1.03 – 1.07)	<0.001					1.04 (1.02 – 1.03)	<0.001
<b>Fertility status</b>										
<b>Parity (continuous)</b>	0.93 (0.84 – 1.02)	0.108								
Primiparous	1.03 (0.90 – 1.19)	0.601			1.02 (0.88 – 1.17)	0.814				
Multiparous	1.00				1.00					
<b>Delivery</b>										
<b>Mode of delivery</b>										
Spontaneous vaginal delivery	1.00				1.00					
Instrumental vaginal delivery <sup>e</sup>	1.12 (0.91 – 1.39)	0.276			1.13 (0.91 – 1.40)	0.287				
Caesarean section	1.29 (1.11 – 1.50)	0.001			1.30 (1.12 – 1.51)	0.001				
<b>Caesarean section (yes/no)</b>	1.27 (1.10 – 1.46)	0.001							1.22 (1.04 – 1.41)	0.012
<b>Perinatal</b>										
<b>Gestational age (days)</b>	0.99 (0.98 – 0.99)	0.001					0.93 (0.99 – 1.00)	0.093	1.00 (0.99 – 1.00)	0.299
<b>Gestational age in categories</b>										
≥ 37 gestational weeks	1.00									
33-37 gestational weeks	1.06 (0.79 – 1.43)	0.680								
29-32 gestational weeks	1.24 (0.55 – 2.76)	0.606								
24-28 gestational weeks	2.05 (0.29 – 14.56)	0.474								
<b>Preterm birth<sup>f</sup></b>	1.09 (0.83 – 1.44)	0.536								
<b>Birthweight (grams)</b>	1.00 (1.00 – 1.00)	0.003					1.00 (1.00 – 1.00)	0.166	1.00 (1.00 – 1.00)	0.086
<b>Birthweight in categories</b>										
Normal	1.00									
Low (< 2'500g)	1.37 (1.02 – 1.84)	0.034								
<b>Infant sex</b>										
Female	1.00						1.00		1.00	
Male	1.04 (0.91 – 1.19)	0.585					1.07 (0.93 – 1.23)	0.362	1.09 (0.94 – 1.26)	0.256







### 5.3 Article 3: Endometrial thickness in NC-IVF

#### **Thin Endometrium Is Also Associated With lower clinical pregnancy rate in unstimulated menstrual cycles: a study based on natural cycle IVF**

##### Contributions

For this project, I supported data collection and completion, and in the interpretation of the results.

I contributed to the writing of the final manuscript.







# Thin Endometrium Is Also Associated With Lower Clinical Pregnancy Rate in Unstimulated Menstrual Cycles: A Study Based on Natural Cycle IVF

Michael von Wolff<sup>1\*</sup>, Monika Fäh<sup>1</sup>, Marie Roumet<sup>2</sup>, Vera Mitter<sup>1</sup>, Petra Stute<sup>1</sup>, Georg Griesinger<sup>3</sup> and Alexandra Kohl Schwartz<sup>1</sup>

<sup>1</sup> Division of Gynaecological Endocrinology and Reproductive Medicine, University Women's Hospital, Inselspital University Hospital, Bern, Switzerland, <sup>2</sup> CTU Bern, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, <sup>3</sup> Division of Gynaecological Endocrinology and Reproductive Medicine, University Women's Hospital, University Hospital Schleswig-Holstein, Lübeck, Germany

## OPEN ACCESS

### Edited by:

William Colin Duncan,  
University of Edinburgh,  
United Kingdom

### Reviewed by:

Andreas Norbert Schüring,  
Universitätsklinikum Münster,  
Germany  
Alicia Yvonne Christy,  
Veterans Health Administration (VHA),  
United States

### \*Correspondence:

Michael von Wolff  
michael.vonwolff@insel.ch

### Specialty section:

This article was submitted to  
Reproduction,  
a section of the journal  
Frontiers in Endocrinology

Received: 01 June 2018

Accepted: 10 December 2018

Published: 20 December 2018

### Citation:

von Wolff M, Fäh M, Roumet M,  
Mitter V, Stute P, Griesinger G and  
Kohl Schwartz A (2018) Thin  
Endometrium Is Also Associated With  
Lower Clinical Pregnancy Rate in  
Unstimulated Menstrual Cycles: A  
Study Based on Natural Cycle IVF.  
Front. Endocrinol. 9:776.  
doi: 10.3389/fendo.2018.00776

**Introduction:** Does the endometrial thickness (EMT) at the time of follicle aspiration correlate with the pregnancy rate in unstimulated menstrual cycles?

**Materials and Methods:** This is a retrospective, observational single center study. 105 women with regular menstrual cycles undergoing their first NC-IVF cycle with an embryo transfer were analyzed. Clinical pregnancy and live birth rates were calculated and data were adjusted for women's age, cycle day of follicle aspiration and body mass index (BMI).

**Results:** Age of participants was 35.0 y [32.0; 37.0]. Follicle aspiration was performed on day 14.0 [12.0; 15.0] of the cycle. Total clinical pregnancy rate was 24.8% and live birth rate 15.2% per transfer. Pregnancy rate in women with endometrial thickness  $\leq 7$  mm ( $n = 27$ ) was 7.4 and 30.8% in women  $> 7$  mm ( $n = 78$ ) (OR 5.56, 1.22–25.36) ( $P = 0.03$ ). Live birth rates were not significantly different. Quadratic regression analysis revealed lower pregnancy rates in women with thin (around  $< 8$  mm) as well as with thick (around  $> 11$  mm) endometria.  $P$ -value after crude quadratic analysis was 0.028 and after adjustment for age, day of aspiration and BMI was 0.039. Significance was not reached for live birth rates.

**Conclusion:** Thin endometrium should also be considered as an independent negative prognostic factor for achieving pregnancy in women without ovarian stimulation.

**Keywords:** endometrium, pregnancy rate, live birth rate, natural cycle IVF, spontaneous cycle

## INTRODUCTION

The importance of the endometrium for the development and maintenance of pregnancy is clearly proven. However, it is unclear which endometrial factors are of relevance (1). Histological examination in couples who wish to conceive makes little sense as a biopsy would be necessary. In transvaginal ultrasound evaluation endometrial thickness, the echo pattern and endometrial perfusion are evaluated (2). Ultrasound analysis of endometrial thickness (EMT) is most commonly performed, as this is the easiest and best reproducible technique.

The significance of the endometrial thickness has been investigated in numerous studies and in meta-analyses. The investigations are essentially limited to *in vitro* fertilization treatments (IVF) with high-dose stimulation therapy and intrauterine insemination treatment (IUI) with different ovarian stimulation regimes.

In IVF treatments, a thin endometrium is associated with lower pregnancy rates. The clinical pregnancy rate is related to a lower chance of pregnancy if endometrial thickness is  $\leq 7$  mm (OR 0.42, 95% CI: 0.27, 0.67) (3). The data regarding a thick endometrium is not so clear. A previous study described reduced pregnancy rates in women with endometrium  $> 14$  mm (4), whereas other studies did not find decreased or found even increased pregnancy rates (5–7).

In women undergoing IUI with low dose stimulation, such a relationship does not appear to exist. In a recent meta-analysis with IUI treatments combined with a gonadotrophin, clomifene citrate, or aromatase inhibitor stimulation, there was no evidence of a difference in EMT between women who conceived and women who did not conceive (MDrandom: 0.51, 95% CI:  $-0.05$ , 1.07) (8).

Because ovarian stimulation treatments were used, the results of these studies cannot be transferred to the unstimulated situation. As a result, the study findings have only limited use in a fertility work-up for infertility to assess the relevance of the endometrium as a cause of sterility.

Based on this, we investigated the pregnancy rate as a function of the endometrial thickness using the Natural Cycle IVF (NC-IVF) model, in which no ovarian stimulation except ovulation induction with human chorionic gonadotropin, hCG, and luteal phase progesterone supplementation was administered.

Since strict inclusion and exclusion criteria such as the transfer of only one embryo were defined and thus numerous confounders on the pregnancy rate could be excluded, this may be the first study which also allows a cautious estimate of the importance of endometrial thickness for a pregnancy event in a spontaneous cycle.

## METHODS

### Study Population and Participants

The retrospective, observational single center study was performed between 2011 and 2016. A total of 225 women, 18–42 years of age with regular menstrual cycles (24–32 days) and basal FSH concentrations  $< 10$  IU/L undergoing their first IVF cycle treatment with transfer of a single embryo were screened. Women had been offered both, NC-IVF and conventional IVF but decided themselves which therapy they preferred. Women without a transfer, with endometriosis  $> rAFS$  II° (revised American Fertility Society) (as diagnosed by laparoscopy or clinical and ultrasound analysis), with fibroids as diagnosed by ultrasound or in case ultrasound was not conclusive by hysteroscopy and with sperm collection by testicular sperm extraction (TESE) were excluded.

NC-IVF patients were monitored using ultrasound and analysis of luteinizing hormone (LH) and  $E_2$  concentrations.

When the follicle diameter reached at least 18 mm and the  $E_2$ -concentration was expected to be  $\geq 800$  pmol/L, 5000 IU of hCG (Pregnyl®, MSD Merck Sharp & Dohme GmbH, Lucerne, Switzerland) were administered and patients were scheduled 36 h later for oocyte retrieval. EMT was measured at the time of oocyte aspiration by different physicians and different ultrasound machines. Endometrium thickness was measured in mm without decimal numbers in our clinical routine as intraindividual and interindividual variations did not justify a more precise measurement. Follicles were aspirated without anesthesia and without analgesia using 19G single lumen needles (220 mmHg) as described elsewhere (9). After aspiration, follicles were flushed and aspirated 3 times each using 2–5 ml flushing medium with heparin (SynVibro® Flush, Origio, Berlin, Germany). The flushing volume was adapted according to the size of the follicles. Fertilization was achieved by standard ICSI in all cases. Embryos were transferred on day 2 or 3 after aspiration as long term culture was not required with only one embryo. Women received luteal phase support with vaginal micronized progesterone. EMT at the time of follicle aspiration as well as biochemical and clinical (defined as ultrasound detection of an amniotic sac) pregnancy rates and live birth rate were analyzed per embryo transfer.

The study was carried out in accordance with the recommendations of the local ethical committee of the IRB Internal Review Board, Inselspital Bern on October 12th 2012 (IRB 12–223). All subjects gave informed written consent in accordance with the Declaration of Helsinki.

### Statistical Analysis

Endometrial thickness was first considered as a categorical variable and therefore women were divided into two endometrial thickness groups ( $\leq 7$  mm vs.  $> 7$  mm). Patients' baseline characteristics were compared for quantitative variables by using the *t*-test, or if normality assumption was not satisfied, by non-parametric Wilcoxon-test. For qualitative variables (cause of infertility), the Chi-square test was used or by Fisher's exact test when the sample size was small.

Clinical pregnancy and live birth rate were compared using a logistic regression. For each outcome, we first assessed the crude (unadjusted) association between EMT categories and the outcome. We then adjusted the model for potential confounders by including women's age, day of follicle aspiration and BMI in the model. The cause of the infertility was not considered as we had been shown in another, not yet published, study, that the cause of infertility is not a prognostic factor in NC-IVF. Endometrial thickness was then considered as a continuous variable and its effect on pregnancy and on live birth was further analyzed using logistic regression. For each outcome, we first assessed the crude (unadjusted) and adjusted association between EMT and the outcome, using endometrial thickness as a linear term. Then, we examined the linearity of the effect of EMT on the outcomes by fitting a crude and adjusted quadratic regression model and by testing whether the addition of a quadratic term significantly increased the fit of the model. Models were compared using likelihood ratio tests. *P*-value and the confidence interval of models parameters were estimated using the normal approximation.

## RESULTS

Two hundred and twenty five women undergoing a NC-IVF cycle were identified. One hundred and eleven women (49.3%) were excluded due to missing transfer (premature ovulation 14%, aspirations without oocyte 15%, oocytes without fertilization or arrested embryo growth 16%), 5 women (2.2%) due to endometriosis, and 4 women (1.8%) due to TESE, resulting in 105 women to be included in the analysis. Cycles and transfers were not canceled due to thin endometrium. The basic characteristics of these women are shown in **Table 1**. Age of participants was 35.0 y [32.0; 37.0], cycle day of follicle aspiration was 14.0 [12.0; 15.0] and duration of infertility was 3.00 y [2.00; 4.00]. Infertility factors were severe male factor (sperm < 5 Mill/ml) ( $n = 26$ , 24.8%), moderate and mild male factor (sperm 5- < 15 Mill/ml or total motility <40%) ( $n = 24$ , 22.9%), tubal factor (peritubal adhesions, blockage of one or both fallopian tubes), endometriosis rAFS I-II<sup>o</sup> and mixed factors ( $n = 22$ , 21.0%), and idiopathic infertility ( $n = 33$ , 31.4%).

Overall AMH concentrations were 12.0 pmol/l [6.0; 22.0]. Clinical pregnancy rate and live birth rate as a function of endometrial thickness are shown in **Figures 1, 2**. Endometrial thickness was 6 mm in 6 women, 7 mm in 21, 8 mm in 31, 9 mm in 17, 10 mm in 15, 11 mm in 9, 12 mm in 5, and 16 mm in 1 woman.

The pregnancy rate was firstly compared in women with endometrial thickness  $\leq 7$  mm ( $n = 27$ ) vs.  $> 7$  mm ( $n = 78$ ). The groups did not differ regarding women's age, cycle day of aspiration, duration of infertility, BMI and cause of infertility (**Table 1**). Clinical pregnancy rates in women with endometrial thickness  $\leq 7$  mm ( $n = 27$ ) vs.  $> 7$  mm ( $n = 78$ ) were 7.4 and 30.8%, respectively.

Crude and adjusted logistic regression, adjusted for women's age, day of follicle aspiration and BMI, showed an increased odds of pregnancy in patients with increased endometrial thickness  $> 7$  mm (crude OR 5.56, 95% CI: 1.22–25.36,  $p = 0.027$ ; adjusted OR 5.50, 95% CI: 1.14–26.62,  $p = 0.034$ ). Likewise, the odds of live birth was also increased in patients with increased endometrial thickness, however, associations were not significant (crude OR 6.19, 95% CI: 0.78–49.27,  $p = 0.085$ ; adjusted OR 5.98, 95% CI: 0.74–48.56,  $p = 0.094$ ).

We also used endometrial thickness as a continuous variable in logistic models. There is a not significant trend of a linear relationship between continuous endometrial thickness and pregnancy [crude OR (per log (mm)): 6.63, 95% CI: 0.61–71.99,  $P = 0.12$ ]; adjusted OR [per log (mm)]: 4.52, 95% CI: 0.38–53.14,  $P = 0.23$ ]. Likewise, there is a non-significant trend of a linear, non-significant relationship between continuous endometrial thickness and live birth [crude OR (per log (mm)): 8.99, 95% CI: 0.54–150.06,  $P = 0.13$ ]; adjusted OR [per log (mm)]: 8.02, 95% CI: 0.41–157.41,  $P = 0.17$ ]. However, the model fit is better when modeling a quadratic relationship instead of a linear relationship between endometrial thickness and clinical pregnancy ( $p$ -value from a model comparison = 0.03). The crude and adjusted quadratic models indicate a decreased odds of pregnancy for thinner (around  $< 8$  mm,  $n = 27$ ) but

also for very thick (around  $> 11$  mm,  $n = 5$ ) endometrium ( $p$ -value for quadratic relationship: crude  $p = 0.028$ ; adjusted  $p = 0.039$ ).

Likewise, there was also a trend of a better model fit when modeling a quadratic relationship between endometrial thickness and live birth ( $p$ -value from a model comparison = 0.08). The crude and adjusted quadratic models indicate a decreased odds of pregnancy for thinner but also for very thick endometrium ( $p$ -value for quadratic relationship: crude  $p = 0.066$ ; adjusted  $p = 0.093$ ).

## DISCUSSION

### Main Findings

This study described for the first time the association of pregnancy rates with endometrial thickness in unstimulated menstrual cycles with fresh embryo transfers. The evaluation was adjusted for the main factors that could influence the chance of pregnancy (age) (10) and the EMT (day of aspiration and BMI) (11).

### Strengths and Limitations

To minimize the influence of possible influencing variables, the investigation was carried out using 105 NC-IVF cycles, in which—as in almost all NC-IVF cycles—only one embryo was transferred. Different numbers of embryos would not have allowed a comparison of pregnancy rates. However, it needs to be noted that first we performed a retrospective analysis and second that the strict inclusion and exclusion criteria resulted in a limited number of participants. This might be a reason why significance was only reached for pregnancy but not for live birth rate.

Endometrium thickness was analyzed by several physicians using different ultrasound machines. Therefore, and due to the intra and interindividual variations of endometrial measurements, EMT was analyzed without decimal numbers, which could have affected the precision of the analysis.


We defined the ultrasound detection of an amniotic sac as a clinical pregnancy, which might explain the high miscarriage rate. However, the miscarriage rate could not be allocated to a specific endometrial thickness.

### Interpretation

In all studies published to date, the association of endometrial thickness with pregnancy rate was performed only with high-dose IVF stimulations, cryopreserved embryos (12) or low-dose IUI stimulations. The IVF studies suggested an increase in the pregnancy rate with an endometrium  $> 7$  mm (3), whereas the IUI studies failed to demonstrate such a relationship (8). Our study confirmed the reduced pregnancy rate in gonadotrophin-stimulated IVF therapies with an endometrial thickness of  $\leq 7$  mm. However, an increase in the pregnancy rate in a particularly thick endometrium of  $> 11$  mm (6),  $> 13$  mm (5), or  $> 14$  mm (7), as demonstrated with gonadotrophin-stimulated IVF therapies, could not be confirmed. In contrast, we even observed a tendency to lower pregnancy rates in women with particularly thick endometrium. In IUI treatments with low dose

**TABLE 1** | Baseline characteristics of all analyzed patients (n = 105) and of women with endometrial thickness ≤7 mm (n = 27) vs. >7 mm (n = 78) (data are shown as median and upper and lower quartile ranges).

	Total (n = 105)	EMT ≤7 mm (n = 27)	EMT >7 mm (n = 78)	P-value
Age at time of aspiration (years)	35.0 (32.0; 37.0)	37.0 (33.5; 39.5)	34.0 (32.0; 36.0)	0.06
Cycle day of follicle aspiration	14.0 (12.0; 15.0)	14.0 (13.0; 15.0)	14.0 (12.0; 15.0)	0.46
Infertility since (years)	3.00 (2.0; 4.0)	3.0 (2.0; 3.0)	3.0 (2.0; 4.0)	0.41
Body mass index, BMI	21.3 (20.0; 23.4)	20.8 (19.2; 22.3)	21.6 (20.2; 23.5)	0.13
Cause of infertility (n, %)				0.98
Severe male factor	26(24.8%)	7(25.9%)	19(24.4%)	
moderate/mild male factor	24(22.9%)	6(22.2%)	18(23.1%)	
Tubal factor, endometriosis rAFS I-II° and mixed factors	22(21.0%)	5(18.5%)	17(21.8%)	
Idiopathic	33(31.4%)	9(33.3%)	24(30.8%)	
Thickness of the endometrium(mm)	8.0 (7.0; 10.0)	7.0 (7.0; 7.0)	9.0 (8.0; 10.0)	Not applicable




gonadotrophin stimulation, neither an increased nor a reduced pregnancy rate (8) was found.

The reason for the reduced pregnancy rates in patients undergoing gonadotrophin-stimulated IVF therapies with an endometrial thickness ≤7mm compared to an endometrial thickness >7mm is unclear. It has been speculated that basal layer endometrial oxygen concentrations are increased in patients with a thin endometrium, which might be detrimental for embryo implantation (13). It was further speculated that embryos developing *in*

*vitro* are especially susceptible to this higher oxygen exposure (8).

In hormone-stimulated IUI treatments, there is no significant correlation between the endometrial thickness and the pregnancy rate (8). As a possible reason for this, it was discussed that embryos develop more robustly *in vivo* and are less susceptible to high oxygen exposure (8). However, this explanation is purely hypothetical. Therefore, it could be speculated that in hormone-stimulated IUI treatments a thin endometrium is associated with lower pregnancy rates, but that this association could not be



detected. In the meta-analysis by Weiss et al. (8), the primary analysis showed a significantly thinner endometrium in women who did not conceive (MD: 0.48, 95% CI: 0.18, 0.77). The significance was only lost when the calculation was performed using a random effects model (MD random: 0.51, 95% CI: -0.05, 1.07) which was chosen due to the heterogeneity of studies. This raises the question of whether a thin endometrium is also associated with lower pregnancy rates in stimulated IUI treatments; however, this association could not be detected due to the heterogeneity across the studies.

Pregnancy rates have also been studied in modified natural cycles with frozen-thawed embryo transfers (12). Mean endometrial thickness did not differ between patients achieving ongoing pregnancy and those who did not. However, the pregnancy rates in women with endometrium of  $< 7$  mm ( $n = 41$ ) was only 9.8% whereas in women with an endometrium of  $\geq 7$  mm it was 21.0% (12). Even though the differences were not statistically different, these data support the hypothesis, that pregnancy rates are lower in women with thin endometrium, even in unstimulated cycles.

Lower pregnancy rates with a thin endometrium in unstimulated cycles are unlikely to be biologically plausible. It is unlikely that a tendency toward a thin endometrium could be inherited if it significantly affected fertility. There are, of course, numerous factors that lead to a thin endometrium or which are associated with a thin endometrium and lower the chances of pregnancy. The most relevant factors are multiple curettages (14) and exposure of the uterus to radiation (15). However, these factors are either iatrogenic or due to an acquired pathology and therefore cannot explain the reduced pregnancy rates with a thin endometrium as described in other studies. In our study only 1/6 (16.7%) of the women with an endometrial thickness of 6 mm and 4/21 (19.0%) with an endometrial

thickness of 7 mm had undergone a curettage and none an uterine radiation. Accordingly a curettage could be a reason for a thin endometrium in a few women but not in the majority.

On the other hand, the question arises of how relevant a reduced pregnancy rate with a thin endometrium really is. Of the 6 non-pregnant women in our study with an endometrial thickness of 6 mm, 3 women became pregnant later on. Thus, the clinical relevance of a thin endometrium without a recognizable cause such as multiple curettages etc., is questionable.

If a patient's endometrium is very thin, and if this may be a possible cause of infertility, the question of possible therapeutic options arises. Stimulation with estrogens can hardly be carried out in a spontaneous cycle, since high estrogen concentrations reduce FSH release and inhibit folliculogenesis and also impair endometrial function (16). Santamaria et al. (17), developed a treatment with bone marrow-derived stem cells, which seems to increase the chances of pregnancy in refractory Asherman's syndrome and endometrial atrophy. Whether such a complex and still experimental therapy is useful in cases with physiologically thin endometrium is questionable, since in such cases the endometrium is thinner but presumably functionally intact.

The differences in studies regarding the effect of a thick endometrium on the pregnancy rate are contradictory. In the gonadotrophin-stimulated IVF studies, a thick endometrium appears to be associated with a higher pregnancy rate (5–7). However, such a dependence could not be demonstrated in hormone-stimulated IUI therapies (8). We even found a tendency toward a reduced pregnancy rate. However, it needs to be noted that this finding is based on a statistical model which only provides a very vague tendency toward a lower pregnancy rate with very thick endometrium. Furthermore, the thickness which leads to decreased pregnancy rates cannot be defined.

The differences of the studies are barely explainable. It possibly concerns physiologically different endometrial function and IVF activity states, which do not allow a comparison of the different treatments as the endometrium is likely to be more proliferated and oedematous with gonadotrophin stimulation. It is also possible that the differences are due to the low number of patients in our study which can be considered a weakness of our study. Since the inclusion and exclusion criteria were very strict to be able to examine a patient population as homogeneously as possible, the patient numbers are limited.

In conclusion, the study confirmed that thin endometrium is also associated with lower pregnancy rates in unstimulated cycles. Therefore, thin endometrium should be regarded as an independent prognostic factor for achieving a pregnancy. However, as the pregnancy rate in women with thin endometrium is not zero but only reduced, thin endometrium should not be regarded as an infertility but rather as a fertility-reducing factor.

## REFERENCES

- Cakmak H, Taylor HS. Implantation failure: molecular mechanisms and clinical treatment. *Hum Reprod Update* (2011) 17:242–53. doi: 10.1093/humupd/dmq037
- Singh N, Bahadur A, Mittal S, Malhotra N, Bhatt A. Predictive value of endometrial thickness, pattern and sub-endometrial blood flows on the day of hCG by 2D doppler in *in vitro* fertilization cycles: a prospective clinical study from a tertiary care unit. *J Hum Reprod Sci.* (2011) 4:29–33. doi: 10.4103/0974-1208.82357
- Kasius A, Smit JG, Torrance HL, Eijkemans MJ, Mol BW, Opmear BC, et al. Endometrial thickness and pregnancy rates after IVF: a systematic review and meta-analysis. *Hum Reprod Update* (2014) 20:530–41. doi: 10.1093/humupd/dmu011
- Weissman A, Gotlieb L, Casper RF. The detrimental effect of increased endometrial thickness on implantation and pregnancy rates and outcome in an *in vitro* fertilization program. *Fertil Steril.* (1999) 71:147–9. doi: 10.1016/S0015-0282(98)00413-0
- Wu Y, Gao X, Lu X, Xi J, Jiang S, Sun Y, et al. Endometrial thickness affects the outcome of *in vitro* fertilization and embryo transfer in normal responders after GnRH antagonist administration. *Reprod Biol Endocrinol.* (2014) 12:96. doi: 10.1186/1477-7827-12-96
- Yuan X, Saravelos SH, Wang Q, Xu Y, Li TC, Zhou C. Endometrial thickness as a predictor of pregnancy outcomes in 10787 fresh IVF-ICSI cycles. *Reprod Biomed Online* (2016) 33:197–205. doi: 10.1016/j.rbmo.2016.05.002
- Ma NZ, Chen L, Dai W, Bu ZQ, Hu LL, Sun YP. Influence of endometrial thickness on treatment outcomes following *in vitro* fertilization/intracytoplasmic sperm injection. *Reprod Biol Endocrinol.* (2017) 15:5. doi: 10.1186/s12958-016-0222-5
- Weiss NS, van Vliet MN, Limpens J, Hompes PGA, Lambalk CB. Endometrial thickness in women undergoing IUI with ovarian stimulation. How thick is too thin? A systematic review and meta-analysis. *Hum Reprod.* (2017) 32:1009–18. doi: 10.1093/humrep/dex035
- von Wolff M, Hua YZ, Santi A, Ocon E, Weiss B. Follicle flushing in monofollicular *in vitro* fertilization almost doubles the number of transferable embryos. *Acta Obstet Gynecol Scand.* (2013) 92:346–8. doi: 10.1111/aogs.12054
- van Loendersloot LL, van Wely M, Limpens J, Bossuyt PM, Repping S, van der Veen F. Predictive factors in *in vitro* fertilization (IVF): a systematic review and meta-analysis. *Hum Reprod Update* (2010) 16:577–89. doi: 10.1093/humupd/dmq015
- Panidis D, Tziomalos K, Papadakis E, Vosnakis C, Betsas G, Tsourdi E, et al. Uterine volume and endometrial thickness in the early follicular phase in patients with polycystic ovary syndrome. *Endocr Pract.* (2014) 20:540–7. doi: 10.4158/EP13058.OR
- Groenewoud ER, Ben J, Al-Oraiby A, Brinkhuis EA, Broekmans FJM, de Bruin JP, et al. Influence of endometrial thickness on pregnancy rates in modified natural cycle frozen-thawed embryo transfer. *Acta Obstet Gynecol Scand.* (2018) 97:808–15. doi: 10.1111/aogs.13349
- Casper RF. It's time to pay attention to the endometrium. *Fertil Steril.* (2011) 96:519–21. doi: 10.1016/j.fertnstert.2011.07.1096
- Azumaguchi A, Henmi H, Ohnishi H, Endo T, Saito T. Role of dilatation and curettage performed for spontaneous or induced abortion in the etiology of endometrial thinning. *J Obstet Gynaecol Res.* (2017) 43:523–9. doi: 10.1111/jog.13254
- Critchley HO, Bath LE, Wallace WH. Radiation damage to the uterus – review of the effects of treatment of childhood cancer. *Hum Fertil.* (2002) 5:61–6. doi: 10.1080/1464727022000198942
- Horcajadas JA, Mínguez P, Dopazo J, Esteban FJ, Domínguez F, Giudice LC, et al. Controlled ovarian stimulation induces a functional genomic delay of the endometrium with potential clinical implications. *J Clin Endocrinol Metab.* (2008) 93:4500–10. doi: 10.1210/jc.2008-0588
- Santamaria X, Cabanillas S, Cervelló I, Arbona C, Raga F, Ferro J, et al. Autologous cell therapy with CD133+ bone marrow-derived stem cells for refractory Asherman's syndrome and endometrial atrophy: a pilot cohort study. *Hum Reprod.* (2016) 31:1087–96. doi: 10.1093/humrep/dew042

**Conflict of Interest Statement:** GG has received consultant fees from MSD, Merck Serono, GlycoTope, Ferring, IBSA, VitroLife, Finox, ReprodWissen GmbH, and TEVA GmbH, ZIVA, Abbott, NMC Healthcare; has received speaker fees from Merck Serono, MSD, IBSA, VitroLife, ReprodWissen GmbH and Abbott.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 von Wolff, Fäh, Roumet, Mitter, Stute, Griesinger and Kohl Schwartz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

#### 5.4 Article 4: Time to live birth in subfertile women

### **Chronic endometritis - Shortened time to live birth in subfertile women undergoing hysteroscopy and endometrial diagnostic biopsy**

#### Contributions

I was involved in the planning and conceptualisation of the study. I supported data collection, and conducted an in-depth literature review.

SG and I wrote the first draft. I contributed significantly to redrafting of the manuscript, introduced most of the references and prepared the final draft.

I prepared the data for analysis, conducted the analysis and interpreted the data.

I produced Figure 1, Figure 3, Table 1 and Table 2.

I also undertook the revision of the analysis and manuscript.

**Submitted**

---





1 **Chronic endometritis - Shortened time to live birth in subfertile women undergoing**  
2 **hysteroscopy and endometrial diagnostic biopsy**

3 Vera R. Mitter, MSc<sup>1</sup>

4 Sheila Meier, MM<sup>1</sup>

5 Tilman T. Rau, MD<sup>2</sup>

6 Tessa Gillon, MD<sup>3</sup>

7 Michael D. Mueller, MD<sup>3</sup>

8 Marcel Zwahlen, PhD, Prof.<sup>4</sup>

9 Michael von Wolff, MD, Prof.<sup>1</sup>

10 and Alexandra S. Kohl Schwartz, MD<sup>1,\*</sup>

11

12 <sup>1</sup> Division of Gynecological Endocrinology and Reproductive Medicine, Bern University  
13 Hospital and University of Bern, Bern, Switzerland

14 <sup>2</sup> Institute for Pathology, Bern University Hospital and University of Bern, Bern,  
15 Switzerland

16 <sup>3</sup> Department of Gynecology and Gynecological Oncology, University Hospital of Bern  
17 and University of Bern, Bern, Switzerland.

18 <sup>4</sup> Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

19

20 \* Correspondence address:

21 Dr. Alexandra S. Kohl Schwartz

22 Division of Gynecological Endocrinology and Reproductive Medicine, Bern University  
23 Hospital, Inselspital, Friedbuehlstrasse 19, Bern 3010, Switzerland

24 Tel: +41 31 632 18 33, E-mail: alexandra.kohl-schwartz@insel.ch

25 **Conflict of interest**

26 The authors have stated explicitly that there are no conflicts of interest in connection with this  
27 article.

28

29 **Funding**

30 The data evaluation for this study was supported by an independent medical grant from Merck  
31 (Switzerland) AG, Zug, Switzerland. The PhD of Vera Mitter is supported by an unrestricted  
32 grant from IBSA Institut Biochimique SA. The funding body did not have any roles in design  
33 or conduct of the study or in the preparation of the manuscript. The authors have no  
34 competing interests.

35

## 36 **Abstract**

### 37 Introduction

38 Research has suggested that chronic endometritis is associated with repeated implantation  
39 failure and recurrent pregnancy loss. However, standardized diagnostic procedures to detect  
40 chronic endometritis and its treatment are still controversially discussed. We therefore aimed  
41 to analyse the effect of endometrial diagnostic biopsy and subsequent antibiotic treatment in  
42 case of chronic endometritis on time to live birth.

### 43 Materials and Methods

44 We conducted a historical cohort study (January 2014 – December 2018) at our University  
45 based infertility center including subfertile women (n=108) with repeated implantation failure  
46 and recurrent pregnancy loss as indications. We excluded women with relevant pathologies  
47 for mentioned indications according to international guidelines. 67 women (62%) had an  
48 endometrial diagnostic biopsy with immunohistochemically staining for CD138 to detect  
49 plasma cells from 2016-2018 (biopsy group), whereas the 41 women treated from 2014-2016  
50 only had an office hysteroscopy (reference group). If  $\geq 1$  plasma cell was detected, women  
51 were diagnosed with chronic endometritis and treated with doxycycline 100 mg twice a day  
52 orally for two weeks. We performed survival analysis (Kaplan-Meier) and Cox regression  
53 stratified for indication.

### 54 Results

55 Biopsy group and reference group did not differ regarding patient's characteristics. The  
56 indications, repeated implantation failure and recurrent pregnancy loss, did not substantially  
57 impact the outcome in sensitivity analysis. Women in the biopsy group had higher chances for  
58 a pregnancy (hazard ratio 2.28; 95% confidence interval 1.23-4.24;  $P = 0.009$ ) and for a live  
59 birth (hazard ratio 2.76; 95% confidence interval 1.30-5.87;  $P = 0.008$ ) compared to women  
60 of reference group. Within the biopsy group, overall live birth rate tended to be slightly higher  
61 in the 42 (63.0%) women diagnosed and treated for chronic endometritis compared to 25  
62 (37%) women without chronic endometritis (live birth: hazard ratio 1.75; 95% confidence  
63 interval 0.57-5.38;  $P = 0.327$ ).

### 64 Conclusions

65 Diagnostic intervention such as endometrial biopsy with subsequent antibiotic treatment in case  
66 of chronic endometritis in women with repeated implantation failure and recurrent pregnancy  
67 loss shortens time-to- live birth, suggesting the procedure to be beneficial.

68

69 **Keywords**

70 Endometrial diagnostic biopsy/ chronic endometritis / recurrent pregnancy loss / repeated  
71 implantation failure / plasma cell / time-to-pregnancy/ time to live birth

72

73 **Abbreviations**

74 CE, Chronic endometritis

75 CE<sub>neg</sub>, group of women with negative diagnosis of chronic endometritis

76 CE<sub>pos</sub>, group of women with positive diagnosis of chronic endometritis

77 CI, 95% Confidence interval

78 HR, Hazard ratio

79 IVF, In vitro fertilisation

80 RPL, Recurrent pregnancy loss

81 RIF, Repeated implantation failure

82 HSC, Hysteroscopy

83

84 **Key message**

85 Diagnostic endometrial biopsy with subsequent antibiotic treatment in case of chronic  
86 endometritis ( $\geq 1$  plasma cell) is associated with a shorter time-to-pregnancy and time to live  
87 birth compared to hysteroscopy assessment in women with recurrent pregnancy loss or  
88 repeated implantation failure.

**89 Introduction**

90 Repeated implantation failure (RIF) and recurrent pregnancy loss (RPL) impose a heavy  
91 burden on women desiring children, especially when etiology remains unclear. Implantation  
92 failure has been identified by the European society of human reproduction and embryology as  
93 one of the main unresolved issues in reproductive medicine.

94 Known risk factors for RIF and RPL are parental age, obesity, environmental exposure  
95 (including smoking and alcohol), genetic factors, uterine malformations or pathologies and  
96 thyroid autoimmunity. (1–3) Additionally, antiphospholipid syndrome is a risk factor for  
97 RPL. (3) Work-up according to guidelines includes not only ultrasound examination, but also  
98 diagnostic hysteroscopy.

99 In RIF the transfer of an embryo following in-vitro fertilization (IVF) treatment fails  
100 repeatedly to reach a stage of clinical pregnancy (more than three good quality blastocysts/ six  
101 good quality cleavage stage embryos). (4) The World Health Organization defines RPL as  
102 three or more consecutive miscarriages; it affects from 1% to 5% of women. (2,5,6)

103 Chronic endometritis (CE) is often subtle and asymptomatic, or it presents with atypical  
104 symptoms such as pelvic pain, vaginal discharge, abnormal bleeding, dyspareunia, and  
105 leucorrhea. While there is no doubt that CE is of high importance clinically, there is still no  
106 universally accepted definition, standardized diagnostic procedure, or treatment confirmed by  
107 randomized clinical trials.(7–9) The prevalence of CE in women with RIF reported in  
108 published studies ranges from 14.0% up to 67.5%; the prevalence of CE in women with RPL  
109 from 9.3% up to 67.6%.(7) It is unclear if this differences in prevalence result from  
110 differences in study populations, prevalence of different pathogens or diagnostic assessment  
111 techniques. (10)

112 By hysteroscopy (HSC) CE can be suspected by the presence of mucosal edema, focal or  
113 diffuse endometrial hyperemia, and micro polyps (<1mm). (11,12) The diagnosis should be  
114 confirmed by an endometrial biopsy stained immunohistochemically with Syndecan-1 for  
115 plasma (CD138) cells.(10,13,14) A meta-analysis showed higher pregnancy and live birth  
116 rates after antibiotic treatment for plasma cell positive chronic endometritis in women with  
117 repeated implantation failure.(15) This was also found in a meta-analysis of trials on  
118 endometrial scratch injury in women who had two or more implantation failures.(16)

119 Overall, the impact of chronic endometritis and its treatment on pathologies like RIF and  
120 RPL, which are both affected by endometritis is still not clear. As chronic endometritis seems  
121 to affect implantation and the early pregnancy, the most relevant outcome parameter would be  
122 live birth rate, or even better time to live birth.

123 Accordingly, the aim of our study was to focus on the effect of endometrial diagnostics and  
124 treatments on time-to-live birth by using the method of survival analysis (Kaplan-Meier) n  
125 women undergoing hysteroscopy for both, RIF or RPL  
126

## 127 **Materials and Methods**

### 128 **Population**

129 We screened retrospectively all women treated at our center for RIF or RPL between January  
130 2014 and December 2018. We defined RIF as a failure to achieve a pregnancy after the  
131 transfer of six or more cleavage-stage embryos.(4) For RPL we used the WHO definition of  
132  $\geq 3$  recurrent pregnancy losses. (2,5)

133 Screening work-up consisted of: thyroid function and antibody testing, exclusion of  
134 antiphospholipid syndrome and assessment of the uterine cavity by ultrasound. Consecutively  
135 we defined the following inclusion criteria for our study: women undergoing HSC or HSC  
136 and biopsy, age $\leq$ 42 years at HSC, body mass index (BMI) between 18 and 35 kg/m<sup>2</sup>, and a  
137 regular uterine anatomy, assessed with transvaginal ultrasound or hysterosalpingosonography.  
138 As exclusion criteria, we defined according to guidelines, the following conditions known to  
139 be associated with RIF and RPL: parental chromosomal abnormalities, sperm retrieved by  
140 testicular sperm extraction, or severe thyroid dysfunction. We did not exclude other  
141 thrombophilic conditions with the exception of antiphospholipid syndrome in women with  
142 RPL (Figure 1).(17,18)

143

### 144 **Diagnosis and histological assessment of chronic endometritis**

145 Before we conducted HSC, we ruled out chlamydia (*Chlamydia trachomatis*) and gonorrhea  
146 (*Neisseria gonorrhoeae*) with PCR from cervical-vaginal swabs. We performed the HSC and  
147 biopsy during late follicular phase, in an outpatient setting without anesthesia. For HSC we  
148 used a rigid 30° view 2·9 mm diameter hysteroscope with an atraumatic tip (TROPHYscope;  
149 Karl Storz, Tuttlingen Germany). We did not provide preoperative analgesia, sedation, or  
150 antibiotics, but cervical preparation with dequalinium chloride (Fluomizin®). We documented  
151 the appearance of the uterine cavity and the endometrium with photos (Figure 2). At the end  
152 of the exam, we performed an endometrial biopsy using a flexible biopsy device (Pipelle) and  
153 we conserved endometrial tissue in 10% formaldehyde solution. We immunohistochemically  
154 stained the sections of the paraformaldehyde-fixed paraffin-embedded endometrial biopsy  
155 samples with a monoclonal antibody against CD138, a specific marker for plasma cells  
156 according to routine protocols (Figure 2). Formalin-fixed paraffin-embedded slides with a

157 thickness of 3µm were pretreated with heat (95°C, 20 minutes) and then incubated with the  
158 CD138 antibody (Serotec, Cologne, Germany) in EDTA buffer at pH 9 for 15 minutes at a  
159 dilution of 1:1600, with diacetylbenzene serving as the chromogenic agent. We  
160 counterstained with hemalaun-eosin (HE) to compare the two diagnostic methods. For the  
161 diagnosis of CE as defined within this study, we relied on immunohistochemistry, considering  
162  $n \geq 1$  plasma cell per whole-slide tissue section (one plasma cell in the hotspot) as sufficient for  
163 the diagnosis of CE.(11) Before 2016 HSC without biopsy was the standard diagnostic  
164 intervention in women with RPL or RIF, these women served as historical controls.

165

### 166 **Treatment of chronic endometritis**

167 Women diagnosed with CE according to immunohistochemistry were treated with  
168 doxycycline 100 mg twice daily for two weeks. Women with an intolerance to doxycycline  
169 received ciprofloxacin 400 mg daily for two weeks. We did not perform a test-of-cure. In case  
170 of recurrent pregnancy loss after treatment, the women were re-biopsied and retreated with  
171 ciprofloxacin as a second-line treatment, as described above.

172

### 173 **Fertility treatment**

174 For women with RIF, IVF treatment was started again after biopsy, one month after  
175 termination of antibiotic therapy, or when the couple felt ready. The subsequent IVF cycles  
176 were conducted either as natural IVF cycle (19) or as conventional gonadotropin-stimulated  
177 IVF, either in an agonist or antagonist protocol. We provided luteal phase support using  
178 progesterone for up to 12 weeks of gestation.(20) For women with RPL we provided vaginal  
179 micronized progesterone 200 mg per day in the subsequent pregnancy.(21,22)

180

### 181 **Statistical analysis**

182 We compared the women from the biopsy group to the women who had HSC only, the  
183 reference group. For subgroup analysis we subdivided the women with biopsy according to  
184 the immunohistochemically diagnosis of plasma cells with CE; biopsy without diagnosis of  
185 CE (CEneg) and biopsy with diagnosis of CE (CEpos). We compared baseline characteristics  
186 and outcomes (pregnancy rates, live birth rates, time-to-pregnancy, and time to live birth  
187 among the biopsy and the reference group and between RIF and RPL. We used chi-squared  
188 test for categorical variables and univariable linear regression for continuous outcomes. For  
189 the time-to-event analyses, follow-up time started at the date of HSC or biopsy (biopsy is  
190 performed during HSC). The follow-up time ended at the event of interest or at last contact

191 date recorded for each woman; the event of interest is either the date of clinical pregnancy  
192 confirmed by ultrasound display of an amniotic cavity (time-to-pregnancy) or the delivery  
193 date (time to live birth). We used survival analysis (Kaplan-Meier) to compare time-to-  
194 pregnancy and live birth or expected live birth between the groups. In further comparisons,  
195 we used multivariable Cox regression models including the following information: age of the  
196 women (continuous) and parity (parous vs nulliparous). We stratified Cox regression models  
197 for RIF and RPL women allowing for different baseline hazards via separate risk set  
198 definitions in the RIF and RPL group. In a sensitivity analysis, we conducted separate Cox  
199 regressions for women with RIF and women with RPL and among the two subgroups, CE<sub>neg</sub>,  
200 and CE<sub>pos</sub>, compared to reference group. For the survival curves in Figure 3 we used inverse  
201 probability weighting to account for different proportions of RIF or RPL women and  
202 different age structure of mothers within the treatment groups.(23) For statistical analysis, we  
203 used STATA version 16.0, (STATA Corporation LLC, Texas, USA). We considered a p-  
204 value < 0.05 as significant.

205

## 206 **Ethical approval**

207 The local ethical committee approved this study (BASEC & Kantonale Ethik Kommission  
208 Bern: 2017-01739), allowing for the use of encoded clinical data after patient information or  
209 the further use of biomaterials after informed consent retrieval.

210

## 211 **Results**

### 212 **Population and diagnosis of chronic endometritis**

213 The flow-chart of the study population is presented in Figure 1. In total, 108 women fulfilled  
214 the inclusion criteria of whom 47 (43.5%) had RIF and 61 (56.5%) had RPL. From 2014-  
215 2016 we performed only HSC in 41 (38.0 %) women (reference group); from 2016- 2018 we  
216 performed HSC with subsequent biopsy in 67 women. 24 (35.8%) women showed suspicion  
217 of CE at hysteroscopy with strawberry aspects, endometrial edema, irregular endometrium,  
218 and hyperemic areas with prominent leukoplakia (Figure 2). Among the women with biopsy,  
219 a total of 42 women were diagnosed positive for CE (CE<sub>pos</sub>) which refers to a prevalence of  
220 62.7%, and 25 (37.3%) women did not have any plasma cells according to histology and  
221 immunohistochemically CD138 staining (CE<sub>neg</sub>).

222 Among the women with a biopsy, with HSC we could correctly identify 18 women as CE  
223 positive out of 42 (sensitivity of 42.8%) and 19 as CE negative out of 25 (specificity of  
224 76.0%) when comparing to immunohistochemically stained biopsy samples ( $P = 0.119$ ). HE



225 staining alone was not sufficient to identify plasma cells as well, with only 11 women  
226 correctly diagnosed as positive for CE (sensitivity of 26.2%) and 21 as negative for CE  
227 (specificity of 84.0%) in comparison to immunohistochemistry ( $P = 0.333$ ). False positive  
228 cells in HE staining were due mainly to pseudo-decidual cells of endometrial stromal cells, which  
229 could display a crescent-like cytoplasmic rim and represent a mimicker of plasma cells  
230 (Figure 2). The 41 patients diagnosed with CE (CEpos) took a first course of doxycycline and  
231 one woman took ciprofloxacin.

232

### 233 **Patient characteristics**

234 Patient characteristics are displayed in Table 1. The reasons for infertility are different  
235 between RIF and RPL patients ( $P < 0.005$ ) but not among the three studied groups. Nine  
236 patients with RPL suffered from endometriosis.

237

### 238 **Observation time**

239 The mean observation time until live birth or last follow-up date was the longest for the  
240 control group, with 1.86 years (SD 1.34). For CEneg the mean time was 0.88 years (SD 0.61),  
241 and for CEpos it was 0.75 years (SD 0.47).

242

### 243 **Fertility outcomes**

244 The chance for a clinical pregnancy and for a live birth was significantly higher for women  
245 with biopsy and subsequent management of endometrial pathology compared to the reference  
246 group (Table 2). The hazard ratio (HR), stratified for indication is 2.28 (CI 95% 1.23 – 4.24,  
247  $P = 0.009$ ) for a clinical pregnancy and 2.76 for a live birth (CI 95% 1.30 – 5.86,  $P = 0.008$ ).  
248 Survival analysis shows a shorter time-to-pregnancy and to live birth for the biopsied women  
249 (Figure 3).

250 In a subgroup analysis the chance for clinical pregnancy is highest for CEpos women (HR  
251 2.39, 95% CI 1.20-4.36,  $P = 0.010$ ) and only somewhat higher for CEneg women (HR 2.04;  
252 95% CI 0.85-4.86,  $P = 0.110$ ). This trend is also confirmed by subgroup analysis, independent  
253 if the women had RIF or RPL. Adjustment for maternal age and parity does not substantially  
254 affect the outcomes. All detailed results of the Cox regression are presented in Table 2.

255 Detailed fertility outcomes are presented in supplemental Table 1.

256

**257 Discussion**

258 This is a historical cohort study on the effect of biopsy with subsequent management of  
259 endometrial pathology on time to live birth in women with RIF and RPL. Our results show  
260 that a diagnostic endometrial biopsy with subsequent diagnosis and treatment in case of CE is  
261 associated with reduced time-to-pregnancy and reduced time to live birth in both conditions,  
262 RIF and RPL. Women who had a biopsy and were treated for CE (CEpos) had the same  
263 chances compared to those without CE and a better chance compared to women with HSC  
264 only (reference group).

265 This leads us to two hypotheses: first, diagnostic endometrial biopsy and CD138 staining with  
266 subsequent treatment of CE is important in the high-risk population of women with RIF and  
267 RPL; and second, even women not diagnosed with CE may achieve a better reproductive  
268 outcome in a shorter time after a diagnostic endometrial biopsy.

269 Our study has two strengths: a differentiated diagnostics with HSC, endometrial biopsy, and  
270 immunohistochemically staining for CD138; an outcome that was not yet investigated in  
271 combination with CE, namely time-to-pregnancy and live birth. The sensitivity of our HSC  
272 investigation correlates well with a study published recently. (12)

273 Our study also has several limitations. First it is an observational historical cohort and the  
274 sample size is limited. We analyzed patients with RIF and RPL as one group. Even though we  
275 did this on purpose, it might be questionable. We therefore focused on time to live birth as the  
276 main outcome and addressed this problem by a stratification of the Cox regression models for  
277 RIF and RPL. For the survival curves in Figure 3 we used inverse probability weighting to  
278 account for different proportions of RIF and RPL and different age structure of mothers.(23)

279 Live birth as outcome is valid for both conditions and subgroup analysis confirmed that the  
280 procedure is mainly beneficial for women diagnosed and treated for CE (CEpos) independent  
281 if they had RIF and RPL. The inclusion of women with ongoing pregnancy might result in  
282 slightly overestimating the results presented for live births. However, we were generally  
283 interested in the long-term follow-up of women after the intervention independent of the  
284 course between intervention and the recorded outcome. Compared to many other studies  
285 looking at one subsequent embryo transfer or the next subsequent pregnancy, we did not  
286 restrict the observation time under the assumption that processes may use some time and  
287 influence of interventions might be beneficial later.

288 Our results is based on the suggestion that hysteroscopy alone or HE staining is no longer  
289 considered sufficient to clearly diagnose CE or to identify plasma cells (13).

290 Immunohistochemically staining of CD138 cells is considered to be best practice, but there

291 are various methods regarding quantification and what threshold should lead to the  
292 confirmation of a diagnosis of CE (10). We chose a more conservative approach of  
293 diagnosing with the threshold of one plasma cell per high power field in the hot spot, which  
294 may have led to an overestimation of CE prevalence.

295 CE is often associated with the presence of bacterial pathogens. This leads to an unbalanced  
296 resident microbiota of the uterus and abnormal pattern of lymphocyte subset in the  
297 endometrium which may influence reproductive immunology (24). The immunological  
298 changes may be associated with poor endometrial receptivity (25). We assume that treatment  
299 of CE helps to reconstitute the uterine microenvironment and patterns of lymphocytes. This  
300 might strengthen the endometrial receptivity and improve reproductive outcome.

301 A prospective study analyzing immunologic cells within the endometrium of 178 RIF and 155  
302 RPL women revealed a significantly higher prevalence of uterine Natural killer cells (NKs)  
303 (53.2 vs 45.2 & 42.9%,  $P < 0.001$ ) in women with RIF compared to women with RPL.

304 However, all sub-fertile populations had increased percentage of peripheral type NKs ( $P =$   
305  $0.001$ ), and exhibited increased of CD69+ activation ( $P = 0.005$ ), higher levels of B cells ( $P <$   
306  $0.001$ ), an elevated ratio of CD4:CD8 ( $P < 0.001$ ) and a higher proportion of Th1+ CD4s ( $P =$   
307  $0.001$ ) (26). Furthermore, defective endometrial prostaglandin synthesis has been observed in  
308 women with RIF (27). Based on the presence of uterine NK cells and defective prostaglandin  
309 synthesis, different immunological responses on the implantation process seems to be  
310 additionally unfavourable in women with RIF compared to women with RPL.

311 Our results show a difference in time-to-pregnancy and, more important, time to live birth  
312 between the biopsy group and the reference group. It is questionable if the biopsy also has an  
313 impact on women without CE (CEneg) as their reproductive outcome also seem so benefit  
314 from the procedure. A scratch induces an inflammatory response and may trigger  
315 immunological reconstitution. (28,29) It might be particularly relevant in a more vulnerable  
316 RIF and RPL population. A large randomized controlled trial has recently shown that  
317 endometrial scratching following IVF or ICSI does not increase the implantation rate in a  
318 subsequent transfer cycle, but its effect in women with RIF or RPL or the long-term effect  
319 were not addressed in this trial.(30) Endometrial scratch injury was shown to be beneficial in  
320 a meta-analysis in women who had two or more implantation failures, but not for women with  
321 one failed embryo transfer only. The greatest effect was associated with double luteal  
322 endometrial scratch injury with pipelle.(16) It is not well researched what reactions are caused  
323 by endometrial scratch injury and by endometrial diagnostic biopsy and to what extent they  
324 can be considered as comparable.(29)

325 Our results support the increasing evidence that in women with either RIF or RPL, CE needs  
326 to be diagnosed and treated. Our results particularly show a shorter time to live birth.  
327 However, prospective studies with larger number of participants are needed.

328

### 329 **Conclusion**

330 Diagnostic endometrial biopsy with subsequent antibiotic treatment in case of chronic  
331 endometritis shortens time to live birth and time-to-pregnancy, compared to women  
332 undergoing hysteroscopy only. Randomized clinical trials are needed to establish standards  
333 for diagnosis and treatment of CE and to cure implantation failure in the future.

334

### 335 **Authors' roles**

336 ASK, VRM, SM, TG and TTR conceptualized and designed the study. AKS, VRM, SM,  
337 MvW, MDM and TTR collected the epidemiological, clinical and pathological data. VRM  
338 and MZ conceptualized and performed the statistical analysis. All authors contributed  
339 substantially to the interpretation of the findings. SM and VRM wrote the first draft of the  
340 manuscript. All authors contributed to redrafting of the manuscript. AKS, VMI, MvW, MDM  
341 and MZ revised the article critically for important intellectual content. All authors approved  
342 the final submitted version.

343

344 **Acknowledgements**

345 The authors gratefully acknowledge Karthiga Poopalan and Kathryn Imboden for the editing  
346 of the manuscript, Sven Trelle for statistical support, Dave Meier for support in data analysis,  
347 Julia Wilhelm for data collection, and Heidrun Janka for literature research.

348

349 **Details of ethical approval**

350 **Kantonale Ethikkommission Bern (KEK): 2017-01739 (Project ID)**

351 Date of approval: 21.12.2017

352

353 **References**

- 354 1. Maconochie N, Doyle P, Prior S, Simmons R. Risk factors for first trimester  
355 miscarriage-results from a UK-population-based case-control study. *BJOG*.  
356 2007;114(2):170-186.
- 357 2. Bender Atik R, Christiansen OB, Elson J, et al. ESHRE guideline: recurrent pregnancy  
358 loss. *Hum Reprod Open*. 2018;2018(2):1-12.
- 359 3. Bashiri A, Halper KI, Orvieto R. Recurrent Implantation Failure-update overview on  
360 etiology, diagnosis, treatment and future directions. *Reprod Biol Endocrinol*.  
361 2018;16(121):1-18.
- 362 4. Coughlan C, Ledger W, Wang Q, et al. Recurrent implantation failure: Definition and  
363 management. *Reprod Biomed Online*. 2014;28:14-38.
- 364 5. World Health Organization. Recommended Definitions, Terminology and Format for  
365 Statistical Tables Related to The Perinatal Period And Use of A New Certificate For  
366 Cause of Perinatal Deaths. *Acta Obstet Gynecol Scand*. 1977;56(3):247-253.
- 367 6. El Hachem H, Crepau V, May-Panloup P, Descamps P, Legendre G, Bouet PE.  
368 Recurrent pregnancy loss: Current perspectives. *Int J Womens Health*. 2017;9:331-345.
- 369 7. Kimura F, Takebayashi A, Ishida M, et al. Review: Chronic endometritis and its effect  
370 on reproduction. *J Obstet Gynaecol Res*. 2019;45(5):951-960.
- 371 8. Kitaya K, Takeuchi T, Mizuta S, Matsubayashi H, Ishikawa T. Endometritis, new time,  
372 new concepts. *Fertil Steril*. 2018;110(3):344-350.
- 373 9. Bouet PE, El Hachem H, Monceau E, Gariépy G, Kadoch IJ, Sylvestre C. Chronic  
374 endometritis in women with recurrent pregnancy loss and recurrent implantation  
375 failure: Prevalence and role of office hysteroscopy and immunohistochemistry in  
376 diagnosis. *Fertil Steril*. 2016;105(1):106-110.
- 377 10. Liu Y, Chen X, Huang J, et al. Comparison of the prevalence of chronic endometritis  
378 as determined by means of different diagnostic methods in women with and without  
379 reproductive failure. *Fertil Steril*. 2018;109(5):832-839.
- 380 11. Cicinelli E, Resta L, Nicoletti R, Zappimbulso V, Tartagni M, Saliani N. Endometrial  
381 micropolyps at fluid hysteroscopy suggest the existence of chronic endometritis. *Hum*  
382 *Reprod*. 2005;20(5):1386-1389.
- 383 12. Song D, Li T-C, Zhang Y, et al. Correlation between hysteroscopy findings and  
384 chronic endometritis. *Fertil Steril*. 2019;111(4):772-779.
- 385 13. Bayer-Garner IB, Korourian S. Plasma Cells in Chronic Endometritis are Easily  
386 Identified When Stained with Syndecan-1. *Mod Pathol*. 2001;14(9):877-879.
- 387 14. Zargar M, Ghafourian M, Nikbakht R, Mir Hosseini V, Moradi Choghakabodi P.  
388 Evaluating Chronic Endometritis in Women with Recurrent Implantation Failure and  
389 Recurrent Pregnancy Loss by Hysteroscopy and Immunohistochemistry. *J Minim*  
390 *Invasive Gynecol*. 2020;27(1):116-121.

- 391 15. Vitagliano A, Saccardi C, Noventa M, et al. Effects of chronic endometritis therapy on  
392 in vitro fertilization outcome in women with repeated implantation failure: a systematic  
393 review and meta-analysis. *Fertil Steril*. 2018;110(1):103-112.
- 394 16. Vitagliano A, Di Spiezio Sardo A, Saccone G, et al. Endometrial scratch injury for  
395 women with one or more previous failed embryo transfers: a systematic review and  
396 meta-analysis of randomized controlled trials. *Fertil Steril*. 2018;110(4):687-702.e2.
- 397 17. Demarmels Biasiutti F. Significance of coagulopathy in recurrent abortions.  
398 Pathophysiology, diagnostics, and therapy. *Gynäkologische Endokrinol*. 2013;(11):95-  
399 99.
- 400 18. Steinvil A, Raz R, Berliner S, et al. Association of common thrombophilias and  
401 antiphospholipid antibodies with success rate of in vitro fertilisation. *Thromb Haemost*.  
402 2012;108.
- 403 19. von Wolff M. The role of Natural Cycle IVF in assisted reproduction. *Best Pract Res*  
404 *Clin Endocrinol Metab*. 2019;33(1):35-45.
- 405 20. van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase  
406 support for assisted reproduction cycles. van der Linden M, ed. *Cochrane Database*  
407 *Syst Rev*. 2011;(10):Art.No.: CD009154.
- 408 21. Stephenson MD, McQueen D, Winter M, Kliman HJ. Luteal start vaginal micronized  
409 progesterone improves pregnancy success in women with recurrent pregnancy loss.  
410 *Fertil Steril*. 2017;107(3):684-690.e2.
- 411 22. Haas DM, Hathaway TJ, Ramsey PS. Progestogen for preventing miscarriage in  
412 women with recurrent miscarriage of unclear etiology. *Cochrane Database Syst Rev*.  
413 2018;(10):Art. No.: CD003511.
- 414 23. Cole SR, Hernán MA. Adjusted survival curves with inverse probability weights.  
415 *Comput Methods Programs Biomed*. 2004;75(1):45-49.
- 416 24. Moreno I, Cicinelli E, Garcia-Grau I, et al. The diagnosis of chronic endometritis in  
417 infertile asymptomatic women: a comparative study of histology, microbial cultures,  
418 hysteroscopy, and molecular microbiology. *Am J Obstet Gynecol*. 2018;218(6):602.e1-  
419 602.e16.
- 420 25. Matteo M, Cicinelli E, Greco P, et al. Abnormal Pattern of Lymphocyte  
421 Subpopulations in the Endometrium of Infertile Women with Chronic Endometritis.  
422 *Am J Reprod Immunol*. 2009;61(5):322-329.
- 423 26. Marron K, Walsh D, Harrity C. Detailed endometrial immune assessment of both  
424 normal and adverse reproductive outcome populations. *J Assist Reprod Genet*.  
425 2019;36(2):199-210.
- 426 27. Achache H, Tsafirir A, Prus D, Reich R, Revel A. Defective endometrial prostaglandin  
427 synthesis identified in patients with repeated implantation failure undergoing in vitro  
428 fertilization. *Fertil Steril*. 2010;94(4):1271-1278.
- 429 28. Gnainsky Y, Granot I, Aldo P, et al. Biopsy-induced inflammatory conditions improve  
430 endometrial receptivity: the mechanism of action. *Reproduction*. 2015;149(1):75-85.

- 431 29. Nastri CO, Gibreel A, Raine-Fenning N, et al. Endometrial injury in women  
432 undergoing assisted reproductive techniques. *Cochrane Database Syst Rev.*  
433 2012;(7):Art. No.: CD009517.
- 434 30. Lensen S, Osavlyuk D, Armstrong S, et al. A Randomized Trial of Endometrial  
435 Scratching before In Vitro Fertilization. *N Engl J Med.* 2019;380(4):325-334.
- 436
- 437



438 **Table and Figure legends**

439 **Table 1 Patient characteristics and fertility characteristics**

440 Patient characteristics of the biopsy group and the reference group

441 AMH: Anti-Müllerian Hormone, BMI: Body Mass Index, CE: Chronic endometritis, cm:  
442 centimeter, HSC: Hysteroscopy, m: mean, na: not applicable, n: number, PCOS: Polycystic  
443 ovary syndrome, RIF: Repeated implantation failure, RPL: Recurrent pregnancy loss, SD:  
444 Standard deviation

445 <sup>a</sup> linear regression, <sup>b</sup> Pearson's chi-squared test

446

447 **Table 2 Chances for clinical pregnancy and live birth (Cox models)**

448 CE: Chronic endometritis, CE<sub>neg</sub>: women diagnosed negative for chronic endometritis,  
449 CE<sub>pos</sub>: women diagnosed positive for chronic endometritis, 95% CI: 95% Confidence  
450 Interval, HR: Hazard ratio, n: no, y: yes, RIF: Repeated implantation failure, RPL: Recurrent  
451 pregnancy loss

452 <sup>°</sup> Cox regression models adjusted for maternal age (continuous) and parity (nullipar vs par)  
453 Stratified Cox regression models all stratified for repeated implantation failure or recurrent  
454 pregnancy loss

455

456 **Figure 1: Study population**

457 RPL: Recurrent pregnancy loss, RIF: Repeated implantation failure, TESE: Testicular sperm  
458 extraction, HSC: Hysteroscopy, CE: Chronic endometritis, CE<sub>neg</sub>: women diagnosed  
459 negative for chronic endometritis, CE<sub>pos</sub>: women diagnosed positive for chronic endometritis

460

461 **Figure 2: Images of patient with and without CE in hysteroscopy, hemalaun-eosin  
462 staining and immunohistochemically CD138 staining**

463 Comparison of a patient with bland endometrium (A,C,E) versus chronic endometritis  
464 (B,D,F) in hysteroscopy (A,B), conventional histology (C,D) and immunohistochemistry for  
465 CD138 (E,F). Note the reddish inflamed mucosal surface in chronic endometritis (B)  
466 and the intermingled plasma cells in endometrial stroma in immunohistochemistry (F, central  
467 region). These differences in plasma cell densities can't be distinguished in conventional  
468 histology (C,D) of the same patients. Of note, regular endometrial glands serve as a positive  
469 internal control as CD138 also known as syndecan-1 is positive in epithelial cells.

470 HSC: Hysteroscopy, CE: Chronic endometritis; HE: Hemalaun-eosin staining

471

472 **Figure 3: Time-to-pregnancy and time to live birth**

473 Kaplan-Meier failure estimates. Observation time: from hysteroscopy or biopsy date to  
474 clinical pregnancy or live birth (expected live birth); with applied inverse probability  
475 weighting to account for the proportion of women with repeated implantation failure and  
476 recurrent pregnancy loss respectively as well as the maternal age structure within each of the  
477 groups compared (according to Cole SR & Hernan MA).

478 *P*-values for the two groups compared:

479 a)  $P = 0.009$  b)  $P = 0.008$  c)  $P = 0.327$  d)  $P = 0.004$

480

**481 Supplemental Table 1: Patient characteristics and fertility characteristics**

482 Patient characteristics of the women diagnosed with chronic endometritis (CEpos group), the  
483 women without chronic endometritis (CEneg group), both from biopsy group, compared to  
484 women with hysteroscopy only (reference group).

485 AMH: Anti-Müllerian Hormone, BMI: Body Mass Index, CE: Chronic endometritis, cm:  
486 centimeter, HSC: Hysteroscopy, m: mean, na: not applicable, n: number, PCOS: Polycystic  
487 ovary syndrome, RIF: Repeated implantation failure, RPL: Recurrent pregnancy loss, SD:  
488 Standard deviation

489 <sup>a</sup> linear regression, <sup>b</sup> Pearson's chi-squared test

490

**491 Supplemental Table 2: Fertility outcomes**

492 Fertility outcomes of the women diagnosed with chronic endometritis (CEpos group), the  
493 women without chronic endometritis (CEneg group) both from biopsy group, compared to  
494 women with hysteroscopy only (reference group).

495 HSC: Hysteroscopy, CE: Chronic endometritis, Tx: Therapy, CP: Clinical pregnancy, n: number of  
496 events or persons, y: year, RIF: Recurrent implantation failure, RPL: Recurrent pregnancy loss, na: not  
497 applicable

498 \*\* Fisher's exact test

499 ° Cox regression

500 + Cox regression stratified for repeated implantation failure and recurrent pregnancy loss


Table 1 - Patient characteristics and fertility characteristics







	Biopsy group							Reference group							Biopsy group vs reference group	
	RIF		RPL		Total		RIF vs RPL	RIF		RPL		Total		RIF vs RPL	P value	P value
	m/n	SD/%	m/n	SD/%	m/n	SD/%	P value	m/n	SD/%	m/n	SD/%	m/n	SD/%	P value		
<b>n</b>	28	42	39	58	67	62		19	46	22	54	41	38		108	61 vs 47
<b>Mean age (years)<sup>a</sup></b>	37.8	3.1	36.9	5.2	37.3	4.4	0.422	37.6	4.0	35.3	3.5	36.4	3.8	0.061	0.294	0.094
<b>Median age (years)</b>	37.9	na	37.4	na	37.7	na	na	37.8	na	35.2	na	37.0	na	na	na	na
<b>Mean weight (kg)<sup>a</sup></b>	65.6	11.1	66.4	10.3	66.1	10.5	0.777	64.3	10.1	63.5	9.8	63.9	9.8	0.806	0.301	0.883
<b>Mean height (cm)<sup>a</sup></b>	166.6	4.8	166.1	7.6	166.3	6.6	0.782	166.5	5.6	165.2	6.6	165.8	6.1	0.529	0.731	0.561
<b>Mean BMI (kg/m<sup>2</sup>)<sup>a</sup></b>	23.7	4.2	24.1	3.8	23.9	3.9	0.689	23.2	3.5	23.3	3.8	23.2	3.5	0.924	0.396	0.661
<b>Current smoker (n)<sup>b</sup></b>	3	10.7	8	20.5	11	16.4	0.286	3	15.8	0.0	0	3	7.3	0.053	0.172	0.957
<b>AMH (pmol/l)<sup>a</sup></b>	34.1	38.6	26.0	31.1	29.7	34.7	0.375	23.1	18.5	23.4	32.3	23.2	26.5	0.971	0.334	0.459
<b>Time from intention to conceive until HSC (years)<sup>a</sup></b>	5.3	3.6	4.0	2.7	4.5	3.1	0.080	4.6	3.3	3.2	1.9	3.9	2.7	0.104	0.257	5.0 vs 3.7 (P=0.02)
<b>Deliveries before treatment (n)<sup>b</sup></b>																
0	23	82.1	23.0	59.0	46.0	68.6		14.0	73.7	11.0	50.0	25.0	0.6			
1	5	17.9	13.0	33.3	18.0	26.7	0.087	5.0	26.3	10.0	45.5	15.0	36.6	0.244	0.522	0.027
2	0	0.0	3.0	7.7	3.0	4.5		0.0	0.0	1.0	4.5	1.0	2.4			
<b>No. of embryos transferred before treatment (RIF)<sup>a</sup></b>	11	7.4					na	10.3	3.5					na	0.645	na
<b>Reason for infertility (n)<sup>b</sup></b>																
male factor	10	35.7						7	3.7							
tubal factor	2	7.1						0	0.0							
endometriosis	3	10.7					na	4	21.0					na	0.492	na
idiopathic	12	42.9						6	31.6							
anovulation/PCOS	1	3.6						2	10.5							





Table 2: Chances for clinical pregnancy and live birth (Cox models)

	Outcome: Clinical pregnancy						Outcome: Live birth					
	unadjusted stratified Cox models			adjusted stratified Cox models <sup>o</sup>			unadjusted stratified Cox models			adjusted stratified Cox models <sup>o</sup>		
	HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value
Reference group (baseline)	1.00			1.00			1.00			1.00		
Biopsy group	2.28	1.23-4.24	0.009	2.62	1.39-4.49	0.003	2.76	1.30-5.86	0.008	2.88	1.35-6.16	0.006
Maternal age (continuous)	0.94	0.88-1.01	0.083	0.92	0.86-0.99	0.018	0.97	0.89-1.06	0.547	0.96	0.87-1.05	0.364
Duration of subfertility (continuous)	1.05	0.96-1.14	0.301				0.95	0.81-1.12	0.572			
Parity (y/n)	0.84	0.47-1.51	0.570	0.84	0.47-1.52	0.568	0.98	0.47-2.05	0.958	0.86	0.40-1.85	0.697
Smoking (y/n)	1.05	0.44-2.51	0.904				1.04	0.40-2.74	0.924			
<b>Subgroup analyses (stratified for RIF/RPL)</b>												
Reference group (baseline)	1.00			1.00			1.00			1.00		
Diagnosed positive for CE	2.39	1.20-4.36	0.010	2.86	1.46-5.63	0.002	3.53	1.48-8.40	0.004	3.91	1.62-9.41	0.002
Diagnosed negative for CE	2.04	0.85-4.86	0.110	2.11	0.88-5.08	0.095	1.95	0.70-5.42	0.203	1.92	0.69-5.35	0.213
<b>Subgroup analyses (not stratified for RIF/RPL)</b>												
RIF and biopsy	2.18	0.73-6.50	0.162	2.12	0.71-6.35	0.179	2.95	0.91-9.62	0.073	2.9	0.89-9.46	0.077
RIF and CEpos	3.03	0.85-10.90	0.089	3.23	0.88-11.89	0.078	5.88	1.42 - 24.28	0.014	6.78	1.63-28.10	0.008
RIF and CEneg	1.73	0.49-6.04	0.390	1.61	0.46-5.67	0.454	2.04	0.52-8.02	0.309	1.88	0.48-7.42	0.367
RPL and biopsy	2.33	1.10-4.96	0.027	2.98	1.36-6.52	0.006	2.63	0.99-7.00	0.052	2.76	1.04-7.35	0.042
RPL and CEpos	2.28	1.06-4.92	0.036	3.06	1.37-6.85	0.006	2.74	0.97-7.70	0.056	3.34	1.13-9.83	0.029
RPL and CEneg	2.73	0.81-9.20	0.107	2.61	0.73-9.35	0.138	2.31	0.75-11.15	0.298	1.62	0.30-8.69	0.573

Figure 1: Study population









Supplemental table 1 - Patient characteristics & fertility characteristics

	Biopsy group (biopsy)													Reference group (ref)						P value				
	not diagnosed with CE (CEneg)						diagnosed with CE (CEpos)							P value						over three groups ref/CEneg/CEpos	over all RIF vs RPL			
	RIF		RPL		Total		P value RPL vs RIF		RIF		RPL		Total		P value RPL vs RIF		RIF		RPL			Total		P value RPL vs RIF
	m/n	SD/%	m/n	SD/%	m/n	SD/%		m/n	SD/%	m/n	SD/%	m/n	SD/%		m/n	SD/%	m/n	SD/%	m/n	SD/%	m/n	SD/%		
<b>n</b>	15	60	10	40	25	23		13	31	29	69	42	39		19	46.3	22	53.7	41	38			108	61 vs 47
<b>Mean age (years) <sup>a</sup></b>	38.3	2.5	34.5	6.4	36.8	4.7	0.046	37.2	3.7	37.7	4.5	37.6	4.2	0.709	37.6	4.0	35.3	3.5	36.4	3.8	0.061	0.431	0.094	
<b>Median age (years)</b>	38.1	na	36.0	na	37.7	na	na	36.3	na	38.7	na	38.1	na	na	37.8	na	35.2	na	37.0	na	na	na	na	na
<b>Mean weight (kg) <sup>a</sup></b>	66.5	7.8	69.4	9.5	67.7	8.4	0.440	64.6	14.1	65.4	10.5	65.2	11.5	0.841	64.3	10.1	63.5	9.8	63.9	9.8	0.806	0.376	0.883	
<b>Mean height (cm) <sup>a</sup></b>	166.8	4.2	169.2	10.6	167.8	7.4	0.458	166.3	5.6	165.1	6.3	165.45	6.1	0.554	166.5	5.6	165.2	6.6	165.8	6.1	0.529	0.372	0.561	
<b>Mean BMI (kg/m<sup>2</sup>) <sup>a</sup></b>	24	3.3	24.3	2.7	24.1	3	0.847	23.4	5	24.04	4.1	23.8	4.4	0.651	23.2	3.5	23.3	3.8	23.2	3.5	0.924	0.676	0.661	
<b>Current smoker (n) <sup>b</sup></b>	2.0	13.3	4	40.0	6.0	24	0.126	1	7.7	4	13.7	5	11.9	0.572	3	15.8	0	0	3	7.3	0.053	0.142	0.957	
<b>AMH (pmol/l) <sup>a</sup></b>	27.1	30.9	29.9	28.3	28.12	29.3	0.834	41.6	45.6	24.7	32.5	30.63	37.9	0.197	23.1	18.5	23.4	32.3	23.2	26.5	0.971	0.603	0.459	
<b>Time from intention to conceive until HSC (years) <sup>a</sup></b>	6.1	4.5	3.34	1.3	5	3.8	0.078	4.5	2	4.2	3	4.29	2.7	0.735	4.61	3.3	3.23	1.9	3.9	2.7	0.104	0.351	5.0 vs 3.7 (p=0.02)	
<b>Deliveries before treatment (n) <sup>b</sup></b>																								
0	13	86.7	7	70.0	20	80		10	76.9	16	55.2	26	61.9		14	73.7	11	50	25	61				
1	2	13.3	2	20.0	4	16	0.392	3	21.1	11	37.9	14	33.3	0.337	5	26.3	10	45.5	15	36.6	0.244	0.456	0.027	
2	0	0	1	10.0	1	4		0	0	2	6.9	2	4.8		0	0	1	4.5	1	2.4				
<b>No. of embryos transferred before treatment (RIF) <sup>a</sup></b>	10.1	4.8					na	12.31	9.59					na	10.3	3.5					na	0.567	na	
<b>Reason for infertility (n) <sup>b</sup></b>																								
male factor	3	20						7	53.8						7	3.7								
tubal factor	2	13.3						0	0						0	0								
endometriosis	2	13.3					na	1	7.7					na	4	21					na	0.069	na	
idiopathic	8	53.3						4	30.8						6	31.6								
anovulation/PCOS	0	0						1	7.7						2	10.5								

Supplemental table 2: Fertility outcomes

	Biopsy group								Reference group (ref)				P value over ref CEneg/CEpos	P value over all RIF vs RPL
	CEneg group			P value RIF vs RPL	Cepos group			P value RIF vs RPL	Reference group			P value RIF vs RPL		
	RIF	RPL	Total		RIF	RPL	Total		RIF	RPL	Total			
n (%)	15 (60%)	10 (40%)	25 (23%)		13 (31%)	29 (69%)	42 (39%)		19 (46.3%)	22 (53.7%)	41 (38%)		108	
Women with a first ClinP after Tx	5 (33.3%)	4 (40%)	9 (36.0%)	1.00**	5 (38.5%)	21 (72.4%)	26 (61.9%)	0.047**	5 (26.3%)	14 (63.6%)	19 (46.3%)	0.028**	0.102	0.001
First ClinP ended in miscarriage	2 (40.0%)	2 (50.0%)	4 (44.4%)	1.00**	1 (20%)	12 (57.1%)	13 (50.0%)	0.322**	0 (0.0%)	6 (42.9%)	6 (31.6%)	0.128**	0.147	
First ClinP ended in live birth	3 (60.0%)	2 (50.0%)	5 (55.6%)		4 (80.0%)	9 (42.9%)	13 (50.0%)		5 (100%)	8 (57.1%)	13 (68.4%)			0.001
Women with a second ClinP after Tx	1 (6.7%)	1 (10%)	2 (8.0%)	1.00**	0 (0%)	5 (17.2%)	5 (11.9%)	0.302**	0 (0.0%)	4 (18.2%)	4 (9.8%)	0.111 **	0.872	0.015
Second ClinP ended in miscarriage	0 (0.0%)	1 (100.0%)	1 (50.0%)	1.00**	0 (0.0%)	3 (60.0%)	3 (60.0%)	na	0 (0.0%)	1 (25.0%)	1 (25.0%)		0.572	0.338
Second ClinP ended in live birth	1 (100.0%)	0 (0.0%)	1 (50.0%)		0 (0.0%)	2 (40.0%)	2 (40.0%)		0 (0.0%)	3 (75.0%)	3 (75.0%)	na		
Total number of ClinP (first and second)	6 (40.0%)	6 (60.0%)	12 (80.0%)	na	5 (38.5%)	26 (89.7%)	30 (71.4%)	na	5 (26.3%)	18 (81.8%)	23 (56.1%)	na	na	na
Total number of miscarriages after ClinP (n)	2 (13.3%)	3 (30.0%)	5 (20.0%)	0.567**	1 (7.7%)	15 (51.7%)	16 (38.1%)	0.172**	0 (3.2%)	7 (31.8%)	7 (17.1%)	0.095	0.339	0.011
Total number of live births (n)	4 (26.7%)	2 (20.0%)	6 (24.0%)		4 (30.8%)	11 (37.9%)	15 (35.7%)		5 (26.3%)	11 (50.0%)	16 (39.0%)		0.445	0.205
median time to ClinP (years)	na	0.48	na	0.237°	0.89	0.47	0.56	0.263°	na	0.62	1.44	0.014°	<b>0.023</b> <sup>+</sup>	<0.001°
median time to live birth (years)	na	1.14	na	0.472	1.14	1.24	1.21	0.223	na	2.08	2.27	0.182	<b>0.013</b> <sup>+</sup>	0.197°
Women with an embryo transfer after Tx (RIF)	12 (80.0%)				9 (69.2%)				14 (73.7%)				0.804	na
Total nb embryos transferred after Tx (n)	43				35				49				0.617	na

## 6. Discussion

### 6.1. Main findings

#### *Small-for-gestational age*

This project investigated birthweight and birthweight percentiles after cIVF and NC-IVF. Birthweight percentile is a better outcome measure than birthweight alone, as it is adjusted for gestational age and sex of the infant. After cIVF, 11.8% of singletons were small-for-gestational-age compared to 2.9% after NC-IVF in the Bern IVF Cohort. The odds were significantly increased when supraphysiological estradiol levels ( $>10'000\text{pmol/l}$ ) in the maternal serum were detected at trigger day (unadjusted OR 4.58 95% CI 1.35 – 15.55;  $p=0.015$ ). After adjustment for maternal height, age and body mass index it remained significant (aOR 3.83; 95% CI 1.06-18.82;  $p=0.041$ )<sup>1</sup>. These findings are in line with the work by Pereira et al. and are also supported by the findings from Sunkara et al. They both found higher risks associated with high estradiol level or a high amount of oocytes collected.<sup>2-4</sup>

#### *Breastfeeding after ART treatment*

It is reassuring that in Switzerland ART treatment does not affect the initiation or duration of breastfeeding in the first year after delivery. Mothers after IVF reach the same high breastfeeding prevalence (93.4 %) compared to mothers from the control group (94.8%).<sup>5</sup> Additionally, hormonal stimulation is not associated with lower breastfeeding prevalence or earlier breastfeeding cessation as no differences between cIVF or NC-IVF were found. Factors associated with lower breastfeeding prevalence or earlier cessation in the whole study population were factors already familiar from the literature: maternal smoking during pregnancy, high BMI, low-birthweight, primiparity, preterm-birth and lower education. Mothers with IVF treatment smoked less and had a lower BMI, but had a slightly higher proportion of low-birthweight, preterm birth and were more often primiparous.

#### *Endometrial thickness in NC-IVF women*

The optimal endometrial thickness for achieving a pregnancy in a NC-IVF treatment is between 8-11mm. The pregnancy rate in women with endometrial thickness  $\leq 7\text{mm}$  was 7.4% and in women with  $>7\text{mm}$  it was 30.8%, but live birth rate did not differ. Quadratic regression analysis showed that thick endometrium is also associated with lower pregnancy success. Thin or very thick endometrium should be considered as a negative predicting factors for achieving a pregnancy in women treated by NC-IVF.<sup>6</sup>

### *Time to pregnancy in women with RPL and RIF*

In a historical cohort of 108 women fulfilling the inclusion criteria, 47 were diagnosed with RIF and 61 with RPL. From 2014 – 2016, 41 women had a hysteroscopic assessment only (reference group). Of 67 women who had a biopsy from 2016-2018, 42 were diagnosed positive for chronic endometritis and 25 were negative in immunohistochemically staining of plasma cells (CD138). Women who had an endometrial diagnostic biopsy with subsequent diagnosis and treatment in case of chronic endometritis had a significantly higher chance for a clinical pregnancy (Hazard ratio (HR) = 2.28, CI 95% 1.23 – 4.24,  $p=.009$ ) and for a live birth (HR = 2.76, CI 95% 1.30 – 5.87,  $p=.008$ ) compared to the reference group. In subgroup analysis it was found that women diagnosed positive for CE also had a high chance for clinical pregnancy (HR=2.39; 95% CI 1.20 – 4.36;  $p=.010$ ) and live birth (HR=3.53; 95% CI 1.48 – 8.40;  $p=.004$ ) compared to the women of the reference group. The indication of RIF or RPL did not substantially affect the outcome of the analysis. This finding demonstrates the importance of endometrial diagnostic biopsy and the subsequent treatment in case of a positive result for CE, in women suffering from both, RIF and RPL. However, it also shows that women without CE might benefit from an endometrial biopsy, which is similar to an endometrial scratch injury caused by the endometrial diagnostic biopsy. This was also found by Vitagliano et al.<sup>7</sup> It has been shown that endometrial scratch injury influences immunological processes in the endometrium of the uterus.<sup>8</sup> It would be important to confirm these findings through a randomized controlled trial.

## 6.2. Broader interpretation of the findings

### *Hormonal stimulation IVF*

Gonadotropin stimulation seems to be especially risky for women with a strong response to stimulation. However, it is difficult to predict a woman's response to the gonadotropin stimulation. Generally, it can be said that women of younger ages, with a good ovarian reserve and a normal body weight, are at higher risk of generating a high response.<sup>9</sup> High-responders are at higher risk of developing OHSS, which may interfere with early pregnancy and may potentially affect the intellect in the offspring.<sup>10</sup> In Natural cycle IVF there is no risk for multiple pregnancies, as usually only one embryo is generated. Natural cycle IVF allows the research of the influence of the hormonal stimulation in singletons born after ART per se, as the only difference between cIVF and NC-IVF is the use of gonadotropins. In both treatments, other underlying factors remain similar. Parents of both treatments suffer from subfertility, and laboratory technologies and embryo culture are comparable. NC-IVF is therefore a suitable model to research the effects of the hormonal stimulation on the health of children.<sup>11,12</sup> On the other hand, NC-IVF is not offered by many centres providing fertility treatment. This makes it difficult to achieve numbers high enough to get sufficient power for

statistical analysis. It would be necessary to collaborate with other centres, even at an international level, to set up cohorts large enough. However, even a reduction in the doses of hormones in minimal stimulation IVF is beneficial for the mother and the child, and should be considered by more treating centres.<sup>13,14</sup>

### *Outcomes of ART research*

One of the most important outcomes in reproductive medicine has long been and remains the pregnancy rate. Clinical pregnancy is usually confirmed by the detection of an amniotic sac by ultrasound. It is not even agreed, if confirmation also involves the heartbeat of a viable embryo. This means that an amniotic sac absent a viable embryo would count as a successful outcome, were the endpoint is defined as such. For some years now, a shift towards live birth rate as a more suitable outcome has been in progress. The aim of the fertility treatment is a healthy newborn, and not a clinical pregnancy with unsure outcome.<sup>15</sup> However, according to the DOHaD theory perinatal health matters, and may matter throughout an entire human life.<sup>16,17</sup> This raises the question – is live birth the correct desired outcome? Should perinatal health, at least, if not long-term health, be assessed? Quite a lot of research exists on childhood health after ART. For adulthood, many of the cohorts are still too young. ART technologies develop so quickly that the health of adults researched today may not be relevant for children born after ART today. Therefore, perinatal health is often the most feasible proxy measure for long term health outcomes. Nevertheless, it remains important to establish cohorts, or to access informative data from existing cohorts and registries and to follow-up existing cohorts until adult life.<sup>18</sup>

### *Unexplained infertility*

In fertility treatment, there are still a high proportion of couples with so-called unexplained infertility. It is possible that some problems leading to unexplained infertility have not yet been identified, and research is scarce. For many suspected causes of unexplained infertility, no randomized controlled trials have been conducted and no treatment guidelines exist.<sup>19,20</sup> This is especially true for infertility due to endometriosis, and for women with RIF and RPL. It seems that immunological problems may play a role in some cases of unexplained infertility. Immunological aspects are also suspected to be associated with RIF, RPL and chronic endometritis.<sup>21</sup>

### *Women's health matters*

Many female health problems are not well researched. A report from Public Health England revealed that 31 % of women suffered from a reproductive or gynaecological problem within a 12 month period, but only a very small proportion of funding is allocated to this area.<sup>22,23</sup> Underfunding may lead to many small observational single-centre analyses. But this will not help to find evidence on

pending questions. What is really lacking for many unresolved issues in female fertility are well-conducted, randomized controlled trials with a sufficient power to detect possible differences among the groups compared. This becomes even more difficult with rare conditions, which would require collaborative efforts. RIF and RPL is a well-documented example of such a condition. Many published studies exist with women suffering from RIF and RPL but most of them are small and of a retrospective study design. Because diagnosis of CE is not standardised, comparability of the results is not possible.<sup>24</sup> Recently, a first RCT on diagnosing CE through fluid hysteroscopy was published.<sup>25</sup> On [www.clinicaltrials.gov](http://www.clinicaltrials.gov) one RCT on antibiotic therapy in CE conducted in China is recorded.<sup>26</sup> Not one single RCT on the treatment of CE has been published so far.

### *Problems in current ART research*

The influence of ART on the health of children is a very complex subject, with many influencing factors, mediators and confounders. It remains difficult to identify the true origin of adverse outcomes in children born after ART. Several factors are involved when a couple seeks fertility treatment. Besides the ART technologies and the hormonal stimulation, other particularly important factors include underlying parental health, parental age and the particular causes of subfertility.<sup>27</sup> As nowadays childbearing is often postponed for many reasons, the average maternal age is above 30 in most European countries, including Switzerland. Parents seeking fertility treatment are usually older; a high proportion is between 35-40 years. Pregnancy at age 35 – 40 is associated per se with higher risks of pregnancy complications and adverse perinatal outcomes.<sup>28,29</sup> One of the pending questions is how to separate the parental influence from any epigenetic changes induced through ART by applying sensible research methodologies. In current ART research, this separation remains especially crucial. Much published research cannot answer these questions. The main problems are: I) Small single-centre cohort studies; II) The selection of an appropriate control group; III) The comparison of diverse reproductive technologies making the aggregation of results difficult for systematic reviews and meta-analyses; and IV) The frequent lack of details on the ART treatment in large population-based studies.<sup>30</sup> The problem of selecting an appropriate group for comparison is discussed by Berntsen et al. Either spontaneously conceived children of subfertile couples or discordant siblings would be valuable controls.<sup>27</sup> To identify spontaneously conceived children born to subfertile couples, pregnancies caused by IUI could be examined. In couples not using any medical support for conception, the time until conception is either not documented, or relies on self-reported information provided by the couple. Discordant sibling couples are rare and difficult to identify. Only a few studies have used discordant siblings as controls.<sup>31-34</sup> One study used sibling couples where one was born after a fresh embryo transfer and the other after FET to explore the cause for LGA.<sup>35</sup> The differences in perinatal outcomes between pairs of siblings were lower

compared to existing research<sup>31,34</sup>, or not present.<sup>33</sup> This supports the hypothesis that parental factors and subfertility are the primary influences on health outcomes in children.

### 6.3. Strengths and limitations

The strengths and limitations of each study are discussed in detail in each of the presented manuscripts.

The Bern IVF Cohort is a unique cohort of IVF children, with data on the parents, the details of the treatments and pregnancies, as well as birth outcome. The proportion of parents consenting is high, and the children are followed-up on until today. This cohort is a great opportunity for future research, including research on long-term health outcomes. The possibility of connecting perinatal outcomes to detailed treatment information and detailed laboratory data is a strength of the projects. Bern is a specialist centre for natural cycle IVF. NC-IVF is offered to all women with regular menstrual cycles, and the decision on treatment is made together with the physician. This is the reason why nearly half of the live births came following an NC-IVF treatment. This allows the study of the influence of gonadotropins. Comparable cohorts are rare, even on an international level.

Generally, all projects face the typical problems of research into ART, as discussed in the introduction. All are using data of one single centre, have a limited sample size and are retrospectively observational. Only one study included a control group for comparison. As patients treated by IVF or ICSI are highly selected already, it is difficult to find a good group for comparison. If, as in the manuscripts presented, data of a sample of the population is used, information on conception is often lacking. Children conceived with the support of ART methods are therefore present in the samples. The proportion of children born after ART in Switzerland is about 2-2.5%.<sup>36</sup> The contamination caused by this proportion can be considered to be low, and will not affect the medians of the groups for comparison.

This thesis demonstrates the possibilities and difficulties of ART research very well. When the goal is to investigate children's outcomes, it is not easy to find enough children born after the different treatment methods. This necessitates the collection of the data over several years, or collaboration with other ART centres. In multicentre studies, there are issues around the comparability of treatment schemes, as well as laboratory procedures, which might be different at each centre. It therefore increases the sample size by introducing more heterogeneity. As ART develops rapidly and the law changes, similar issues arise with collecting data over many years. For example, in 2017 the reproductive medicine act (RMA) was changed and allowed the extension of cultural duration until

day 5. Since then, pregnancy rates have increased in Switzerland.<sup>37</sup> But it also introduced an additional confounder when comparing children created before or after the change.

It is important to understand that ART is quite a special domain within medicine. Firstly, there are strict laws in place, clearly defining what is allowed and what is forbidden. Many ethical aspects are linked to ART. Society and politics may influence the scope of such a law. The RMA of Switzerland is, in comparison to other European countries, rather strict. It does not allow surrogate motherhood or egg donation. Furthermore, it does not allow the treatment of homosexual couples. However, it does allow sperm donation, which raises questions as to gender equity regarding accessing fertility treatment.

Fertility treatment is not covered by the mandatory health insurance, which all persons have in Switzerland. Only diagnosis, and up to three IUI and/or the stimulation of ovulation by hormones up to one year, is reimbursed. All IVF or ICSI treatments have to be paid for by the couples themselves. This leads to a selection bias, as more couples who are able to afford treatment will go for fertility treatment. For less privileged couples, it may lead to a further delay of treatment onset, as money may have to be saved first.

All these aspects may limit the transferability of the results of ART research to other countries.

## 6.4. Implications for future research

### *Access to data*

The Swiss Society for Reproductive Medicine (SGRM) collects data on fertility treatment within Switzerland via its national database on ART (FIVNAT-CH). FIVNAT-CH was founded in 1993 and remains active today. It reports key figures on a yearly basis to the Federal Statistical Office (FSO). The RMA requires the cantons to collect the data, and to monitor the quality of fertility treatment.

In the FIVNAT-CH, data on fertility treatment on a national level is available for monitoring and quality control.<sup>38</sup> It would be desirable to allow access to this data for research. This would require certain changes in the way the SGRM and the FIVNAT-CH are organised. First, the FIVNAT-CH would need ethical approval to collect the data for the purpose of research. Only recently, Swissethics introduced a basic ethical approval for registries collecting health-related personal data.<sup>39</sup> Several medical associations have published guidelines on how to establish a medical registry.<sup>40</sup> This would of course require the centres to adequately inform their patients, and to collect informed consent. Second, the SGRM would need to clearly regulate access to the data for the purposes of research. A process of requesting data, and of the validation of research projects by the steering board of SGRM



or FIVNAT-CH would need to be put in place. It would allow research with larger dataset on a national level.<sup>40</sup> Standardized and high-quality data, including pregnancy and birth outcomes, should be collected systematically. Variable collection could be extended to allow the investigation of important research questions. Follow-up research on families, where informed consent is granted accordingly, would be possible. This would allow the contacting of families for future research on the long-term health consequences of ART. ART data collection must also adequately follow changes in treatment options. Today, with the possibility of freezing oocytes for social or medical reasons, or the vitrification of embryos, the fertility treatment of the same individual can last over decades.<sup>41,42</sup>

### *Transparency*

Data collected within FIVNAT-CH is used to monitor the number of cycles conducted in fertility treatment and the number of children born following ART in Switzerland.<sup>38,43</sup> It allows certain conclusions to be drawn about the characteristics of the couples in treatment, treatment success and the children born. However, it is not yet used to assess the quality and outcome of the centres in a standardized way. Instead, each centre is asked to provide its own key performance indicators. Even if they are defined, differences in assessing them may exist. Each centre also determines how transparently they report their figures. Calculating the key performance indicators should be done centrally and independently by using the numbers of FIVNAT-CH. FIVNAT-CH should include all variables necessary to be able to independently calculate the performance of the centres.

Furthermore, FIVNAT-CH and the FSO only collect data on couples seeking treatment in Swiss fertility clinics. Compared to other European countries, RMA in Switzerland is still rather restrictive, and costs for fertility treatment are high. This leads to reproductive tourism, with Swiss couples seeking fertility treatment abroad. In Switzerland, it is impossible to estimate the number of couples seeking help abroad, or to know how many children are born in Switzerland after ART treatment abroad. FIVNAT-CH, on the other hand, documents foreign couples seeking treatment within Switzerland. A European or international collaboration of national registries would be necessary to enable the extent of reproductive tourism to be estimated. It would also require standardized data collection on an international level to better aggregate and exchange data. ISMAARC and ESHRE are currently improving their data collection.<sup>44</sup> This will possibly help in future to estimate the extent of fertility tourism by Swiss couples.<sup>18,41</sup>

### *Health of children should be the focus*

Research on perinatal outcomes in children born after ART in Switzerland has so far been limited to qualitative aspects analysed within the FIVNAT-CH data.<sup>38,43</sup>

The Bern IVF Cohort is the first Swiss cohort to have been set up with the aim of also investigating the long-term health of children born after different ART treatments.

Previously, research conducted by fertility specialists on the long-term health consequences in children born after ART in Switzerland did not exist. It was a bit of a surprise when cardiologists around Urs Scherrer communicated the higher cardiovascular health risks they discovered in children born after ART. It led to a media response throughout Switzerland, and even at international level. Many fertility specialists in Switzerland found themselves confronted with patients asking critical questions. This would be the moment for specialists engaged in fertility treatment to wake up and to create a supportive atmosphere to facilitate research. It is the moment to seek collaborations. It is our responsibility towards our patients to become more engaged in research, or at least to facilitate it with better data and improved access to it.<sup>45</sup>

#### *Future research projects*

As a first step, it would be important to investigate the perinatal health of children born after ART in comparison to that of children born to fertile couples within Switzerland. FIVNAT-CH and the Bern IVF Cohort could be a good basis on which to establish research focused on long-term follow-up in Switzerland.

Long-term cardiovascular consequences should be investigated in collaboration with cardiologists. Children from the Bern IVF Cohort could be asked to participate in follow-up investigations.

Linkage studies with data from FIVNAT-CH would allow the identification of risks of other diseases. Many registries exist in Switzerland, some on typical childhood diseases. A linkage with the registry for childhood cancer, for example, would be an option.

A linkage with the Swiss NeoNet registry would allow the identification of children born at very low gestational age, to further research and follow up the risks of very preterm birth after ART.

A randomized, blinded multicentre study should be set up on the diagnosis and treatment of women with RIF and RPL. It would be important to define clear inclusion criteria. As number of women with these conditions are not many, an international approach could be considered. Women diagnosed with CE would get a blinded course of antibiotics or placebo. One month later, a test for cure should be performed by endometrial biopsy. A crossover design could be considered to give the chance for treatment to each woman participating in the trial. The women should then be followed up for at least one year.

## 6.5. Implications for future policy

### *Society and fertility*

The trend towards the postponement of childbearing has been observed for decades across all European countries. Many explanations highlight changes in women's position and opportunities within society. However, women's actual reasons for the postponement of childbearing are not well researched nor understood. Especially in Switzerland, not much research exists on topics such as fertility awareness, parity progression, child wish or aimed family size. This leads to the fact that it is not well known how women could be motivated to move towards having children at younger ages. Which political measures would have to be taken to encourage younger couples to build a family? To sociologically and demographically research these questions might allow politics to improve circumstances for couples to start families earlier. The positive effect would be to lower the use of ART due to ageing.

### *Access to fertility treatment*

Unequal access to fertility treatment may be increasing the risks for offspring. In Switzerland, only very basic fertility treatment is paid for by the mandatory health insurance. Neither IVF nor ICSI are covered, denying access to couples with lower financial resources. It also leads to couples delaying treatment during their more fertile years increasing risks for the mothers and the children. Access to fertility treatment should be equal for all genders and couples independent of their sexual orientation.<sup>46</sup>

### *Towards safer ART in Switzerland*

Research, alongside ever-increasing experience and knowledge, leads to a reduction of some of the risks associated with birth following ART. For example, many countries have now moved towards a single embryo transfer policy. Low-dose stimulation schemes and variations, and the further development of cIVF have also reduced certain risks associated with gonadotropin stimulation as well as the number of embryos generated. Laboratory procedures have developed rapidly, and freeze-all strategies avoid the interference of hormonal stimulation with the onset of pregnancy. However, while clear answers are missing for some of the new technologies, the causes of any poorer perinatal outcomes often seem to be a combination of parental factors and ART itself. The one thing that is crystal clear is that multiple pregnancies bear the highest risk of adverse perinatal outcomes. Despite this clear evidence, the transfer of multiple embryos is still common in many countries, leading to twin and higher-order pregnancies. It would be advisable for Switzerland to employ a policy of single embryo transfer in both fresh and frozen cycles.



## 7. Conclusion

The following findings can be drawn from the different research projects described in this thesis:

- I) There is a need to further investigate the effects of gonadotropin stimulation; and NC-IVF provides an opportunity to do this;
- II) Child health and long-term outcomes should be the focus of reproductive medicine, rather than the current focuses of pregnancy rates and live birth rates;
- III) Many reasons for infertility and women's health are still unresolved and require further, more focused and well-designed research.

The main conclusion is that fertility treatment matters and better research on fertility treatment should be encouraged, especially in Switzerland. Numbers are often too low in any one centre so collaboration would be key to expanding and improving research.

It remains difficult to disentangle all the influencing factors on child health. Gaining more knowledge on these aspects is crucial. Especially in a country, where maternal age at child birth, infertility and the use of ART will increase further, it is of tremendous importance to further improve the safety of ART treatment and to follow-up their future children.

### *Personal conclusion*

This thesis was an excellent chance for me to increase my experience in research. It gave me insight in a topic, ART, where I had not previously had any knowledge. It also allowed me to combine my main interests: women's health, reproduction, demography and child health. I am very happy for this experience.



## 8. References

1. Kohl Schwartz AS, Mitter VR, Amylidi-Mohr S, et al. The greater incidence of small-for-gestational-age newborns after gonadotropin-stimulated in vitro fertilization with a supraphysiological estradiol level on ovulation trigger day. *Acta Obstet Gynecol Scand.* 2019;98(12):1575-1584.
2. Pereira N, Reichman DE, Goldschlag DE, Lekovich JP, Rosenwaks Z. Impact of elevated peak serum estradiol levels during controlled ovarian hyperstimulation on the birth weight of term singletons from fresh IVF-ET cycles. *J Assist Reprod Genet.* 2015;32:527-532.
3. Pereira N, Elias RT, Christos PJ, et al. Supraphysiologic estradiol is an independent predictor of low birth weight in full-term singletons born after fresh embryo transfer. *Hum Reprod.* 2017;32(7):1410-1417.
4. Sunkara SK, La Marca A, Seed PT, Khalaf Y. Increased risk of preterm birth and low birthweight with very high number of oocytes following IVF: An analysis of 65 868 singleton live birth outcomes. *Hum Reprod.* 2015;30(6):1473-1480.
5. Gross K, Späth A, Dratva J, Zemp Stutz E. *SWIFS - Swiss Infant Feeding Study.* Basel; 2014.
6. von Wolff M, Fäh M, Roumet M, et al. Thin Endometrium Is Also Associated With Lower Clinical Pregnancy Rate in Unstimulated Menstrual Cycles: A Study Based on Natural Cycle IVF. *Front Endocrinol (Lausanne).* 2018;9(776):1-6.
7. Vitagliano A, Di Spiezio Sardo A, Saccone G, et al. Endometrial scratch injury for women with one or more previous failed embryo transfers: a systematic review and meta-analysis of randomized controlled trials. *Fertil Steril.* 2018;110(4):687-702.
8. Gnainsky Y, Granot I, Aldo P, et al. Biopsy-induced inflammatory conditions improve endometrial receptivity: the mechanism of action. *Reproduction.* 2015;149(1):75-85.
9. Nastri CO, Teixeira DM, Moroni RM, Leitão VMS, Martins WP. Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention. *Ultrasound Obstet Gynecol.* 2015;45(4):377-393.
10. Xu GF, Zhou CL, Xiong YM, et al. Reduced Intellectual Ability in Offspring of Ovarian Hyperstimulation Syndrome: A Cohort Study. *EBioMedicine.* 2017;20:263-267.
11. Nakashima A, Araki R, Tani H, et al. Implications of assisted reproductive technologies on term singleton birth weight: An analysis of 25,777 children in the national assisted reproduction registry of Japan. *Fertil Steril.* 2013;99(2):450-455.
12. Mak W, Kondapalli LA, Celia G, Gordon J, Dimattina M, Payson M. Natural cycle IVF reduces the risk of low birthweight infants compared with conventional stimulated IVF. *Hum Reprod.* 2016;31(4):789-794.
13. Nargund G, Hutchinson L, Scaramuzzi R, Campbell S. Low-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of IVF cycles. *RBM Online.* 2007;14(6):682-685.
14. Kamath MS, Kirubakaran R, Mascarenhas M, Sunkara SK. Perinatal outcomes after stimulated versus natural cycle IVF: a systematic review and meta-analysis. *Reprod Biomed Online.* 2018;36(1):94-101.

15. Barnhart KT. Live birth is the correct outcome for clinical trials evaluating therapy for the infertile couple. *Fertil Steril*. 2014;101(5):1205-1208.
16. Barker D. Infant Mortality, Childhood Nutrition, and Ischaemic Heart Disease in England and Wales. *Lancet*. 1986;327(8489):1077-1081.
17. Barker DJP. The origins of the developmental origins theory. *J Intern Med*. 2007;261(5):412-417.
18. De Geyter C. Assisted reproductive technology: Impact on society and need for surveillance. *Best Pract Res Clin Endocrinol Metab*. 2019;33(1):3-8.
19. Siristatidis C, Bhattacharya S. Unexplained infertility: does it really exist? Does it matter? *Hum Reprod*. 2007;22(8):2084-2087.
20. Ray A, Shah A, Gudi A, Homburg R. Unexplained infertility: an update and review of practice. *Reprod Biomed Online*. 2012;24(6):591-602.
21. Ehsani M, Mohammadnia-Afrouzi M, Mirzakhani M, Esmailzadeh S, Shahbazi M. Female Unexplained Infertility: A Disease with Imbalanced Adaptive Immunity. *J Hum Reprod Sci*. 2019;12(4):274-282.
22. Mann S, Davison M, Logan L, et al. *What Do Women Say? Reproductive Health Is a Public Health Issue*. London; 2018.
23. Fisk N, Atun R. Systematic analysis of research underfunding in maternal and perinatal health. *BJOG An Int J Obstet Gynaecol*. 2009;116(3):347-356.
24. Liu Y, Chen X, Huang J, et al. Comparison of the prevalence of chronic endometritis as determined by means of different diagnostic methods in women with and without reproductive failure. *Fertil Steril*. 2018;109(5):832-839.
25. Cicinelli E, Vitagliano A, Kumar A, et al. Unified diagnostic criteria for chronic endometritis at fluid hysteroscopy: proposal and reliability evaluation through an international randomized-controlled observer study. *Fertil Steril*. 2019;112(1):162-173.
26. US National Library of Medicine. [Clinicaltrials.gov](https://clinicaltrials.gov).
27. Berntsen S, Söderström-Anttila V, Wennerholm U-B, et al. The health of children conceived by ART: 'the chicken or the egg?' *Hum Reprod Update*. 2019;25(2):137-158.
28. Pinheiro RL, Areia AL, Mota Pinto A, Donato H. Advanced Maternal Age: Adverse Outcomes of Pregnancy, A Meta-Analysis. *Acta Med Port*. 2019;32(3):219.
29. Kahveci B, Melekoglu R, Evruke IC, Cetin C. The effect of advanced maternal age on perinatal outcomes in nulliparous singleton pregnancies. *BMC Pregnancy Childbirth*. 2018;18(1):343.
30. Yeung EH, Kim K, Purdue-Smithe A, et al. Child Health: Is It Really Assisted Reproductive Technology that We Need to Be Concerned About? *Semin Reprod Med*. 2018;36(3-4):183-194.
31. Henningsen AKA, Pinborg A, Lidegaard Ø, Vestergaard C, Forman JL, Andersen AN. Perinatal outcome of singleton siblings born after assisted reproductive technology and spontaneous conception: Danish national sibling-cohort study. *Fertil Steril*. 2011;95(3):959-963.
32. Romundstad LB, Romundstad PR, Sunde A, von Düring V, Skjærven R, Vatten LJ. Increased risk of placenta previa in pregnancies following IVF/ICSI; a comparison of ART and non-ART pregnancies in the same mother. *Hum Reprod*. 2006;21(9):2353-2358.



33. Romundstad BL, Romundstad PR, Sunde A, et al. Effects of technology or maternal factors on perinatal outcome after assisted fertilisation: a population-based cohort study. *Lancet (London, England)*. 2008;372:737-743.
34. Dhalwani NN, Boulet SL, Kissin DM, et al. Assisted reproductive technology and perinatal outcomes: conventional versus discordant-sibling design. *Fertil Steril*. 2016;106(3):710-716.e2.
35. Pinborg A, Henningsen AA, Loft A, Malchau SS, Forman J, Andersen AN. Large baby syndrome in singletons born after frozen embryo transfer (FET): Is it due to maternal factors or the cryotechnique? *Hum Reprod*. 2014;29(3):618-627.
36. Federal Statistical Office. Fruchtbarkeit. <https://www.bfs.admin.ch/bfs/de/home/statistiken/bevoelkerung/geburten-todesfaelle/fruchtbarkeit.html>.
37. Schweizerische Gesellschaft für Reproduktionsmedizin. [www.sgrm.org](http://www.sgrm.org).
38. De Geyter C, Fehr P, Moffat R, Gruber IM, Von Wolff M. Twenty years' experience with the Swiss data registry for assisted reproductive medicine: Outcomes, key trends and recommendations for improved practice. *Swiss Med Wkly*. 2015;145(w14087):1-13.
39. swissethics. *Leitgedanken Zu Registern in Der Humanforschung*. Bern; 2019.
40. Busch P, Heller R, Kraft E, et al. *Empfehlungen Zum Aufbau Und Betrieb von Gesundheitsbezogenen Registern*. Bern; 2019.
41. De Geyter C. Assisted reproductive medicine in Switzerland. *Swiss Med Wkly*. 2012;142:w13569.
42. De Geyter C, Wyns C, Mocanu E, de Mouzon J, Calhaz-Jorge C. Data collection systems in ART must follow the pace of change in clinical practice. *Hum Reprod*. 2016;31(10):2160-2163.
43. Van den Bergh M, Hohl MK, De Geyter C, Stalberg A, Limoni C. Ten years of Swiss National IVF Register FIVNAT-CH. Are we making progress? *RBMOnline*. 2005;11(5):632-640.
44. Adamson GD, de Mouzon J, Chambers GM, et al. International Committee for Monitoring Assisted Reproductive Technology: world report on assisted reproductive technology, 2011. *Fertil Steril*. 2018;110(6):1067-1080.
45. Brison DR, Roberts SA, Kimber SJ. How should we assess the safety of IVF technologies? *Reprod Biomed Online*. 2013;27(6):710-721.
46. Insogna IG, Ginsburg ES. Infertility, Inequality, and How Lack of Insurance Coverage Compromises Reproductive Autonomy. *AMA J Ethics*. 2018;20(12):E1152-E1159.



## *ACKNOWLEDGEMENTS*

I would like to thank cordially my supervisor Michael von Wolff for giving me the chance to do this PhD at the University Women's Hospital. I am his first non-medical PhD student, and it was a new experience for both of us. I would like to thank you for your trust, your patience, your support and your openness to my ideas. I value the fact that together we started to confront the SGRM, to convince them to work up their data and use it for research. This PhD set the spark for this, and I hope it will continue.

A special thanks goes to my co-supervisor Marcel Zwahlen. Your calm and pragmatic methodological support allowed me to successfully complete this PhD. I could count on you 100% for any question I addressed to you. I would particularly like to thank you for your support for the early post-doc application. The discussion with you helped me to bridge the differences between the clinical and the methodological world.

I also would like to thank Alexandra Kohl Schwartz, who is more to me than just a research colleague is. I think it is rare to have so many aspects combined in one person. She is a good friend, a challenging colleague and a supportive team member. Our discussions covered topics from motherhood, scout life, leadership, gender equality, medicine and science, research and daily life problems.

Susanne Singer has been a mentor to me since we studied together in London. I thank you for all the intense discussions, the very wise advice and the interest in me as a person and friend. Our friendship means a lot to me.

I also thank the team of the Gynaecological Endocrinology and Reproductive Medicine, Anja Fink, Anja Wüest, Susanna Weidlinger, Petra Stute, Isotta Magaton, Markus Eisenhut and Bruno Laborde, Laurence Richoz, Livia Zumstein, Jacqueline Ritter, Ramona Guelpa and Lorella Gerber. Thank you for sharing coffee and lunch breaks and helping me out with administration or medical questions on stimulation, embryo development and MediTEX.

This PhD would not have been possible without the support I received in my neighbourhood and family - the "village" - all the people who looked after my kids during courses, deadlines, meetings, congresses and conferences. It is very healing for a mother to know their kids are

happy and well cared for. My truly sincere thanks go to: Sima, Alfred, Babette, Isabelle, Andrea, Nicole, Fabienne, Ann, Nathalie and Lennard, Karin, Julia and Krishnan, and to our babysitters Aliyya, Patricia and Jenny. I would also like to thank the team of the day school at the Horbern in Muri, and the Kita and Kindergarten Sputnik in Bern.

My mother, Christiane Iseli, and my mother in law, Barbara Guta, also helped out a lot in childcare, in family support and management, and I also would like to thank them for the understanding of my unpopular professional way and the economic, emotional and organisational support they give to us as a family.

My parents fuelled my interest in medicine, animals and nature from very early on. My father inspired my love for plants and biological processes. Even if he is not among us anymore. To both of you, I owe the creativity and the out of the box thinking.

My husband, Mike Mitter and I have been on our way together since high school. You made it through every exam, all the years of university, two Masters theses, and without your support this thesis would not have been possible. I appreciate you for your love, your understanding and your quality as a father and husband.

Last but not least I would like to thank all my friends, supporters and colleagues: Claudia Berlin, Sanda Branca, Corina Rüegg, Susanne Singer, Anne Grossenbacher, Priska Wölfli and a very special thank goes to Anne Fröhlich, who designed the title page.

Robert Cohen I would like to thank for editorial support, and Martin Schaffner and Christian Furrer I would like to thank for support in printing and binding the manuscript, and the interesting discussions we have.

## CURRICULUM VITAE

### Personal Information

Name	Vera Ruth Mitter-Iseli
Date of birth	04.01.1980
Place of birth	Bern, Switzerland
Marital status	Married
Children	Lenny, 03.12.2011 & Malin, 02.07.2014

### Education

09.2018 – present	PhD in Health Sciences, <b>Division of Gynecological Endocrinology and Reproductive Medicine</b> , University Women's Hospital, Insel Gruppe AG, & Graduate School for Health Science, University of Bern, Switzerland & Swiss School of Public Health (SSPH+)
09.2008 – 10.2009	MSc Demography & Health, <b>London School of Hygiene and Tropical Medicine</b> , London, UK
09.2003 – 11.2005	Federally graduated Pharmacist, <b>University of Basel</b> , Switzerland
08.2002 – 08.2003	cand. pharm, <b>École Polytechnique Fédéral de Lausanne (EPFL)</b> , Lausanne; <b>Pharmacy du Croset</b> , Ecublens, Switzerland
08.2000 – 08.2002	Pharmacy, University of Bern
08.1995 – 05.2000	<b>Gymnasium Bern-Kirchenfeld</b> , High school with focus on economics and law

### Work Experience

11.2014 – 01.2018	Pharmacist, Clinical Trial Coordinator, <b>Institute of Hospital Pharmacy</b> , Insel Gruppe AG, Bern, Switzerland
08.2016 – 08.2017	Research Assistant (20%), <b>Division of Gynecological Endocrinology and Reproductive Medicine</b> , University Women's Hospital, Insel Gruppe AG, Bern, Switzerland
10.2009 – 11.2014	Project coordinator of the Swiss Childhood Cancer Registry, <b>Institute of Social and Preventive Medicine</b> , University of Bern, Switzerland
01.2010 – 03.2012	Pharmacist, emergency service, <b>Notfall Apotheke</b> , Basel, Switzerland (20%)
05.2008 – 09.2008	Pharmacist, <b>St. Jakobsapotheke</b> , Basel, Switzerland
03.2008 – 09.2008	Trainer/Coach for professionals on health products and sale, <b>Health Invest</b>
03.2007 – 01.2008	Hospital pharmacist, <b>St. Claraspital</b> , Basel, Switzerland
07.2006 – 08.2006	IAESTE Traineeship, sales and marketing, <b>Supor Pharmaceuticals</b> , Hangzhou, China
01.2006 – 05.2006	Pharmacist, <b>Apotheke zur Waage</b> , Basel, Switzerland

**Teaching activity**

- 03.2018                    **Good clinical Practice und Ethics** – Ethische Fragen im klinischen Forschungsalltag, Lecturer, Bachelor Pharmacy and Biology, University of Basel, Switzerland (1 lesson per year 2018 – 2020)
- 2015 – 2017                **The Role of the Hospital Pharmacy in Clinical Trials**, Lecture, Clinical Investigators II: Advanced GCP and clinical research training course, CTU Bern, Switzerland (2 lessons per year in 2015, 2016; 3 lessons 2017)
- 2016                        **The Role of the Hospital Pharmacy in Clinical Trials**, Lecture, CAS Clinical Research Coordinator, Bern University of applied Sciences, Switzerland (1 afternoon in 2016)
- 06.2011                    **Das Schweizer Kinderkrebsregister – ein Beispiel für ein Diagnoseregister**, Gastlesende in Gesundheitspsychologie, University Wuppertal, Germany
- 11.2009                    **Risks associated with fertility and fertility control**, ISPM Bern, Research Meeting, University of Bern, Switzerland

**Supervision of students for master theses****Main Supervisor**

- 2014                        Diana Moser, cand. MSc of Science in Pharmacy, “Cardiac late effects after treatment of cancer in childhood”
- 2014                        Sandra Blau, cand. MSc of Science in Pharmacy, “Secondary tumours as late effects after treatment of cancer in childhood”

**Co-Supervision** of medical master students, not official supervisor, supervision and support for coordination, data management, patient contact and consent as well as statistical analysis.

- Marlen Berchtold, Master 2017
- Daniela Steiner, Master 2017
- Mirja Minger, Master 2017
- Livia Purtschert, Master 2017
- Pascale Fasel, Master 2017
- Maria Paulsson, Master 2018-2020
- Flavia Grädel, Master 2018
- Ursina Küng, Master 2018
- Lena Bommer, Master 2018
- Caroline Imhoof, Master 2020

## PUBLICATIONS

### Peer reviewed Journals

Kohl Schwartz AS\*, **Mitter VR\***, Amylidi-Mohr S, Fasel P., Minger MA, Limoni C, Zwahlen M, von Wolff M. The greater incidence of small-for-gestational-age newborns after gonadotropin-stimulated in vitro fertilisation with a supraphysiological estradiol level on ovulation trigger day. *Acta Obstetrica et Gynecologica Scandinavica*. 2019; 98:1575-1584

\* **shared first authorship**

von Wolff M, Fäh M, Roumet M, **Mitter V**, Stute P, Griesinger G, Kohl Schwartz A. Thin Endometrium is also Associated with Lower Clinical Pregnancy Rate in Unstimulated Menstrual Cycles: A Study Based on Natural Cycle IVF. *Frontiers in Endocrinology*, 2018 Dec 20;9:776

Singer S, **Mitter V**, Porsch U. No Evidence for Benefits of the Depression Coach. *Psychotherapy and Psychosomatics*, 2018 Sep 21:1 [letter to the editor]

Purtschert LA, **Mitter VR**, Mosimann B, Zdanowicz JA, Minger MA, Fasel P, von Wolff M, Kohl Schwartz AS. Breastfeeding following in vitro fertilization in Switzerland – does mode of conception affect breastfeeding behaviour? [submitted]

**Mitter VR**, Meier S, Gillon T, Rau TT, Mueller MD, Zwahlen M, von Wolff M, Kohl Schwartz AS. Chronic endometritis- shortened time to live birth in subfertile women undergoing hysteroscopy and endometrial diagnostic biopsy. [submitted]

### Non peer reviewed journals

Kohl Schwartz AS, **Mitter V**, von Wolff M. Eizellen für die Zukunft. *Gynäkologie*, Juli 2017





## CONFERENCE PRESENTATIONS

**Mitter V**, Kohl Schwarz A, Fäh M, Griesinger G, von Wolff M. Endometrial thickness is associated with the clinical pregnancy rate in unstimulated menstrual cycles – a study based on Natural Cycle IVF.

Poster presentation at the Conference of *European Society of Human Reproduction and Embryology* 2017, Geneva, Switzerland – Abstract published: *Human Reproduction*, Vol 32, Supp 1, 2017 Abstract book; P-473; p i351.

**Mitter VR**, Kohl Schwartz AS, Amylidi-Mohr S, Fasel P, Zwahlen M, Von Wolff M. The risk for «small for gestational age» after gonadotropin-stimulated in-vitro fertilisation (IVF) compared to natural cycle IVF: a cohort study. Poster presentation at the *Symposium of the Graduate School for Health Sciences* 2018, University of Bern, Switzerland

**Mitter VR**, Fasel P, Minger M, Purtschert L, Zwahlen M, von Wolff M, Kohl Schwartz AS. The Bern IVF Cohort: Perinatal outcomes compared to births to the general population of Switzerland. Talk at the Swiss Public Health Conference 2019, Winterthur, Switzerland

**Mitter VR**, Science Flash Talk, Finalist, Swiss Public Health Conference 2019, Winterthur, Switzerland

**Mitter VR**, Meier S, Kohl Schwartz AS. Time to live birth in subfertile couples and couples with recurrent pregnancy loss, Talk at the *Symposium of the Graduate School for Health Sciences* 2019, Gunten, Switzerland

**Mitter VR**, Krebs D, Paulsson M, Mosimann B, von Wolff M, Kohl Schwartz AS. Getting consent – challenges and difficulties for conducting research using health-related patient data. Talk at the 21. Jahrestagung of the Evidence based Medicine- Network, February 2020, University of Basel, Switzerland

**Mitter VR**, Meier S, Rau TT, von Wolff M, Zwahlen M, Kohl Schwartz AS. Shortened time to live birth in subfertile women undergoing endometrial diagnostic biopsy. Accepted as ePoster for the Conference of *European Society of Human Reproduction and Embryology* 2020, Copenhagen, Denmark; (virtual instead because of COVID-19 pandemic)



## Declaration of Originality

**Last name, first name:** Mitter Vera

**Matriculation number:** 00-104-828

I hereby declare that this thesis represents my original work and that I have used no other sources except as noted by citations.

All data, tables, figures and text citations which have been reproduced from any other source, including the internet, have been explicitly acknowledged as such.

I am aware that in case of non-compliance, the Senate is entitled to withdraw the doctorate degree awarded to me on the basis of the present thesis, in accordance with the “Statut der Universität Bern (Universitätsstatut; UniSt)”, Art. 69, of 7 June 2011.

Place, date

Muri b. Bern, 27.04.2020

Signature

A handwritten signature in black ink, appearing to read 'V. Mitter', with a long horizontal flourish extending to the right.